

ME/CFS MYALGIC ENCEPHALOMYELITIS/ CHRONIC FATIGUE SYNDROME



DIAGNOSIS AND MANAGEMENT IN YOUNG PEOPLE: A PRIMER

INTERNATIONAL
WRITING GROUP
FOR PEDIATRIC
ME/CFS
2017 EDITION



MYALGIC ENCEPHALOMYELITIS/ CHRONIC FATIGUE SYNDROME DIAGNOSIS AND MANAGEMENT IN YOUNG PEOPLE: A PRIMER

MEMBERS OF THE INTERNATIONAL WRITING GROUP FOR PEDIATRIC ME/CFS

PETER C. ROWE, Division of General Pediatrics and Adolescent Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States

ROSEMARY A. UNDERHILL, Independent Researcher, Palm Coast, FL, United States

KENNETH J. FRIEDMAN, Pharmacology and Physiology, New Jersey Medical School, Newark, NJ, United States

ALAN GURWITT, Yale Child Study Center, Harvard Medical School, University of Connecticut School of Medicine, Newton Highlands, MA, United States

MARVIN S. MEDOW, Division of Pediatric Gastroenterology, Hepatology and Nutrition, New York Medical College, Valhalla, NY, United States

MALCOLM S. SCHWARTZ, Drexel University College of Medicine, Philadelphia, PA, United States

NIGEL SPEIGHT, Paediatrician, Durham, United Kingdom

JULIAN M. STEWART, Division of Pediatric Cardiology, New York Medical College, Valhalla, NY, United States

ROSAMUND VALLINGS, Primary Care/Chronic Fatigue Syndrome Clinic, Howick Health and Medical, Auckland, New Zealand

KATHERINE S. ROWE, Department of General Medicine, Royal Children's Hospital, Murdoch Children's Research Institute, Melbourne, Victoria, Australia

CONTRIBUTING AUTHORS

FAITH NEWTON, Department of Education, Delaware State University, Dover, Delaware, United States

EVAN SPIVACK, Department of Pediatric Dentistry, Rutgers School of Dental Medicine, Newark, New Jersey, United States

The authors declare that this monograph was written in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

ACKNOWLEDGEMENTS

The authors are most grateful to "Solve ME/CFS Initiative" which funded the publication of this manuscript from the SMCI Medical Education Fund. The funder had no role in the writing or the approval of the manuscript. The authors gratefully acknowledge funding for the professional indexing of this monograph from "Open Medicine Foundation." The authors thank Lia Di Stefano for the graphic design of the book and its cover. We thank Lilly Klontz for the cover drawing.



First published by:

REVIEW ARTICLE Front. Pediatr., 19 June 2017 | <https://doi.org/10.3389/fped.2017.00121>

Copyright © 2017 Rowe, Underhill, Friedman, Gurwitt, Medow, Schwartz, Speight, Stewart, Vallings and Rowe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

CONTENTS

PREFACE	2	5:7 Immune system support	21
SUMMARY	3	5:8 Depression and anxiety	21
1. INTRODUCTION & OVERVIEW	4	5:9 Support and coping skills	21
1:1 Nomenclature	4	5:10 Dietary management	22
1:2 Epidemiology	4	5:11 Alternative and complementary medicine	23
1:3 Presentation, course of the illness, prognosis	4	6. COMORBID MEDICAL CONDITIONS	23
1:4 Diagnosis	5	6:1 Orthostatic intolerance	23
1:5 Role of the health practitioner in diagnosis and management	5	6:2 Joint hypermobility, connective tissue laxity, Ehlers Danlos syndrome	26
2. ETIOLOGY and PATHOPHYSIOLOGY	5	6:3 Gynecological issues	27
2:1 Etiological factors	5	6:4 Gastrointestinal issues	27
2:2 Pathophysiological basis for symptoms	6	6:5 Allergies	28
3. ADOLESCENT DEVELOPMENT	7	6:6 Neuro-anatomic abnormalities	28
4. CLINICAL DIAGNOSIS	8	6:7 Oral and dental issues	28
4:1 Patient history	8	7. AREAS OF SPECIAL CLINICAL CONCERN	29
Clinical diagnostic worksheet	9	7:1 Severely affected and very severely affected young patients	29
4:2 Physical examination	10	7:2 The possible impact of ME/CFS on the family	30
4:3 Laboratory testing	10	7:3 Immunizations	31
4:4 Differential diagnosis, exclusionary medical conditions	11	7:4 Considerations regarding surgery	31
4:5 Coexisting medical conditions	11	8. THE SCHOOL SYSTEM	31
4:6 Cognitive impairment	11	9. REFERENCES	33
4:7 Psychological reactions secondary to ME/CFS: Distinction from depression and anxiety disorders	12	10. APPENDICES	
4:8 Psychiatric illnesses that may be misdiagnosed in young patients with ME/CFS	13	A. 1994 Fukuda diagnostic criteria	40
5. MANAGEMENT	16	B. Table of differential diagnosis	41
5:1 Approach to Management	16	C. Fact sheet for patients and parents	42
5:2 The acute stage of ME/CFS	17	D. Fact sheet for schools	44
5:3 Sleep problems	17	E. Example of a helpful physician's letter for school personnel	46
5:4 Pain	18	F. Patients anticipating surgery: Special considerations	47
5:5 Fatigue, post-exertional symptoms, exercise intolerance	19	G. Orthostatic intolerance: Diagnosis, testing	48
5:6 Cognitive impairment	20	INDEX	53

PREFACE

Myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome (CFS) or ME/CFS, affects children and adolescents as well as adults. This primer has been written to provide the information necessary to understand, diagnose, and manage the symptoms of ME/CFS in children and adolescents. Some information in this primer overlaps with information in a similar primer for adults, *Chronic Fatigue Syndrome, Myalgic Encephalomyelitis, Primer for Clinical Practitioners*, that was published under the sponsorship of the IACFS/ME and is available at www.iacfsme.org. This pediatric primer was developed to cover the many unique aspects of the diagnosis and management of pediatric ME/CFS.

The published literature on pediatric ME/CFS is modest. Many studies on ME/CFS have only enrolled adults. Where it has been helpful, we have sometimes cited studies in adults, and this is explained in the text. Where published studies are lacking, our recommendations are based on the clinical expertise of experienced medical practitioners.

The text was developed by consensus of the members of International Writing Group for Pediatric ME/CFS, who have made every effort to ensure that the information is accurate and up to date. Statements, opinions, and study results published in this primer are those of the authors and the studies cited. The recommendations contained in any part of this primer do not indicate an exclusive course of treatment or course of action. Nothing contained in this primer should serve as a substitute for the medical judgment of a treating provider.

SUMMARY

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease that affects children and adolescents, as well as adults. The etiology has not been established. While many pediatricians and other health-care providers are aware of ME/CFS, they often lack essential knowledge that is necessary for diagnosis and treatment. Many young patients experience symptoms for years before receiving a diagnosis. This primer, written by the International Writing Group for Pediatric ME/CFS, provides information necessary to understand, diagnose, and manage the symptoms of ME/CFS in children and adolescents.

ME/CFS is characterized by overwhelming fatigue with a substantial loss of physical and mental stamina. Cardinal features are malaise and a worsening of symptoms following minimal physical or mental exertion. These post-exertional symptoms can persist for hours, days, or weeks and are not relieved by rest or sleep. Other symptoms include cognitive problems, unrefreshing or disturbed sleep, generalized or localized pain, lightheadedness, and additional symptoms in multiple organ systems. While many young patients can attend school on a full- or part-time basis, others are unable to advance their education, and can be wheelchair dependent, housebound, or bedbound. Prevalence estimates for pediatric ME/CFS vary from 0.1 to 0.5%.

Because there is no diagnostic test for ME/CFS, diagnosis is purely clinical, based on the history and the exclusion of other fatiguing illnesses by physical examination and medical testing. Coexisting medical conditions, including orthostatic intolerance (OI), are common.

Successful management is based on determining the optimum balance of rest and activity to help prevent post-exertional symptoms worsening. Medications are helpful to treat pain, insomnia, OI and other symptoms.

The published literature on ME/CFS, and specifically that describing the diagnosis and management of pediatric ME/CFS, is very limited. Where published studies are lacking, recommendations are based on the clinical observations and practices of the authors.

1 INTRODUCTION AND OVERVIEW

Pediatric myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease characterized by overwhelming fatigue and a substantial loss of physical and cognitive function. The etiology is uncertain and there is no curative treatment. The cardinal feature is a sensation of feeling ill (malaise) and worsening of symptoms following minimal physical or mental exertion. This post-exertional worsening can persist for hours, days, or weeks, and is not relieved by rest or sleep. Other symptoms include unrefreshing or disturbed sleep, cognitive impairment, and a multitude of immune, neurological, and autonomic symptoms. Orthostatic intolerance (OI) is a common comorbid condition. Significant pathophysiological changes found in ME/CFS show that it is an organic/physical illness. Secondary psychological symptoms can be present in some patients, as occurs in many other chronic illnesses, but psychological factors have not been shown to be the cause.

1:1 NOMENCLATURE

Myalgic Encephalomyelitis (ME) and chronic fatigue syndrome (CFS) were names given to two well-documented cluster outbreaks of a clinically similar illness in London, UK in 1955 and in Nevada, USA in 1984. Several different but overlapping case definitions have been published for ME and for CFS to aid in diagnosing sporadic cases. Research studies tend to use the term CFS because a case definition was written for this purpose (1). The name CFS has been criticized for trivializing the illness (2), and it can be confused with the non-specific term chronic fatigue, which is a common symptom in other illnesses. The World Health Organization classifies ME as a disease of the central nervous system, G93.3 (3).

Less common names for the illness include chronic fatigue immune dysfunction syndrome, myalgic encephalopathy, and neuro-endocrine-immune dysfunction syndrome. In 2015 a new name, systemic exertion intolerance disease (SEID) and a new case definition were suggested (2). Currently the new name is under discussion and the new case definition has not yet been clinically validated. This publication will use the acronym ME/CFS.

Symptoms of ME/CFS sometimes follow an acute illness, such as influenza or infectious mononucleosis (4). If symptoms resolve within 6 months, the term post-infectious fatigue syndrome is used to describe the illness.

1:2 EPIDEMIOLOGY

Myalgic encephalomyelitis/chronic fatigue syndrome is globally endemic. Most cases are sporadic, but cluster outbreaks have occurred worldwide. In several outbreaks, the illness has been prominent in schoolchildren (5, 6). In sporadic cases, the disease is not thought to be transmitted by casual contact. ME/CFS affects all ages, races, and socioeconomic groups. In sporadic ME/CFS, two peak ages of onset are seen, 11–19 years in young patients and 30–39 years in adults (7). Although adolescents are more likely than younger children to have ME/CFS, children as young as 2 years old have developed the illness (5, 8). In adolescents, approximately 3–4 times as many girls as boys

have ME/CFS. There is less data on the sex ratio in younger children.

Estimates of the prevalence of pediatric ME/CFS vary in different studies from 0.1 to 0.5% (9, 10). More than one young person in a family can be affected. Research studies have shown that 84–91% of adult patients who satisfy diagnostic criteria for ME/CFS have not been diagnosed (11, 12). One study with a comparable result has been done in children and adolescents (13).

1:3 PRESENTATION, COURSE OF THE ILLNESS, PROGNOSIS

Myalgic encephalomyelitis/chronic fatigue syndrome can begin suddenly, gradually, or with an abrupt increase in the intensity and frequency of milder chronic symptoms. There can be a history of repeated minor relapsing and remitting prodromal illnesses over the months, or years, preceding the onset. An acute onset of fever and viral-like symptoms is common, and the onset can also be marked by severe orthostatic symptoms. ME/CFS can follow a known illness such as infectious mononucleosis (4). A gradual onset is more common in younger children and can occur over months or years.

While all patients experience a substantial loss of physical and cognitive functioning, there is a wide spectrum of severity. Mildly affected young people might be able to attend school full-time or part-time, but they might have to limit sport and after-school activities and have frequent school absences. ME/CFS has been found to be the most common cause of long-term absence from school (9, 13–16). More severely affected young people can be wheelchair dependent, housebound, or bedbound. The more impaired might even have difficulty participating in home tutoring sessions. In young persons with ME/CFS, overall self-reported quality of life is often lower than in other illnesses such as diabetes, epilepsy, and cystic fibrosis (17, 18).

Symptoms often fluctuate significantly during the day and from day to day. Commonly, patients are slow to get moving upon awakening, with somewhat better function later in the day. Reduced ability to function after activity (physical, cognitive, emotional, orthostatic stress, or academic pressure)—often referred to as “a crash” by patients—with prolonged recovery is a feature. In girls, ME/CFS symptoms are often worse at or just before the menstrual period. The unpredictable level of function from day-to-day can interfere with planning ahead for school attendance, social outings, or family obligations.

The course of ME/CFS is very unpredictable but must often be measured in years, not weeks or months. Remissions and relapses are common. Relapses can be caused by overexertion, infectious illnesses, or failure to recover from a “crash” (see above). Dramatic improvement sometimes occurs in the first 4 years, but slow improvement over time is more likely.

It is generally accepted that young people with ME/CFS have a more favorable prognosis than adults. There have been few studies with sufficient numbers and duration of

severity of symptoms, or age at onset, have not been shown to be reliable predictors of long-term outcomes. In a follow-up study of nearly 700 young people, the average duration of illness of those who report having “recovered” was 4–5 years, with a range from 1 to 15 years. By 5 years, 60% reported recovery, and by 12 years, 88% reported recovery. Of those who reported recovery, about one-third admitted to modifying their activities to remain feeling well (19). Several other studies found that although many patients improved, 20–48% showed no improvement, or actually had worse fatigue and physical impairment at follow-up times ranging from 2 to 13 years (20–22). Even among those who report having completely recovered, many describe persistent symptoms that are not reported by healthy individuals (20).

Feedback from young people indicated that an important determinant of their functioning as adults was the effort made to enable them to remain engaged in education. This might have followed relatively unconventional pathways but it enabled them to remain socially connected, and to feel they were able to achieve their aspirations fully, or in part. From this group, more than 95% were either studying or working part or fulltime (23).

1:4 DIAGNOSIS

No valid, reliable laboratory test that confirms the diagnosis of ME/CFS is currently available. The diagnosis is purely clinical and is based on the patient’s history and the exclusion of other fatiguing illnesses by physical examination and medical testing. Routine blood tests are usually normal. If the typical symptom pattern is not recognized, the diagnosis will be overlooked. The diagnosis depends on the patient’s symptoms meeting the criteria of one of several overlapping case definitions (1, 2, 24–27). Most of the case definitions were developed for adults and they can exclude some young people with ME/CFS. Some case definitions are also quite complex for use in primary care and some do not require the cardinal symptom of post-exertional exacerbation of symptoms to be present. We recommend the diagnostic criteria shown in section 4: “Clinical Diagnosis.”

1:5 ROLE OF THE HEALTH PRACTITIONER IN DIAGNOSIS AND MANAGEMENT

Young people who appear to have ME/CFS should be evaluated by a physician. A comprehensive history, a thorough

are necessary to make the diagnosis and to exclude other fatiguing illnesses. Some patients with an initial diagnosis of ME/CFS are later found to have a different, treatable illness. Comorbid illnesses are common and require appropriate treatment (see section 6: “Comorbid Medical Conditions”).

Establishing a diagnosis frequently provides the patient and parents much relief. Early diagnosis of ME/CFS can lessen the impact of the illness through timely support and intervention. The unequivocal advice for careful avoidance of overexertion can help to both avoid deterioration and facilitate improvement.

Since there is no medication or intervention which will cure ME/CFS, clinical care focuses on managing symptoms and improving function. A management plan might include:

- Educating the patient, the parents, the family, and the school about the illness (e.g., using handouts, see Appendices C–E).
- Guidance on determining the optimum balance of rest and activity to help prevent post-exertional symptom worsening.
- Advice on diet, social interactions, and education.
- The treatment of symptoms with non-pharmacological interventions and/or medications.
- Regular assessment of progress and watchfulness for the emergence of other illnesses.

The chronicity of ME/CFS signifies the need for continuing management and periodic re-evaluation. Regular monitoring can support the young patient and uncover a change of symptoms, or the emergence of a new illness. Young patients can do well when treated in a primary care setting, but given the complexity of this illness, appropriate referral to other health practitioners (preferably those familiar with ME/CFS) is often needed.

The health practitioner has an important role helping to ensure that the young patient receives the most appropriate schooling by educating the young person’s school personnel about the effect of the illness on scholastic performance, and providing appropriate documentation to education authorities.

2 ETIOLOGY AND PATHOPHYSIOLOGY

The underlying etiology of ME/CFS has not been established. Well-documented pathophysiological changes demonstrate that ME/CFS is a multisystem physical disease, not a psychological disorder. The wide variety of pathophysiological findings has led to multiple hypotheses for etiology. These include: infectious agents, immune dysfunction, autoimmune disorders, circulatory abnormalities, neuroendocrine disorders, metabolic disturbances, brain dysfunction, toxins, genetic susceptibility, abnormal gene expression, or a combination of any of these mechanisms.

2:1 ETIOLOGICAL FACTORS

There is evidence that several predisposing and precipitating factors can contribute to the illness, but evidence for perpetuating factors is limited.

PREDISPOSING FACTORS

The prevalence of ME/CFS is 3–4 times higher in adolescent girls than in boys (9, 28). There is less information on the sex ratio in younger children. Genetic factors may produce a susceptibility to the illness in some families. Studies have shown

that in approximately 20% of patients, ME/CFS affects more than one family member and that in 90% of such cases, the affected relatives were genetically related (29). The prevalence of ME/CFS was found to be 5.1% in the offspring of mothers with ME/CFS (29). Another study showed an excess relative risk for developing ME/CFS in first (2.7), second (2.3), and third (1.9) degree relatives (30). Twin studies have shown that the concordance rate for an ME/CFS-like illness was 55% in monozygotic twins and 19% in dizygotic twins (31). Approximately 60% of adolescents with ME/CFS have joint hypermobility, compared to approximately 20% of healthy adolescents (32). The mechanism by which this changes the risk of illness is not understood.

PRECIPITATING FACTORS

Sporadic cases of ME/CFS can be preceded (triggered) by a viral, bacterial, or parasitic infection, an immunization, significant physical or emotional trauma, overexertion, ("overtraining"), chronic sleep deprivation, exposure to a toxin, or an atypical adverse reaction to a medication. In some patients no precipitating factor can be identified.

PERPETUATING FACTORS

It is difficult to determine factors that perpetuate the illness, although it has been suggested that factors that aggravate the illness can also contribute to its persistence. Few studies have investigated this issue. Aggravating factors include failure to diagnose the illness promptly, resulting in poor management in the early stages of the illness; overexertion resulting in "crashes"; stress, inadequate sleep, and comorbid conditions such as OI.

2:2 PATHOPHYSIOLOGICAL BASIS FOR SYMPTOMS

Despite the wide variability in precipitating factors and in pathophysiological findings, there appear to be some common underlying mechanisms behind the most prevalent symptoms.

INFECTION

Although sporadic cases are more common, ME/CFS can also occur in cluster outbreaks, suggesting an important etiologic role for microbial pathogens. This assumption is supported by the common pattern of an abrupt onset in association with flu-like symptoms in many sporadic cases. In the absence of evidence of persistent replication of an infectious agent, the main scientific debate currently centers around whether there is an occult, active persistent infection or whether infectious agents have been cleared, but have triggered chronic symptoms due to a maladaptive host immunologic response.

Pediatric ME/CFS sometimes follows an acute infection, including most prominently Epstein-Barr virus (EBV). After monospot-positive infectious mononucleosis, 13%, 7%, and 4% of adolescents met criteria for ME/CFS at 6, 12, and 24 months after infection, respectively (4). As in adults, the most important factor associated with developing ME/CFS was the severity of the initial illness, as reflected by the number of days spent in bed with acute symptoms (33). Several other

ubiquitous infectious agents or their antibodies have been found in patients with ME/CFS and their presence can influence symptom severity. Although individual cases of ME/CFS have been identified in association with *B. burgdorferi*, cytomegalovirus, human herpesvirus 6, Coxsackie virus, enterovirus, adenovirus, or parvovirus B19, a large Norwegian pediatric study did not identify a prominent etiologic role for any of these organisms (34).

Some studies in adult patients with ME/CFS report benefit from anti-viral treatment, suggestive of a viral pathophysiology, but other studies have not confirmed the efficacy of anti-viral treatment (35–37). We are not aware of studies of anti-viral agents in young patients.

IMMUNE DYSFUNCTION

Another prominent theory is that ME/CFS symptoms can be a consequence of a prolonged immunologic host response to infection. A limited number of immunological studies have been performed in pediatric patients. Studies in adults show immune system changes that are often inconsistent and tend to wax and wane over time (38). The most consistent immune responses are immune activation, defective cell-mediated immunity, decreased natural killer cell (NK) cytotoxic activity that correlates with the severity of the illness (39, 40), and the occasional finding of low levels of autoantibodies including rheumatoid factor, anti-thyroid antibodies, anti-gliadin, anti-smooth muscle antibodies, and cold agglutinins in some patients. These immune responses are not unique to ME/CFS.

In pediatric patients, evidence of poor NK cell function is less robust than in adults (41), but few studies have been performed. Individual studies have reported cutaneous anergy (42), increased prevalence of autoantibodies (41), a beneficial response to intravenous immunoglobulin (IVIG) (42), increased rates of apoptosis in peripheral white blood cells (43), and abnormal T-cell inhibitory or proliferative responses to stimuli (44). Although one small study showed elevations or reductions in some cytokine populations (45), a larger investigation found no evidence of cytokine abnormalities (46). Very little research has been devoted to whether allergies, food intolerance, or mast cell activation play a contributing role in the pathophysiology of ME/CFS symptoms.

A small randomized trial in adults demonstrated improvement in ME/CFS symptoms after rituximab-mediated B-cell depletion (47). There have been no pediatric studies.

CIRCULATORY ABNORMALITIES

Lightheadedness is very common in pediatric ME/CFS, and prolonged upright posture can aggravate other symptoms, including fatigue, headache, nausea, and cognitive dysfunction (48–50). Controlled studies have shown a higher prevalence of postural tachycardia syndrome (POTS) and neurally mediated hypotension (NMH) in pediatric patients with ME/CFS (49, 51–55). More work is needed to define the causes of NMH and POTS. Both can follow infectious illnesses, and themselves can be secondary to autoimmune phenomena. Other circulatory abnormalities in pediatric ME/CFS include a delayed recovery of cerebral oxygenation

after a brief period of standing compared to healthy controls (54), and the demonstration that cognitive problems are exacerbated by orthostatic stress (50, 56).

Low blood volume has also been found in some adult patients with ME/CFS (57–60). The initiation of treatments directed at OI can sometimes relieve ME/CFS symptoms in pediatric as well as adult patients (section 6:1, Orthostatic Intolerance).

NEUROENDOCRINE ABNORMALITIES

The similarity in symptoms between ME/CFS and adrenal insufficiency has prompted investigation into abnormal hypothalamic-pituitary-adrenal axis function in both adults and adolescents. Several (albeit not all) pediatric ME/CFS studies have identified statistically lower cortisol levels and urine cortisol: creatinine values in ME/CFS patients compared to healthy controls (34, 44, 61–63). However, cortisol values in those with ME/CFS are still within the normal range, raising questions regarding the clinical relevance of these findings. Treating ME/CFS with supplemental cortisol brings only modest clinical benefits, and in adult studies is associated with the development of potentially life-threatening adrenal insufficiency (64).

METABOLIC ABNORMALITIES

Profound exhaustion and post-exertional worsening of symptoms are hallmarks of ME/CFS. Adult studies have shown impaired oxygen consumption during exercise and activation of anaerobic metabolic pathways in the early stages of exercise (75, 76). When exercise testing is conducted on two consecutive days, there is a decline in exercise performance and an abnormal recovery response (decline in VO₂ max) on the second day (77, 78). In single day pediatric exercise studies, those with CFS exercised less efficiently than controls who had recovered from mononucleosis, but significant differences in peak work capacity were not found (79).

These findings in adults, together with increased ventricular lactate have led to the hypothesis that ME/CFS symp-

toms might be due to a problem in mitochondrial bioenergetics and ATP production (80, 81). Thus far, the exact role of mitochondrial dysfunction in ME/CFS has not been clearly established.

BRAIN IMAGING ABNORMALITIES

The high prevalence of cognitive dysfunction has focused attention on the hypothesis that abnormalities in the central nervous system are important in the pathophysiology of ME/CFS. Using several brain imaging techniques, some small studies in adults have shown a variety of differences between ME/CFS patients and controls including increased activation of microglia or astrocytes (65), volume loss in white and gray matter (66, 67), reductions in absolute cerebral blood flow (68), and increased ventricular lactate (69, 70). Both pediatric and adult studies have shown that patients activate a wider distribution of neural resources to perform a specific cognitive task (71–73). Improving brain blood flow improves cognitive performance in those with ME/CFS (74).

GENE STUDIES

Studies in adult patients with ME/CFS have shown alterations in the expression of genes controlling immune modulation, oxidative stress and apoptosis. Several subtypes were reported, and the presence of some of these subtypes correlated with symptom severity (82, 83). Moderate exercise increased the expression of sensory, adrenergic, and immune genes in patients with ME/CFS, but not in controls (83). Epigenetic differences between those with ME/CFS and healthy controls have recently been described (84).

The prevailing theories related to pathophysiological mechanisms are not necessarily mutually exclusive. Circulatory dysfunction, for example, can be caused by infections and immune mechanisms, and in turn can have effects on inflammation, oxygen delivery to cells, and microglial activation. A more complete discussion of the potential pathophysiological mechanisms of ME/CFS symptoms is beyond the scope of this primer.

3 ADOLESCENT DEVELOPMENT

Puberty is defined as the time when a young person's body, feelings, and relationships change from those of a child into those of an adult. Changes occurring in the young person's body include a growth spurt, enlargement of the genitalia, development of androgen hair, and the onset of sexual functions including ejaculation or menses. Striking emotional and psychological changes occur. Puberty is a time of significant development of self-awareness, abstract thinking, increased sensitivity, and mood changes.

ME/CFS preceding puberty can impact the development of both the physical, pubertal changes and the young person's emotional state and self-image. There can be delay or accel-

eration of pubertal changes or alteration of physiological processes including hypofunction or, less commonly, hyperfunction of the neuroendocrine system. The development of ME/CFS following puberty can be associated with a delay in normal psychological development fostered by social isolation. Cessation of menstruation can also occur and this can be of great concern to the patient.

Puberty, with its physiological changes, can also significantly exacerbate pre-existing ME/CFS symptoms. The risk of developing ME/CFS increases after puberty especially in females compared to males. The post-pubertal F:M sex ratio is 3–4:1.

4 CLINICAL DIAGNOSIS

The diagnosis of ME/CFS is based on a careful clinical history, recognition of the pattern of symptoms, and the exclusion of other illnesses that might explain the symptom complex. Currently, there is no valid, reliable laboratory test that confirms the diagnosis. Moreover, although the physical examination is often not entirely normal, there are no specific diagnostic clinical signs and frequently the patient does not look ill. The diagnosis is often overlooked or delayed and is sometimes made retrospectively when the child is older.

Several varied clinical criteria are currently used to diagnose ME/CFS in children and adolescents. None have been clinically validated in formal studies. The 1994 Fukuda case definition (1), see Appendix A, is often used, but was designed for research purposes in adults and can exclude some young patients with ME/CFS and include others who are later found to have another illness (27). The 2003 Canadian clinical case definition (CCC) (24) is widely used in adults because it emphasizes the core symptoms of the illness. A pediatric case definition based on the CCC was published in 2006 (27). The latter is somewhat complex for use in clinical practice. The following diagnostic criteria are offered by our experienced clinicians and are based on their collective experience and insight. The criteria provide useful diagnostic sensitivity within a heterogeneous pediatric ME/CFS patient population. A symptom severity scoring system is included to increase the specificity of the diagnostic criteria.

ME/CFS is characterized by numerous symptoms in multiple body systems, but its diagnosis requires only the presence of a group of specific core symptoms.

- The cardinal feature of ME/CFS is malaise and the exacerbation of symptoms after a variety of forms of effort (most commonly physical or cognitive activity or orthostatic stress). Post-exertional symptoms can persist for hours, days, or weeks and are not relieved by rest. This symptom is uncommon in other illnesses.
- Other core symptoms are impaired physical and cognitive function, fatigue, sleep disturbance, cognitive symptoms, and pain.
- Some or all symptoms are present every day (symptoms often fluctuate significantly in intensity during the day or from day to day).
- Symptoms are mostly moderate to severe.
- Symptoms have persisted or recurred for at least 6 months (a provisional diagnosis and appropriate management can be instituted before 6 months).
- Other fatiguing illnesses must be excluded by history, physical examination, and medical testing.

Additional symptoms can be present in multiple organ systems. Those that are commoner in young patients include:

(a) orthostatic intolerance (OI): prolonged upright posture can induce symptoms such as lightheadedness, increased fatigue, cognitive worsening, headaches, and nausea; postural tachycardia syndrome (POTS), neurally mediated hypotension (NMH), or both, are often present;

- (b) hypersensitivities to light, noise, touch, odors, or medications;
- (c) thermoregulatory imbalance including low body temperature, intolerance to heat and cold, and cold hands and feet;
- (d) gastrointestinal symptoms such as abdominal pain, nausea, and anorexia;
- (e) worsening of fatigue in the days before and during the onset of menses can occur in young women;
- (f) other comorbid conditions can be present and are discussed in detail in section 6 “Comorbid Medical Conditions.”

The diagnostic criteria are set out as a **Clinical Diagnostic Worksheet** which can be used in clinical practice. The worksheet can also be completed at follow-up visits to confirm the diagnosis, or to track progress. The pattern of ME/CFS symptoms is distinctive and the diagnosis can easily be made in most cases, but there can be some diagnostic challenges. Younger children, especially those under 10 years of age, might not report symptoms accurately. They might not remember having experienced full health and might assume tiredness is normal. The first sign of the illness might be the child’s marked limitation of physical or mental activity, noticed by a parent or a teacher. Young patients with ME/CFS might not necessarily recognize that they have symptoms such as cognitive problems or malaise until their health has improved. Some patients might not consider themselves as having post-exertional symptoms because they have learned to pace their activities. Symptoms of ME/CFS wax and wane over time. Some patients might report that one particular symptom was present previously, but has improved by the time of the clinic visit. Symptoms that persist are more easily recalled.

4:1 PATIENT HISTORY

It is critical to allocate enough time for a careful, comprehensive history to be taken from the patient and the parents. The history is not only vital to diagnosis, but also taking the history in a thorough and empathetic manner engenders the trust of the patient and family, shows that the clinician takes the patient’s illness seriously, and is an important prelude to management. Teenagers usually need an opportunity for discussion without a parent present. The initial evaluation might require more than one office visit because the history is sometimes lengthy and the patient might lack sufficient stamina. Some patients might need to lie down during office visits. For other more severely affected patients, an office visit might be impossible, and they require home visits.

The clinician might find it helpful to first ask the patient to list current symptoms in order of severity so as to get a sense of the areas that will need to be explored. It is important to ask the patient and the parents what their major concerns are. This can be an opportunity to correct misinterpretations, e.g., “I think I might have cancer.” Then the history requires attention to the full range of defining symptoms of ME/CFS, recording both frequency and severity.

PEDIATRIC ME/CFS: CLINICAL DIAGNOSTIC WORKSHEET

Name _____ Age _____ Date _____

CRITERIA FOR THE DIAGNOSIS OF ME/CFS IN CHILDREN AND ADOLESCENTS:

- Impaired function, post-exertional symptoms, fatigue, sleep disturbance, neurocognitive problems and pain.
- Some or all symptoms are present every day (symptoms often fluctuate significantly in intensity during the day or from day to day).
- The symptoms are mostly moderate to severe.
- Symptoms have persisted or recurred for at least six months (a provisional diagnosis and appropriate management can be instituted before six months).
- Other fatiguing illnesses have been excluded by history, physical examination and medical testing.

HAVE THE FOLLOWING SYMPTOMS PERSISTED OR RECURRED DURING THE PAST SIX MONTHS?	PRESENT	SYMPTOM SEVERITY IN THE PAST MONTH: ABSENT – 0 MILD – 1 MODERATE – 2 SEVERE – 3
1. Impaired function: There is loss of mental and/or physical stamina and a substantial reduction in ability to take part in personal, educational, or social activities.	Yes <input type="checkbox"/> No <input type="checkbox"/>	
2. Post-exertional symptoms: Normal activity or mild/moderate exertion is followed by worsening of malaise, fatigue, and other symptoms. Recovery takes more than 24 hrs.	Yes <input type="checkbox"/> No <input type="checkbox"/>	
3. Fatigue: The fatigue is not the result of ongoing exertion, is not relieved by rest and is medically unexplained. Fatigue can worsen with prolonged upright posture.	Yes <input type="checkbox"/> No <input type="checkbox"/>	
4. Sleep problems: Sleep is unrefreshing, with disturbed quantity or rhythm that can include daytime hypersomnia, nighttime insomnia, day/night reversal.	Yes <input type="checkbox"/> No <input type="checkbox"/>	
5. Cognitive problems: Any of the following: difficulty in concentration or focusing, difficulty understanding information or expressing thoughts, difficulty finding words or numbers, impaired short-term memory, absent mindedness, slowness of thought. Cognitive problems can be provoked by, or worsen with, prolonged upright posture or physical or mental activity. Some patients do not recognize these problems, but they might be noticed by a parent or teacher.	Yes <input type="checkbox"/> No <input type="checkbox"/>	
6. Pain: Can be widespread or localized; commonly seen are: chronic daily headaches, myalgias, abdominal pain, joint pains, sore throats, painful lymph nodes. Pain can be worsened by prolonged upright posture. Rarely is pain absent.	Yes <input type="checkbox"/> No <input type="checkbox"/>	
TOTAL SYMPTOM SEVERITY SCORE:		

OTHER SYMPTOMS PRESENT IN MANY, BUT NOT ALL, PEDIATRIC PATIENTS WITH ME/CFS:

Orthostatic intolerance: prolonged upright posture can induce symptoms that can include lightheadedness, increased fatigue, cognitive worsening, headaches, or nausea. Postural tachycardia syndrome (POTS), neurally mediated hypotension (NMH), or both are often present.

Hypersensitivities: to light, noise, touch, odors, medications

Thermoregulatory imbalance: low body temperature, intolerance to heat and cold, and cold hands and feet

Gastrointestinal symptoms: abdominal pain, nausea, and anorexia

TO DIAGNOSE ME/CFS:

- Symptom criteria 1, 2 and 3 are present together with at least two of criteria 4, 5 and 6 Yes ☐ No ☐
- Symptoms are present for six months and some or all symptoms are present daily Yes ☐ No ☐
- No alternative diagnosis found from the history, physical examination and medical testing Yes ☐ No ☐
- Symptom severity score: 0-4 ME/CFS unlikely; 5-12 mild/moderate ME/CFS; 13-18 moderate/severe ME/CFS Yes ☐ No ☐

☐ Patient meets criteria for ME/CFS.

☐ Full criteria not met. Patient should be monitored and symptoms should be managed.

Information about diet, sleep patterns, depressed mood, anxiety, school performance, relationships with family and friends, drug use, and family and developmental history needs to be obtained. The family history might reveal siblings or other family members with ME/CFS symptoms and there is also a higher prevalence of disorders such as fibromyalgia, joint hypermobility, syncope, temporomandibular joint dysfunction, anxiety, and irritable bowel disease.

To assess function, ask about what happens when the young person tries to do activities that were previously tolerated, and about activities that the individual must now limit or avoid. This can indicate very significant life changes and losses experienced by the patient.

Frequent monitoring of the patient once every 1–3 months, depending on the level of illness severity, is important. Young patients who are ill appreciate continuing care. Functional improvement can be judged by determining how much activity generates post-exertional worsening of symptoms. Progress should be measured over time, rather than at a single clinic visit. In patients who are improving, fatigue is often the last symptom to resolve, since young patients often prefer to increase their activities and tolerate the resulting fatigue. The practitioner must be alert for the emergence of new symptoms. They might not be related to ME/CFS, but due to another illness.

4:2 PHYSICAL EXAMINATION

A thorough physical examination, including a neurological exam, is important to exclude other causes of fatigue. Physical signs in ME/CFS are subtle and none are diagnostic. Many patients do not look ill, but noticeable facial pallor is sometimes apparent and often precedes the onset of extreme tiredness in the patient. The pallor can be associated with suborbital dark shadows. The pharynx can show nonexudative pharyngitis, and cervical and axillary lymph nodes might be palpable and tender. Muscle tenderness is a feature of comorbid juvenile fibromyalgia. Fibromyalgia is less common in children with ME/CFS than in adults.

The hands and feet can be unusually cold and dependent rubor of the legs is often present when standing or sitting. The physical exam should include an assessment for common comorbid conditions such as OI [heart rate (HR) and blood pressure (BP) sitting and standing], joint hypermobility, and postural dysfunctions (see section 6, “Comorbid Medical Conditions”).

At illness onset, pyrexia can be present and this can persist for some weeks. If fever is present several months into the illness, other causes of fever should be sought. In established cases, slightly subnormal temperature, 96.8–98.0°F (36.0–36.7°C), is common. Some children with ME/CFS have higher resting HRs than expected and occasional patients have resting hypotension. More commonly, HR and BP abnormalities emerge in response to upright posture. The diagnosis and management of orthostatic problems is discussed in section 6: “Comorbid Medical Conditions.”

4:3 LABORATORY TESTING

Basic laboratory studies (**Table 1**) should be performed to identify other causes of fatigue and any organ system dysfunction. Most routine laboratory tests are within the normal range, and do not correlate with overall function, even in the presence of substantial debilitation. Measures of iron stores, vitamin B 12 level, and screening for celiac disease are recommended because of their subtle or absent manifestations on physical examination.

Additional testing (**Table 2**) is based on history, examination and laboratory findings. For example, a search for infections such as Lyme disease depends on the symptoms and on whether the young patient resides in, or has traveled to, endemic areas. Serology for some infectious illnesses can be weakly positive. Although standard serology for EBV and CMV can help with categorizing whether the illness might have been initiated by these organisms, these test results usually do not change management. MRIs of the brain and spine are not routinely indicated, but clearly are important if there are abnormal neurological signs.

TABLE 1. INVESTIGATION OF ME/CFS: ROUTINE LABORATORY TESTING

<ul style="list-style-type: none"> • Complete blood count with differential • Erythrocyte sedimentation rate • Electrolytes • Calcium • Phosphate • Fasting glucose • C-reactive protein • Liver function: bilirubin, alkaline phosphatase, gamma glutamyl transaminase, alanine transaminase, aspartate transaminase • Total protein and albumin/globulin ratio 	<ul style="list-style-type: none"> • Renal function: urea, creatinine, glomerular filtration rate • Thyroid function: thyroid stimulating hormone, free thyroxine (free T4) • Antinuclear antibodies • Iron studies: serum iron and transferrin or ferritin • Vitamin B 12 and folate • Vitamin D3, 25-hydroxy cholecalciferol • Celiac screening: tissue transglutaminase IgA and IgG, with serum IgA • Urinalysis
---	---

TABLE 2. INVESTIGATION OF ME/CFS: TESTS TO BE CONSIDERED WHEN INDICATED

- Allergic: skin tests, RAST tests, serum tryptase
- Cardiac: chest x-ray, EKG (ECG), echocardiogram in those with heart murmurs, tilt testing for those with prominent orthostatic symptoms, but no hemodynamic abnormalities in the office 10-minute standing test
- Endocrine/metabolic: morning cortisol, FSH, LH, estradiol, testosterone, prolactin, lactate, pyruvate, IGF-1 and IGF-3, thyroid autoantibodies
- Gastrointestinal: upper GI endoscopy, colonoscopy, gastric emptying study, HIDA scan, ultrasound of gallbladder
- Gynecological: ultrasound, laparoscopy, ovarian venogram (to evaluate for ovarian varices)
- Immunological: anti-double stranded DNA, antineutrophil cytoplasmic antibodies (ANCA), quantitative immunoglobulins, functional antibodies, response to pneumococcal vaccination
- Infectious diseases: Infectious mononucleosis, Lyme and other tick-borne diseases (*Babesia microti*, *Anaplasma phagocytophilum*, *Ehrlichia chaffeensis*) in endemic areas
- Neurological: MRI studies if Chiari malformation, cervical stenosis, tethered spinal cord, or MS are suspected
- Pulmonary: pulmonary function tests
- Sleep: polysomnography, multiple sleep latency testing
- Urological: cystoscopy

4:4 DIFFERENTIAL DIAGNOSIS, EXCLUSIONARY MEDICAL CONDITIONS

Myalgic encephalomyelitis/chronic fatigue syndrome should not be diagnosed if the patient has an identifiable medical or primary psychiatric condition that could plausibly account for the presenting symptoms. If ME/CFS symptoms persist after adequate treatment of other confounding illnesses, a diagnosis of ME/CFS can be considered.

Fatigue is an early symptom in many medical conditions and can be present before the appearance of the diagnostic

features of the underlying illness. Careful follow-up over time is needed in order to identify illnesses that might mimic ME/CFS in their early stages. The presence of post-exertional malaise and exacerbation of symptoms after increased cognitive or physical effort increases the likelihood that ME/CFS is the correct diagnosis. The more common conditions in the differential diagnosis are shown in **Table 3**. For a more comprehensive list of the less common disorders in the differential diagnosis, see Appendix B. If there is diagnostic uncertainty and referral is necessary, it should preferably be to a specialist familiar with ME/CFS.

TABLE 3. COMMON CONDITIONS IN THE DIFFERENTIAL DIAGNOSIS

- | | |
|--|---|
| <ul style="list-style-type: none"> • Adrenal insufficiency • Athletic overtraining syndrome • Bowel disorders: celiac disease, inflammatory bowel disease, eosinophilic gastroenteritis • Chiari malformation or cervical spine stenosis • Lyme disease and other tick-borne infections • Major depression | <ul style="list-style-type: none"> • Narcolepsy • Obstructive or central apnea • Post-concussion syndrome • Severe anemias • SLE and similar autoimmune conditions • Untreated hypo- or hyperthyroidism |
|--|---|

4:5 COEXISTING MEDICAL CONDITIONS

A number of non exclusionary conditions can coexist with ME/CFS (**Table 4**). If present, coexisting conditions should be evaluated independently and treated appropriately. Some coexisting medical conditions that are often seen in young patients with ME/CFS and significantly reduce the patient's functional capacity are discussed in more detail in section 6: "Comorbid Medical Conditions."

4:6 COGNITIVE IMPAIRMENT

Cognitive deficits (sometimes called "brain fog") are some of the most functionally disabling symptoms of ME/CFS. They are of great concern to children and adolescents because they impact their ability to learn and attend school (section 8, The School System). Cognitive impairments are similar in both adult and young patients with ME/CFS. Slow mental processing speed, impaired working memory, poor learning of new information, difficulty with word retrieval,

increased distractibility, decreased concentration and attention span, and inability to multitask may be found (85–87).

The severity of cognitive problems fluctuates together with disease activity both during the day and from day to day. Cognitive deficits can be related to abnormal neurological pathophysiology and reduced cerebral blood flow (see Etiology and Pathophysiology).

Any form of mental activity can be followed by diminished cognitive functioning as well as other post-exertional symptoms in a manner similar to the exacerbation following physical exertion. Cognitive symptoms can also be aggravated by a multitude of other factors including pain (especially headaches), poor sleep, prolonged upright posture, a noisy classroom, eye fatigue from staring at a computer screen for too long, carrying heavy books around school, and social interactions. Young patients might be motivated to keep up with their peers and push themselves mentally, physically, and

socially beyond their comfort zone, and suffer cognitive consequences. Cognitive problems can also be exacerbated by the stress of living with a chronic, often undiagnosed illness

(section 4: Psychological Reactions Secondary to ME/CFS: Distinction from Depression and Anxiety Disorders.)

TABLE 4. NON-EXCLUSIONARY OVERLAPPING CONDITIONS

Autoimmune Sicca syndrome	Gastrointestinal Eosinophilic esophagitis Gastroesophageal reflux GI motility disturbances IgE-mediated food allergy Non-IgE-mediated milk protein or other food protein hypersensitivity Irritable bowel syndrome Lactose/fructose intolerance Celiac artery compression/MALS	Neurological Chiari 1 malformation Hypersensitivity to light, touch, sound, odors, medicines Migraines Thoracic outlet syndrome
Cardiovascular Autonomic dysfunction Mitral valve prolapse Orthostatic intolerance Neurally mediated hypotension (NMH) Postural tachycardia syndrome (POTS) Delayed orthostatic hypotension or tachycardia	Gynecological Dysmenorrhea Endometriosis Pelvic congestion syndrome/ pelvic venous incompetence Premenstrual syndrome/ dysphoric disorder Vulvodynia	Respiratory Allergic rhinitis Asthma Chronic sinusitis
Endocrine/metabolic Hypoglycemia Insulin resistance Metabolic syndrome Polycystic ovary syndrome Severe obesity	Hematological Iron deficiency Mast cell activation disorder	Rheumatological Joint hypermobility syndrome Juvenile fibromyalgia Myofascial pain syndrome Ehlers-Danlos syndrome Temporomandibular joint disease
		Sleep disorders Periodic limb movement disorder Restless leg syndrome
		Urinary Interstitial cystitis

4:7 PSYCHOLOGICAL REACTIONS SECONDARY TO ME/CFS: DISTINCTION FROM DEPRESSION AND ANXIETY DISORDERS

Studies focusing on psychological problems in pediatric ME/CFS patients are limited. In this section, available studies have been supplemented by the insights of our experienced clinicians. It is important to distinguish: (a) normal emotional reactions to ME/CFS from (b) clinically significant psychiatric symptoms such as depression or anxiety secondary to ME/CFS and from (c) a primary psychiatric illness such as Major Depressive Disorder (MDD) or an anxiety disorder without coexisting ME/CFS.

POTENTIAL EMOTIONAL RESPONSES TO A CHRONIC ILLNESS

Emotional responses to the difficulties of ME/CFS are common. These responses are similar to the responses of young patients with other chronic illnesses. Grief and anger can arise over illness-related losses, from negative responses to the illness from family members, friends and school staff, and from the pervasive stigmatization of this particular illness. Apprehension commonly follows the onset of an illness that can be undiagnosed and about which there is generally ignorance. There can be frustration with the inability to do things that were easily done beforehand. Outbursts of weeping can stem from excessive tiredness or from feeling overwhelmed. Emotional distress can also occur because of disbelief by others regarding the reality of

the illness, or because of the prescription of inappropriate remedies by health-care providers.

Some young patients despair of medical care and plead to decline hospital admission due to previously experiencing the hostile and disbelieving attitudes of some health care providers or the exacerbation of their illness by increased hospital-related activity and the noisy environment. These emotional responses to the illness do not ordinarily rise to the level of a psychiatric disorder, but occasionally, psychiatric symptoms are more severe, and a clinically diagnosable, psychiatric disorder can coexist with ME/CFS.

IDENTIFYING CLINICALLY SIGNIFICANT DEPRESSION AND ANXIETY COEXISTING WITH ME/CFS

The most common secondary psychiatric symptoms are depression and anxiety. These symptoms can be present together in the young patient. Clinically significant depression and anxiety can be uncovered by clinical evaluation and the use of standardized questionnaires. Occasionally, depression or anxiety predate the onset of the illness, but distinctive, abnormal, pre-illness personality characteristics have not been identified in young patients with ME/CFS.

Identifying psychological disorders in younger children can be difficult. They might not manifest depressed mood, as they might not be developmentally able to sense and verbalize their moods. Rather, they might show behavioral symptoms such as irritability, low frustration tolerance, tantrums, somatic complaints, or withdrawal.

Many young patients with ME/CFS are miserable and discouraged (fed up) by being ill, but are not necessarily depressed. There is a higher incidence of clinical depression when the young patient has encountered disbelief in the reality of the illness.

In otherwise healthy young people, approximately 2% of children and 4–8% of adolescents have a diagnosable, major depressive disorder (MDD). Less severe episodes of depression can be seen in another 5–10% of children and adolescents. In adolescents, twice as many females as males meet criteria for depression. In one large study of ~400 patients with ME/CFS, 25% had clinical depression using the Beck scale, while the baseline level of depression in the adolescent population was 20% (88).

Raised apprehension levels are a common response to illness. Anxiety secondary to ME/CFS can arise with the illness onset and persist because the illness affects all aspects of the young person's life. Clinical observation suggests that the incidence of panic attacks might be higher in young patients with ME/CFS than in a normal population of teenagers. Clinical observation has also shown a higher degree of anxiety in patients with comorbid OI and joint hypermobility. It is postulated that the anxiety might be associated with raised levels of catecholamines and reduced brain blood flow in these conditions.

DIFFERENTIATING ME/CFS FROM PRIMARY PSYCHIATRIC DISORDERS WITHOUT COEXISTING ME/CFS

This can be challenging. Symptoms common to both ME/CFS and psychiatric illness include fatigue, change in activity levels, reluctance to engage in social activities, difficulty sleeping, poor memory and concentration, appetite/weight changes, and absence from school.

Some features distinguishing ME/CFS from primary psychiatric illnesses are shown in **Table 5**. In patients with ME/CFS, long-lasting, post-exertional exacerbation of fatigue and other symptoms can follow mild exertion or even normal activity, whereas patients with major depression or anxiety often feel better after increased activity, exercise, or mental effort. OI, hypersensitivities to light, noise and medications and/or low body temperature, and intolerance to heat and cold are typical of ME/CFS, but not typical of psychiatric illnesses. Young women with ME/CFS often experience greater premenstrual mood lability.

Most teenagers with ME/CFS are highly motivated to recover and return to their previous lives. They generally have a strong desire to be more active, but cannot tolerate the necessary exertion. In contrast, patients with major depression do not have the desire to be more active but could be.

Adolescents with MDD show depressed mood, a sense of worthlessness or guilt, low self-esteem, loss of interest in socializing in previously enjoyable circumstances (anhedonia), and a lack of interest in the future. Although these are typical symptoms of MDD, some young people with ME/CFS (but without comorbid depressive illness) might also feel guilty because their illness has disrupted their family, and a parent might have had to give up work to care for them. They might

also be reluctant to make plans to socialize, because they know from past experience that they might find themselves at the time of the event to be too ill to participate, have to cancel, and let down their friends. Anhedonia has not been reported in ME/CFS unless MDD was also present. Young people with ME/CFS often take much pleasure in previous activities, even if the activities exceed their energy reserves and cause subsequent symptom exacerbation.

In young people with MDD, suicidal thoughts and suicide attempts can occur, more so in adolescents than in younger children. If suicidal thoughts are present, a suicide evaluation should be done and referral to a child psychiatrist is often helpful. Suicidal thoughts are only seen in ME/CFS when MDD is also present.

ME/CFS has a significant impact on a young patient's parents and siblings. This impact of the illness on family members can have a secondary effect on the patient (section 7:2, Impact of ME/CFS on the Family). Psychiatric symptoms persisting during the recovery phase of ME/CFS can make it difficult to determine whether the patient's limitations are due to ME/CFS or due to associated psychiatric illness.

4:8. PSYCHIATRIC ILLNESSES THAT MAY BE MISDIAGNOSED IN YOUNG PATIENTS WITH ME/CFS

Lack of familiarity with the clinical diagnostic features of ME/CFS and skepticism about its existence has often resulted in a misdiagnosis with one of the following conditions:

- Factitious disorder by proxy (Munchausen syndrome by proxy, fabricated or induced illness) (FDP/MSBP)
- School refusal (school phobia)
- Pervasive refusal syndrome (PRS)
- Somatoform disorder

FACTITIOUS DISORDER BY PROXY (MUNCHAUSEN'S SYNDROME BY PROXY, FABRICATED OR INDUCED ILLNESS)

In cases of FDP/MSBP, the perpetrator, usually the mother, induces illness in the victim who is often her very young child. (The average age of patients with FDP/MSBP is 4 years old and 50% of patients are <2 years old (89)). Such cases are extremely rare. Most pediatricians only see 1–2 cases in their whole professional careers. FDP/MSBP can be difficult to diagnose but it is a diagnosis that needs to be made, as it is a form of child abuse and can result in the death of the child.

FDP/MSBP is sometimes falsely diagnosed in young persons with ME/CFS. A report in the press showed that of 143 young persons diagnosed with ME/CFS, but alleged to be victims of FDP/MSBP, who were assisted by a charity, none were found to be cases of FDP/MSBP (90).

Thus, the treating physician might need to firmly establish the diagnosis of ME/CFS and show how ME/CFS differs from MSBP/ FDP. Some distinguishing features are shown in **Table 6** (89).

TABLE 5. SYMPTOM COMPARISON BETWEEN DEPRESSION/ANXIETY DISORDERS AND ME/CFS IN CHILDREN AND ADOLESCENTS

SYMPTOMS	DEPRESSION/ ANXIETY DISORDERS	ME/CFS	COMMENTS
Fatigue, lack of energy, difficulty sleeping, cognitive problems, weight gain or loss	Yes	Yes	These symptoms occur in both conditions. In ME/CFS, fatigue tends to fluctuate during the day and from day to day.
Absence from school	Yes	Yes	ME/CFS is the most common medical cause of prolonged absence from school.
Depression, feeling sad for no apparent reason	Yes	Sometimes	Young patients with ME/CFS might be sad, discouraged and fed up. Clinical depression is more likely in those who encounter disbelief in the reality of their illness.
Anxiety	Yes	Sometimes	In young patients with ME/CFS, anxiety can be associated with having an undiagnosed illness, ignorance about ME/CFS, and/or skepticism about the reality of the illness from family members, physicians, or staff at school. Panic attacks are occasionally seen. There is a higher degree of anxiety in young patients with comorbid orthostatic intolerance and joint hypermobility.
Feelings of worthlessness, guilt, low self esteem	Yes	No	Occasionally, young patients with ME/CFS feel guilty because the illness has caused family disruption. These feelings are secondary to the illness.
Anhedonia (lack of interest and/or pleasure in activities previously enjoyed)	Yes	No	Young patients with ME/CFS often wish to engage in previous activities but are physically unable to do so. They might still enjoy, previous activities even when the activities exceed their energy limits. Patients with depressive illness do not wish to engage in, or enjoy previous activities, but are physically able to do so.
Severe depression with suicidal thinking	Yes	No	Severe depression with suicidal thinking is not present in ME/CFS without comorbid major depressive disorder.
Lack of interest in friendships/relationships	Yes	No	Young patients with ME/CFS often want to socialize, but are physically and cognitively unable to do so. Patients with depressive illness often do not wish to socialize.
Post-exertional symptom worsening	No	Yes	This is a hallmark of ME/CFS. Patients with depression/anxiety often feel better after exertion.
Orthostatic intolerance	Occasionally	Sometimes	Much more common in young patients with ME/CFS.
Hypersensitivities to light, noise, odors, medications	No	Sometimes	Common in young patients with ME/CFS. Can contribute to feeling anxious and overwhelmed.
Difficulty with thermoregulation, low body temperature, intolerance to heat and cold	No	Sometimes	Common in young patients with ME/CFS.

During history-taking, the parents sometimes refuse permission for the clinician to speak to the young person without a parent being present. The young patient and parents might have had previous unhappy, or unhelpful experiences, with other professionals. Similarly, a young person with ME/CFS may turn to her/his parents when being questioned. This is a natural response in an ill child who has

cognitive dysfunction or is exhausted. These behaviors by themselves do not support a diagnosis of FDP/MSBP. Suspicion of FDP/MSBP can result in referral to child protection services (CPS). Young persons with ME/CFS placed in CPS do not fare well. When separated from their parents and sent to live with foster parents or admitted to psychiatric institutions, their ME/CFS symptoms have often worsened.

TABLE 6. COMPARISON BETWEEN ME/CFS AND FACTITIOUS DISORDER/MUNCHHAUSEN'S SYNDROME BY PROXY/FABRICATED OR INDUCED ILLNESS

	PEDIATRIC ME/CFS	FACTITIOUS DISORDER BY PROXY*
Prevalence	Approximately 100-500 per 100,000	Very rare, approximately 0.4-2 per 100,000
Age and age range	Peak age 10-17 years, range 2-17 years	Average age 4 years; > 50% of patients are aged < 2 years; extremely rare in adolescents
Symptoms	Consistent pattern of symptoms: reduction in activity, post-exertional worsening of symptoms, fatigue and loss of stamina, unrefreshing sleep, cognitive problems, orthostatic intolerance, headaches. History of surgeries is uncommon.	No consistent symptoms. Most frequently reported are: apnea/cyanosis, anorexia/feeding problems, diarrhea, seizures, asthma, allergy, fevers, behavioral problems, and other sometimes bizarre symptoms. History of surgeries is common.
Clinical signs	Intermittent conspicuous facial pallor, acrocyanosis, joint hypermobility is common, blood pressure can fall or heart rate rise on prolonged standing.	No consistent clinical signs, many patients have multiple surgical scars.
Orthostatic Intolerance	Many patients have POTS or NMH	Not reported
Family History	Occasionally, patients' siblings or other relatives have ME/CFS	FDP can occur in patients' siblings
Blood testing	Routine blood tests usually normal	Routine blood tests can show bizarre abnormalities
Neuroimaging	Neuroimaging can reveal defects in brain perfusion and/or metabolism	No reports of neuroimaging
Multiple doctors seen	Common	Common
Hospital admissions	Hospital admissions unusual	Hospital admissions very common
Medical knowledge	Parents can be very knowledgeable about ME/CFS	Parent/perpetrator can be knowledgeable about medical conditions
School attendance	ME/CFS is the most common medical cause of prolonged school absence.	Most patients are pre-school age. Poor attendance is common in school-age patients.
Separation from parents	Detrimental. Patient does not recover, illness often worsens	Patient improves/recovers when separated from a parent/perpetrator
Mortality	Extremely low	Approximately 10% in patients and 25% in patients' siblings

*Shaw RJ, et al. (89)

SCHOOL REFUSAL (SCHOOL PHOBIA)

School refusal has an estimated prevalence of 1–5% and is more common than ME/CFS. It occurs predominately in children less than 12 years of age (91). Children with school refusal fail to attend school because attendance causes emotional distress and anxiety. At the prospect of going to school, the young person exhibits behavioral symptoms, including temper tantrums, crying, angry outbursts, threats to hurt her/himself, and/or a variety of somatic complaints, such as nausea, dizziness, pains, diarrhea, or trembling.

In contrast, young people with ME/CFS usually want to attend school but are prevented from doing so by physical limitations. Other distinguishing features of ME/CFS are post-exertional malaise with exacerbation of other symptoms, and OI. Symptoms in those with school refusal improve once the child is allowed to stay at home and resolve during weekends and school vacations. By contrast, in the young patient with ME/CFS, symptoms persist during weekends and school vacations, but can improve slightly due to decreased activity. During convalescence from severe ME/CFS, the young patient

might find it difficult to return to school, having been absent for a variable period of time, having lost contact with many of her/his friends, and because of concern those symptoms might worsen. Such hesitancy should not be misdiagnosed as "school refusal." It should be managed with understanding by the parents, the physician, and school personnel.

PERVASIVE REFUSAL SYNDROME (PRS)

This condition describes a young patient who has despaired of any help from medical care and has lost all hope, as if wanting to die and, therefore, rejects medical care. It is extremely rare. Individual case reports are still being published. The young person refuses food and fluids, and might pull out IV cannulas and nasogastric tubes. It has occurred in young patients with neoplastic disease sickened by too many interventions and it has been described subsequent to sexual abuse. PRS is sometimes wrongly diagnosed in very severe cases of ME/CFS, when the young patient is physically incapable of sitting up or even swallowing. In contrast to PRS, the young person with severe ME/CFS usually wants to get better and co-operates

with medical help such as tube feeding. Management of the two conditions consists of the avoidance of stress, medical help with nutrition, assistance with living confined to bed, and an empathetic form of management to which the young person gives consent. A mistaken diagnosis of PRS in a patient with very severe ME/CFS can result in transfer of care to a psychiatrist whose management might include detrimental regimes, such as forced exercise and separation from family.

SOMATOFORM DISORDERS

Somatoform disorders are psychiatric disorders that cause bodily symptoms that cannot be traced back to a physical cause. Prior to diagnosing a somatoform disorder, it is necessary to rule out medical conditions with overlapping symptoms, such as ME/CFS. Symptoms such as pain occur in both ME/CFS and somatoform disorders, but post-exer-

tional exacerbation of symptoms and orthostatic intolerance are found in ME/CFS, but not in somatoform disorders. Serious deterioration can occur in young patients with ME/CFS who are misdiagnosed as having somatoform disorders and given psychiatric treatment that includes rigidly enforced exercise.

OTHER PSYCHIATRIC CONDITIONS

Some additional psychiatric conditions might need to be differentiated from ME/CFS. ME/CFS symptoms, such as poor concentration and loss of short-term memory, noticed in the patient's classroom, can sometimes lead to an erroneous diagnosis of attention deficit disorder without hyperactivity. If the young patient is unable to eat properly due to nausea and gastrointestinal symptoms, ME/CFS must be distinguished from an eating disorder. ME/CFS may also need to be distinguished from substance abuse.

5 MANAGEMENT / TREATMENT

Myalgic encephalomyelitis/chronic fatigue syndrome impacts a young person's entire life. Coping with debilitating medical symptoms, changed relationships within the family, absence from school, and loss of socializing with peers can all result from the illness. These losses can trigger confusion and crisis. Often, the patient might not have been diagnosed and might not have received appropriate help from previous health practitioners, since the young person may not look ill and may have a normal physical examination as well as normal routine laboratory tests.

Given the paucity of peer-reviewed literature on the management of ME/CFS in this age group, this chapter is a compendium of the experience of several clinicians, each of whom has treated children and adolescents with ME/CFS for over 20 years. The chapter provides recommendations primarily for ambulatory patients who are able to attend office visits even if using a wheelchair. Special consideration is given in section 7:1: "Severely Affected and Very Severely Affected Young Patients," for young people who are housebound or bedridden.

5:1 APPROACH TO MANAGEMENT

Currently, there is no treatment protocol or intervention which will cure ME/CFS. Therefore, the role of the physician is to first, do no harm; second, try to improve daily function, expand activity, and ameliorate symptoms; and third, support the patient and the family. School personnel often need to be educated about ME/CFS and made aware that it is a physical/organic illness, not a psychological disorder. We caution against reliance on internet-based information because much of it is anecdotal, uncorroborated, and may be designed to sell unproven products or services.

Due to variation in symptoms and comorbid conditions, no single approach works for all patients. Management requires careful attention to factors that provoke the symptoms and a willingness to try several approaches before improvement is achieved.

Most young people can achieve functional improvement. But even in the absence of improvement, the practitioner can help affected young people simply by continuing to evaluate them, providing encouragement, and discussing any new treatments that emerge. A survey of adolescents with ME/CFS found that doctors were considered to be most helpful when they validated the illness, acknowledged its effects, provided ongoing support, and monitored progress (23).

Management is based on early diagnosis, educating the patient, the family, and school personnel about the illness, determining the dominant causes of post-exertional symptoms, treating symptoms with non-pharmacological and pharmacological interventions, providing guidance on activity, diet, maintaining social contacts and educational opportunities, and monitoring progress.

Establishing the diagnosis of ME/CFS and acknowledging that the patient has a recognized illness can produce much relief. In explaining the illness, it is important to reassure the patient that the illness is real despite often normal blood-test findings. The potential for functional improvement should be emphasized. A firm diagnosis can relieve fears of other illnesses such as malignant diseases, relieve fears of imminent mortality, validate the presence of symptoms, facilitate the development of a therapeutic partnership with the patient and family, enable the establishment of a management plan, and help organizations such as the young person's school to provide appropriate education.

Misinformation or absence of information about ME/CFS is common. Educating the patient, the parents, the wider family and school personnel about the illness is important, e.g. providing handouts (Appendices C–E). Sometimes, school personnel and child protection services might need to be persuaded that their misapprehension that the young patient has factitious disorder by proxy (Munchausen's syndrome by proxy) or pervasive refusal syndrome is wrong and that these misdiagnoses can seriously harm the young patient.

Clinical management can be improved by the following suggestions:

- Obtain a written list of the patient's most troublesome symptoms.
- Agree with the patient and family to focus on a limited number of symptoms.
- Recommend that a family member write down or record medical advice.

In reviewing the patient's most troublesome symptoms, special attention should be paid to factors which exacerbate symptoms, e.g., upright posture. Then a decision can be made about which symptoms should be addressed first.

Management focuses on non-pharmacological and pharmacological interventions. Medication can be most helpful in the relief of some individual symptoms. Since many pediatric patients with ME/CFS respond to much lower than standard doses of medication (1/2 or 1/4 of the usual dose), the dosage should start low and be increased slowly. In general, any change in medication should be made one medication at a time, so that any favorable or unfavorable effects can be attributed to one medication.

Guidance needs to be given on an activity plan that helps the young person to function. Adolescent patients are encouraged to propose a personal, optimal balance of social, physical, and academic activities (and include something pleasurable outside of the home). Very little else is under their control. At each visit, the activity plan can be adjusted, in relation to symptom severity or improvement. Advice on schooling depends on the severity of the illness (section 8 "The School System").

Successful symptom management requires a regular review of symptoms and symptom severity. Visits every 1–3 months or so, depending on level of severity can be helpful. In patients who are improving, fatigue can be one of the last symptoms to subside. Young people often expand their activity level as they start to improve, preferring to tolerate some symptoms rather than remain on restricted activities so as to experience less fatigue. Thus, measuring improvement by asking solely about fatigue can underestimate progress. Functional improvement can be judged by determining how much activity it takes to provoke post-exertional worsening of symptoms. It can be helpful to use questionnaires/forms which measure activity, cognitive function, and mood to quantify the severity of the illness and document progress. Brief questionnaires used in some pediatric ME/CFS studies include the Functional Disability Inventory (92), Peds QL (93), and Wood Mental Fatigue Inventory (94). Progress should be measured over months or years, rather than at a single clinic visit.

The young patient should be encouraged to report any changes or additional symptoms, as symptoms of ME/CFS wax and wane. The physician might need to determine whether new or changing symptoms represent an altered ME/CFS symptomology, the onset of common comorbid conditions, or whether new symptoms are suggestive of an alternative diagnosis. Changes to medications and/or their dosages might be required. Reassurance that medical advice

from the treating physician will continue to be available can help the patient and family cope with the disease. Telephone or Skype contact can serve the same purpose for those who are more severely affected and unable to travel, or those who are geographically remote.

5:2 THE ACUTE STAGE OF ME/CFS

In the early, acute, febrile stage of ME/CFS, the diagnosis can be uncertain and other causes of fever need to be considered. Adequate rest and activity management are the mainstays of treatment. Premature resumption of activity or attempts to return to school can result in a relapse or increased severity of symptoms.

5:3 SLEEP PROBLEMS

Patients with ME/CFS experience unrefreshing sleep. Disturbed sleep patterns include difficulty falling or staying asleep, frequent awakenings, vivid dreams, day/night reversal, and hypersomnia. For many patients, naps are important to get through the day, but marked daytime sleepiness can result from conditions such as sleep apnea. Sleepiness can be measured using the Epworth sleepiness scale (95).

Hypersomnia (sleeping for up to 20 h a day) can occur in the early stages of the illness and can persist for weeks and occasionally months. Young people who sleep for more than 12 h at a time can develop dehydration. During wakeful periods, the young patient's parents/caregivers need to ensure adequate hydration and nourishment. When oral hydration and nourishment are inadequate, tube feeding is necessary. If hypersomnia persists for months, the young person should be evaluated by a sleep specialist, preferably one who is familiar with ME/CFS.

Conventional sleep hygiene measures for insomnia in otherwise healthy people can be ineffective in young people with ME/CFS, but the following can be helpful:

- Balance daytime activity with rest (pacing of activity), to avoid post-exertional symptom exacerbation, which can interfere with sleep (section 5:5, Fatigue, Post-Exertional Symptoms, Exercise Intolerance).
- Eliminate caffeine-containing beverages in the late afternoon and evening.
- Avoid television, computers, and electronic devices before and after bedtime (light from electronic devices can aggravate insomnia and fatigue).
- A carbohydrate snack at bedtime might be helpful (96).

If insomnia or sleep reversal is profound, sleep medications can be started at a low-dose. The risk of adverse effects should be balanced with the gains from a better night's sleep and sleeping the same hours as other family members. The medications chosen should be safe for long-term use and should be taken early enough to be effective at bed time. Non-pharmacological remedies can include herbal teas such as chamomile. Commonly used medications are listed in **Table 7**. For more severe problems, zolpidem and trazodone can be used with caution. Controlling pain (section 5:5, Pain) will often help sleep.

TABLE 7. MEDICATIONS FOR SLEEP

Medication	Usual adolescent dose	Comments
Melatonin	3 mg (range 1-12 mg)	Use dose that is effective given half to one hour before bedtime.
Diphenhydramine	25 mg at bedtime	Can cause excessive sedation or dry mouth.
Tricyclics (TCAs) Amitriptyline Dothiepin	10-25 mg at bedtime 25 mg at bedtime	Can be helpful for pain and headaches. Can cause weight gain, dry mouth, lightheadedness, and excessive sedation.
Clonazepam	0.5-1 mg at bedtime	Helpful if anxiety is affecting sleep. Can help restless leg syndrome. Using low doses, taken only at night, physiological dependence is unlikely.

5:4 PAIN

Pain in ME/CFS can be widespread or localized. Sometimes pain is so severe that the patient is unable to tolerate even a gentle touch. Common types of pain include headache, abdominal pain, myalgia, joint pain, sore throat, tender lymph nodes, eye pain and occasionally pelvic pain or dysuria (97, 98). It is important to treat localized pain such as headache, because pain can amplify other symptoms.

Chronic, daily headaches, which can fluctuate in severity from week to week, are common. If they are episodic, a diagnosis of migraine should be considered. Possible triggers include inadequate sleep, stress, skipped meals, and specific foods and supplements (including but not limited to chocolates, nuts, and aspartame). Initial intervention focuses on avoiding the common triggers. Migraine-prevention drugs are worth a trial for both episodic and non-episodic chronic,

daily headaches. Commonly used medications are shown in **Table 8**. Beta blockers can help headaches that are associated with OI (see Orthostatic Intolerance).

Comorbid fibromyalgia can be found in 10 to 30% of pediatric patients with ME/CFS but is less common than in adults with ME/CFS (98). Abdominal pain and nausea are common (98, 99). Abdominal hyperalgesia may also occur.

Helpful non-pharmacological remediation for pain includes pacing of activity to avoid flare-ups (section 5:5, Fatigue, Post-exertional Symptoms, Exercise intolerance); hot or cold packs for treatment of tender points; warm baths; muscle liniments; physical therapy; transcutaneous electrical nerve stimulation; acupuncture; massage, yoga or Tai Chi; biofeedback; and mindfulness-based stress reduction techniques. These interventions might not be effective in some patients and might be poorly tolerated in others.

TABLE 8. MEDICATIONS FOR HEADACHES

Medication	Usual adolescent dose	Comments
Supplements: Riboflavin Magnesium Coenzyme Q10	200 mg bid or 400 mg daily 250 mg daily 300 mg daily in 2-3 divided doses	Available as a single supplement or in a combination with others (e.g., MigreLief).
Antihistamines: Pizotifen Cyproheptadine	0.1-1.5 mg nightly 2-8 mg nightly	Helpful for comorbid insomnia and for poor appetite. Can cause weight gain. Pizotifen is not available in all countries.
Tricyclics: Amitriptyline	10-25 mg nightly, (Up to 50 mg may be tolerated)	Useful for comorbid fibromyalgia and abdominal hyperalgesia. Can cause lightheadedness and fatigue even at low doses. Can take 4 weeks to become effective.

For persistent pain, medications might be needed. Over-the-counter medications such as aspirin, acetaminophen, paracetamol, and NSAIDs are rarely effective for ME/CFS pain, but NSAIDs can ameliorate dysmenorrhea. Topical treatment for pain includes lidocaine patches. Some commonly used prescription pain medications and their dosages for adolescents are listed in **Table 9**. We recommend beginning at a low dose and increasing very cautiously. If pain is generalized, the higher dosages might be needed. Multiple trials of medication might be necessary to achieve adequate relief.

Young people with severe pain sometimes need strong analgesics. Opiates are occasionally necessary. Their use requires full documentation. For young people with complex pain syndromes, referral to a pain clinic (preferably one that is familiar with ME/CFS) might be helpful. We have received anecdotal information from some young patients that their chronic pain was improved by the use of cannabis or synthetic cannabinoids. There have been no clinical trials of this medication.

TABLE 9. MEDICATIONS FOR GENERALIZED PAIN

Medication	Usual adolescent dose	Comments
Tricyclics:		See Table 7
Selective serotonin reuptake inhibitors or SNRIs:		Consider in patients with comorbid anxiety or depression. These medications should not be stopped suddenly. Patients should be weaned very gradually off them, especially duloxetine.
Sertraline HCl	25-100 mg daily	
Escitalopram	5-20 mg daily	
Venlafaxine HCl	37.5-225 mg daily	
Duloxetine HCl	20-60 mg daily	Duloxetine can be helpful for fibromyalgia.
Bupropion HCl	150-300 mg daily	
Anticonvulsants:		This class of medication can be helpful for widespread pain, continuous, or frequent headaches, and fibromyalgia.
Topiramate (Topamax)	25-100 mg bid	Topiramate can cause weight loss. Adverse effects of topiramate include suicidal feelings and cognitive problems with doses > 50 mg daily.
Valproic acid	250-500 mg bid	Gabapentin can cause somnolence and weight gain.
Gabapentin	300-1,200 mg tid	
Pregabalin (Lyrica)	25-50 mg at night, increasing to 25-100 mg tid	

5:5 FATIGUE, POST-EXERTIONAL SYMPTOMS, EXERCISE INTOLERANCE

Myalgic encephalomyelitis/chronic fatigue syndrome is characterized by the body's inability to produce adequate energy for the normal range of human activity. Patients with ME/CFS experience persisting, overwhelming physical and cognitive exhaustion that is not relieved by rest or sleep. There is a loss of physical and mental stamina. Sometimes there is a feeling of being tired and wired (overstimulated). Fatigue in ME/CFS is pathological. It is qualitatively and quantitatively different from the normal fatigue experienced by healthy people following exertion which is relieved by a good night's sleep.

Following even minor physical, cognitive or orthostatic activity, the fatigue and other ME/CFS symptoms are worsened. This worsening of symptoms can occur any time from immediately following activity to up to 48 hours following activity, and it can last for days, or weeks, or months. This phenomenon of post-exertional malaise is the cardinal feature of ME/CFS.

Although the overall mechanism for triggering post-exertional symptoms is currently unknown, fatigue, post-exertional symptoms, and exercise intolerance in ME/CFS might be related to defective energy metabolism. Aerobic metabolism has been shown to be impaired in adult patients with ME/CFS (100). This impairment leads to an increased reliance on anaerobic metabolism which is much less efficient at producing energy.

ACTIVITY AND EXERCISE

Activities of daily living, education, and social activities can comprise a tolerable amount of energy expenditure for some patients, but these activities can be too much for others. Adding an exercise program to the schedule of a young person who can barely manage to cope with limited educational activities can be counterproductive. Exercise has been pro-

moted as therapeutic in patients with ME/CFS, but many patients drop out of exercise studies because exercise clearly made them worse (101). Some individuals with ME/CFS mistakenly over-exercise in an attempt to reduce fatigue and then incur post-exertional relapse. No studies have shown that exercise can produce a cure for ME/CFS.

Occasionally an excess of caution in young patients and/or their caregivers can result in too much rest. Prolonged periods of complete bed rest should be avoided, except in the most severely affected patients. Studies in adults have shown that 2 weeks of complete bed rest can be followed by a substantial reduction in plasma volume, and by OI (102). Striking the right balance between rest and activity while avoiding post-exertional symptoms requires trial and error.

However, for some patients with less severe ME/CFS, or during a remission, a suitable exercise program can improve function and provide some enjoyment. Any exercise program should not take priority over activities of daily living, education and socialization. Special care also needs to be taken to ensure that exercise is not advanced too rapidly or too soon, as, by definition, excessive exercise can exacerbate ME/CFS symptoms.

PACING AND THE ENERGY ENVELOPE

Young people with ME/CFS often do better when they (and their parents) learn to adapt their lifestyles to live within their capabilities, and pace, or spread out, their activities so that they can avoid a boom-and-bust cycle of overactivity on a given day, followed by a "crash" the following day. Remaining as active as possible, while avoiding post-exertional flare-ups defines an optimal zone of activity termed the "energy envelope." It has been shown in adults that fatigue severity declines when patients stay within their energy envelope (103).

Activities can be planned by the young patient over a weekly period. She/he should be encouraged to balance in-

tellectual, social, and physical activities, and to make a commitment to undertake segments of each component regularly. This allows the patient and family members to regain some control over their lives. It must be remembered that activity levels fluctuate from day to day and that patients sometimes experience setbacks in their available energy reserves. Family members need to recognize that setbacks can occur and that any activity plan needs to be flexible.

RECOMMENDATIONS FOR IMPROVING ACTIVITY LEVELS

Exercise guidelines for healthy but sedentary young people are inappropriate for patients with ME/CFS, because strict adherence to these guidelines can cause post-exertional relapse. For some young patients, it might be necessary to first treat their OI, and improve their ability to remain upright before any exercise can be adequately tolerated. Consultation with a physical therapist or rehabilitation specialist knowledgeable about ME/CFS is often helpful.

For the Most Impaired Young People

Advice for those who are homebound, or confined to bed, can be found in section 7:1: “Severely Affected and Very Severely Affected Young Patients.”

For the Moderately Impaired

Exercise while lying down should be advised when exercise while sitting, or standing, is poorly tolerated. Manual forms of physical therapy to improve mobility can be a bridge to tolerating exercise without prolonged exacerbations, especially for those with impaired range of motion on examination (104). Exercise should begin with as little as 1–2 min of gentle stretching followed by rest. When recovery has occurred, another 1–2 min can be attempted. When stretching exercises do not trigger post-exertional symptoms, intervals of recumbent exercise can be added, such as leg lifts while supine or the use of a recumbent stationary bicycle. The individual can be encouraged to increase the duration of activity very gradually, provided that the prior period of activity has not aggravated symptoms, until a reasonable exercise volume has been achieved. Rest between activities is needed, and young people are advised to avoid the “push-crash” cycle of excessive activity on a good day followed by prolonged post-exertional collapse. Exercise in a swimming pool is sometimes better tolerated, provided the water is not too warm, as there is an external counter-pressure from the water that can improve circulatory function.

Mildly Impaired Patients

Leisurely walking, with an initial duration of 5–15 mins, followed by a rest, is suggested. The duration or pace of the walking can be increased gradually, provided post-exertional symptoms do not occur.

Higher Functioning Patients

An exercise program might involve joining some organized sporting activities at school, but with modified participation. The effect of exercise on ME/CFS should be discussed with the student, the parents, and the school personnel. Everyone should be reminded that when the patient feels that

she/he has done enough, she/he *must* stop and rest, and never force her/himself to achieve more. Fluctuations in illness severity are also common and patients might find that they need to reduce their activities for a period of time.

MEDICATIONS FOR FATIGUE

Trials of medications for fatigue have not been conducted in children and adolescents with ME/CFS. A limited number of controlled trials have been conducted in adults. Dexamphetamine 5–10 mg twice daily for 4 weeks was tested in 20 adults with ME/CFS. The dexamphetamine group had a significant improvement in Fatigue Severity Scale scores at the end of the trial (105). Methylphenidate 10 mg twice daily for 4 weeks was tested in 60 adults with ME/CFS. Compared to placebo, it reduced the severity of fatigue and concentration problems (106). Lisdexamphetamine was helpful for executive function, fatigue, and pain in adults with CFS in a small, randomized trial (107). Modafinil has been shown to be effective for fatigue in adults with multiple sclerosis. When tested in 14 adults with ME/CFS, the treatment effect was uncertain, but these data need to be viewed with caution due to the small number of patients tested (108).

Low vitamin B 12 levels can be associated with fatigue, cognitive problems, balance difficulties, and hypotension. This has led some clinicians to administer vitamin B 12 injections to adults with ME/CFS in an attempt to improve symptoms and function. The typical dose used is 1,000 µg IM weekly for 4 weeks to assess the response and estimate the duration of effect (typically 3–7 days). Some patients rated results as good in a patient survey of treatment (109). There have, however, been no randomized, placebo-controlled, trials of vitamin B 12 for ME/CFS in young people.

Many patients self-medicate with caffeine in coffee and popular energy drinks. While this can be useful, patients should be cautioned against consuming excessive amounts of caffeine as this can cause tachycardia and agitation.

Medications for fatigue might need to be reserved for potentially exhausting occasions such as school exams. If effective, the young person should try to avoid exceeding her/his individual energy envelope.

5:6 COGNITIVE IMPAIRMENT

Cognitive difficulties are an integral part of ME/CFS and they have a significant impact on schooling. Advice on educational accommodations is given in section 8: “The School System.” The young patient needs to recognize activities that aggravate cognitive difficulties and, when possible, avoid them. Aggravating factors include mental and physical activity, distraction by noise or bright lights, and prolonged standing.

Cognitive problems can be improved by:

- Pacing of activities: the young person should be mentally active for short periods of time, followed by adequate periods of rest; she/he should learn to recognize when she/he is tired.
- Performing mental work lying down can sometimes be better than doing so sitting up.

- The effective treatment of insomnia, pain, depression, and/or anxiety.
- Snacks and frequent drinks.
- Self-medicating with caffeine-containing drinks.
- The use of prescribed stimulants such as low-dose methylphenidate can benefit some patients. The patient should be warned that there is a risk that a sense of well-being can lead to overactivity.
- Learning to cope with the stress of having a chronic illness (section 5:9, Support and Coping Skills).

5:7 IMMUNE SYSTEM SUPPORT

A limited number of trials of intravenous immunoglobulin (IVIG) have been undertaken in adults, with mixed results. In adolescent patients, a double-blind, placebo-controlled, randomized trial of IVIG 1 g/kg monthly (max dose 60 g) for 3 months was found to have moderate effectiveness for overall function (a combination of school attendance, school work, social activities, and physical activities). Patients also reported general improvements in all ME/CFS symptoms, many reporting feeling completely well by the 6-month follow-up. The placebo group also improved but more gradually, matching the functioning of the intervention group after 5–7 years of follow-up. The trial showed that the benefit from IVIG was in reducing the duration of illness (42). However, IVIG is relatively expensive, is not always available due to health insurance restrictions and other limitations, and it can be associated with serious adverse effects, e.g., aseptic meningitis after infusion, and anaphylaxis in those with IgA deficiency (110).

5:8 DEPRESSION AND ANXIETY

Mild, or moderate, secondary psychiatric problems often can be managed by the primary care physician, provided the physician feels comfortable with informal counseling. Giving support and encouragement to the patient can be adequate treatment. Various forms of support and psychotherapy, helpful for learning to cope with the illness, are given in section 5:9: “Support and Coping Skills.” When referral to a child psychiatrist or psychologist is needed, it is likely to be more successful if the clinician is familiar with ME/CFS.

The treatment of other symptoms of ME/CFS such as pain or insomnia can also help to relieve emotional distress. If antidepressant medications are indicated, it should be noted that young patients with ME/CFS often respond to smaller than expected dosages of these medications and careful follow-up is important.

5:9 SUPPORT AND COPING SKILLS

The young person with ME/CFS needs to learn to adapt to the reality of the illness, and integrate it into a meaningful life despite sometimes severe physical and cognitive limitations. Above all, the young patient needs to develop a sense of achievement in her/his life, however small. All aspects of the young person’s life might need to be addressed. She/he might need to deal not only with physical and cognitive limitations, but also with misunderstanding

of the illness, fear, grief, anger, guilt, and isolation. Sometimes having ME/CFS can result in abnormal illness behavior, such as denial of the reality of the illness.

A patient’s needs early in the illness might differ from her/his needs in later years, if health improvement is being achieved. Young patients should be encouraged to verbalize their fears and needs. Only the young person knows how she/he really feels. For instance, many young people fear getting behind their peers academically, never being able to catch up, and consequently losing friends. There should be opportunities to talk things through with a trusted professional who understands the illness. Although the parents can be present, the discussion should be primarily with the patient, so that she/he is also involved in decision making and feels part of the team approach. Teenagers usually need an opportunity for discussion without a parent present.

Our experience suggests that the following elements of basic, supportive therapy can be helpful:

- Exploring what the patient and the parents already know about the illness.
- Teaching the patient and the family about ME/CFS, and correcting any misinformed notions about cause, course of the illness, and forms of management.
- Making it clear that ME/CFS is a medical/biological illness but that often there can be understandable, secondary emotional reactions.
- Clarifying and discussing the patient’s and family’s particular anxieties and mood changes.
- Discussing strategies such as pacing of activities (section 5:5, Fatigue, Post-Exertional Symptoms, Exercise Intolerance) that enable the patient to live within the limitations of the illness.
- Ensuring the medical management of symptoms.
- Making clear that you (as the treating physician or therapist) will be available as new questions arise and scheduling up follow-up appointments.

These steps can be carried out by the primary care physician if she/he is comfortable doing so. If not, or if the patient’s situation is complex or severe, a social worker, psychologist, or child psychiatrist, preferably one who is knowledgeable about ME/CFS, can be consulted.

COPING SKILLS TRAINING

Young patients with ME/CFS benefit from practical suggestions for coping with chronic illness. It can be helpful to provide strategies for demystifying the illness and explaining it to other people. For example, ME/CFS is like having mononucleosis (glandular fever) and then not recovering from it.

We recommend:

- A private space at home, so that the young patient’s rest will be undisturbed and she/he is able to work without being distracted.
- Developing a daily routine, especially for patients who are housebound.
- Attempting to achieve a normal day/night cycle, to help the patient fit in with the family’s daily schedule and make school possible.

- Encouraging participation in education, however minimal, but without undue pressure (see The School System).
- Providing time for meeting with friends and for family treats.
- Incorporating rewards for achievements.
- Joining a local patient support group (if available, and if it has competent leadership).
- The use (when appropriate) of stress reduction techniques such as music, visualization, self-hypnosis and/or mindfulness-based cognitive therapy (111).

COGNITIVE BEHAVIORAL THERAPY (CBT)

The benefit of CBT as a psychotherapeutic intervention for ME/CFS is currently ambiguous. CBT has been shown to be helpful for some pediatric ME/CFS patients (112–115). However, in adults, the effect size of CBT is rather modest and the effects are not always sustained (116). CBT can produce adverse effects (101). The assertion that CBT can “reverse” or cure the illness is not supported by follow-up studies (117), and immunological changes found in the illness have been shown not to be reversed by CBT (118).

The hypothesis underlying the rationale for the use of CBT in ME/CFS patients proposes that the patient’s poor health is perpetuated by avoidance of activity and by maladaptive fears, such as anxiety about symptoms that emerge after activity (119). CBT aims to improve coping with the illness by changing these “maladaptive cognitive responses” and encouraging graded exercise as well as incremental increases in other activities. The notion that the illness is perpetuated solely by dysfunctional attitudes and beliefs is speculative, lacks empirical support, and is not consistent with our current understanding of the pathophysiology of ME/CFS (section 2, Etiology and Pathophysiology). This hypothesis has led to patients being blamed for failure to recover, because, in the view of the therapist, they have not changed their so-called “maladaptive cognitive responses.” Furthermore, CBT that includes rigidly enforced graded exercise frequently leads to severe relapse in patients with ME/CFS.

Nevertheless, some of the elements of CBT are part of a common sense management of many medical problems, provided they are introduced in a pragmatic and flexible manner to help individuals cope with chronic illness (113–115, 120, 121). These elements include recommendations already given in this section. It is important for a patient with ME/CFS that any attempt to increase activity, or to exercise be flexible, rather than rigid, permitting the patient to avoid exceeding her/his energy limit. The patient should also be advised that CBT does not cure the illness, but it can help in learning to live within its limitations. CBT is not always available and it can be costly. It is likely to be more successful if the therapist is knowledgeable about ME/CFS.

5:10 DIETARY MANAGEMENT

This section discusses nutrition in patients who are able to take adequate nourishment by mouth. Patients unable to

maintain adequate nourishment by mouth are discussed in section 7:1: “Severely Affected and Very Severely Affected Young Patients.”

Many young people with ME/CFS experience a variety of gastrointestinal symptoms that can interfere with nutrition. Common complaints are lack of appetite, especially in the morning, nausea, abdominal pain that might or might not be associated with eating, heartburn, feeling “full” even after a small meal, abdominal bloating, and discomfort that can be associated with particular foods, e.g., dairy or wheat. Comorbid gastrointestinal conditions are present in some young patients. These are discussed in section 6:4: “Gastrointestinal Issues.”

Reduced food intake can stem from food fads. The young person might be a fussy eater, might claim to be “allergic” to almost all foods, or might be fearful that certain foods make the illness worse. Some young people with ME/CFS have a very disordered body clock—up all night, asleep all day—making mealtimes very awkward. As a result of these problems, some young people with ME/CFS develop weight loss. Alternatively, others become obese due to lack of exercise or increased “snacking” for an energy boost, from boredom, or occasionally due to increased appetite from medications. If there is no logical explanation, weight changes should be investigated.

Parental concern and pressure to eat more can contribute to stress in the family. The goal is for the young person to get a balanced nutritional diet, including food they enjoy, with plenty of variety. Educating the patient about how the body needs fuel to function and provide energy can be helpful. We recommend:

- Regular, small meals, little and often, and between meal snacks.
- Plentiful salt for those with comorbid OI.
- Avoiding too much fluid with meals if experiencing bloating.
- A carbohydrate snack at bedtime or if wakeful during the night can encourage sleep.

Extra foods that can be incorporated into the diet in some circumstances include yogurt, if the illness began with or is complicated by gastrointestinal infection, ginger drinks for nausea, peppermint for indigestion, or garlic to help overcome/prevent infection. Evidence for these being helpful is anecdotal. Snacks should be readily available and nutritious, but include some treats. In school, permission might be needed to have snacks and drinks readily available, particularly during long exams.

Fluid intake should be liberal:

- Drinks should be readily available, water is ideal. Do not “over-drink.”
- Electrolyte drinks can be helpful, avoid those containing fermentable oligo-, di-, mono-saccharides and polyols (FODMAPs, see below)
- Avoid alcohol and too much caffeine (coffee, cola, energy drinks).

Recent attention has focused on dietary FODMAPs. These are short chain carbohydrates (oligosaccharides, disaccharides, monosaccharides and related alcohols) that are commonly found in the modern western diet and are poorly absorbed in the small intestine. They include short chain polymers of fructose (fructans), galactose (galactans), disaccharides (lactose), monosaccharides (fructose), and sugar alcohols (polyols) such as sorbitol, mannitol, xylitol and maltitol. There is evidence that restriction of FODMAPs can have a beneficial effect for those with irritable bowel syndrome and other functional gastrointestinal disorders. It might, therefore, be useful to restrict the dietary intake of these types of carbohydrates for ME/CFS patients with comorbid gastrointestinal symptoms.

SUPPLEMENTS

If the diet is good, supplements should not be needed, although sometimes they can be beneficial. Occasionally, an excess of supplements can cause problems e.g., too much vitamin C can lead to diarrhea. The following supplements can sometimes be useful:

- Vitamin D: if the patient lacks sunlight, due to light sensitivity or if seldom outside. Low vitamin D levels can be associated with headaches and pain and these symptoms improve with raising vitamin D blood levels.
- Magnesium at bedtime can help with pain and cramps (take with apple juice or apple to aid absorption). It also helps relieve constipation.
- Vitamin B 12 injections can help with low energy/brain fog, or vitamin B 12 can be taken as sub-lingual tablets.
- Probiotics can help irritable bowel symptoms, or if taking antibiotics.

- Iron tablets for iron deficiency with or without anemia (the cause of anemia should be determined). Take with citrus juice to aid absorption.

5:11 ALTERNATIVE AND COMPLEMENTARY MEDICINE

Many alternative and complementary therapies have been promoted for ME/CFS. It is difficult to determine whether these therapies actually work, because the symptoms of ME/CFS vary so much from day to day. Anecdotal evidence suggests that acupuncture, massage, Pilates, and yoga can help pain in some adults, but no published studies have assessed their benefit in young people.

The clinician should identify the use of herbal/natural remedies or supplements. The contents of complementary medicines are not regulated for dose or composition. Caution must be exercised regarding side effects because if used with prescribed medications, there can be interactions.

Unfortunately, in the hope of a cure, parents of young patients with ME/CFS often ask the young patient to try costly, non-established and speculative treatments but find little or no clinical improvement. Feedback from young people with ME/CFS indicated that 80% had tried up to 30 different alternative therapies. Only massage for pain relief and “good dietary advice” achieved “some benefit” in up to 30% of patients. A common comment from the patients was that they “were glad when their parents stopped shopping around for a cure.” (23). A review of alternative medicine studies in adults with ME/CFS revealed generally poor methodologies and limited evidence of any benefit (122, 123).

6 COMORBID MEDICAL CONDITIONS

Comorbid conditions are seen frequently in young patients with ME/CFS and are major contributors to illness severity. Their successful management can result in substantial lessening of the burden of illness. A list of comorbid conditions is given in **Table 4**. This section will discuss those comorbid conditions that can have a significant impact on the illness, including orthostatic intolerance, joint laxity, gynecological problems, gastrointestinal problems, allergies, intolerances and neuro-anatomic abnormalities.

6:1 ORTHOSTATIC INTOLERANCE (OI)

The term OI refers to a group of conditions in which symptoms worsen with upright posture and are improved, but not always abolished by lying down. Typical symptoms are those of cerebral hypo-perfusion or sympathetic activation. Studies report higher rates of OI in pediatric patients with ME/CFS than in healthy children and higher rates than in adult patients with ME/CFS. An estimated 60–95% of young patients with ME/CFS have orthostatic symptoms (49). OI is more common in girls after puberty (sex ratio 3:1). OI can follow an infectious illness or an immunization.

Because there are more patients needing help with the

management of OI than specialists trained to meet their needs, we have included the salient points of diagnosis and management of OI in this section. There is more detailed information on the pathophysiology and testing for OI in Appendix G.

Symptoms of OI in young patients can precede the onset of ME/CFS or they can arise after a period of time following the onset of ME/CFS. Some young patients with symptoms of OI do not develop symptoms of ME/CFS, while in others, the concurrent diagnosis of ME/CFS has been missed, because symptoms such as post-exertional worsening have not been asked about.

Orthostatic symptoms include any of the following: increased fatigue, lightheadedness, whiteouts or blackouts of the visual field, visual dimming, mental fog, headaches, nausea, pain, or shortness of breath. Upright posture consistently aggravates ME/CFS symptoms and patients report worsening fatigue and other symptoms while standing in line, in hot environments like a shower, or in the summer heat. Many patients adopt postural counter-maneuvers—such as sitting with knees to chest, doing homework in a reclined position, crossing the legs when standing, fidgeting in line—but are not aware of why they have done so. Some

adolescents might not report lightheadedness, so asking about symptoms that emerge during prolonged upright posture can be revealing.

Characteristic physical appearances include facial pallor and a reddish-purple discoloration of the dependent limbs (acrocyanosis) when sitting or standing for more than a few minutes. Symptoms of OI can occur without prominent changes in heart rate and blood pressure, but are often associated with objective circulatory disorders. Postural tachycardia syndrome (POTS) is the most common, neurally mediated hypotension (NMH) is less common, and orthostatic hypotension (OH) is uncommon in pediatric patients. The detection of POTS, NMH, and OH require a prolonged period of orthostatic stress and they can be missed with brief duration, 1–2 min, orthostatic, vital sign measurements. We recommend a 10-min, standing test in all young people with ME/CFS, to ascertain whether orthostatic symptoms occur and determine whether POTS and/or OH are present (**Table 10**). Patients with NMH are generally symptomatic soon after standing, but longer duration tilt-table testing is required to elicit the hypotension. Tilt-table testing requires referral to a specialist center and is costly.

POTS: In adolescents, this diagnosis requires the presence of consistent orthostatic symptoms, the absence of OH, and at least a 40 bpm increase in HR from supine to 10 minutes upright (124). Some individuals who have POTS early in upright posture go on to develop NMH, if the orthostatic challenge is prolonged beyond 10 min.

NMH: requires the production of orthostatic symptoms with a 25 mm Hg drop in systolic BP usually without an increase in HR and can be associated with junctional rhythm (recognized by a loss of P waves on the EKG) at the time of pre-syncope or syncope. The terms vasovagal syncope, neuro-cardiogenic syncope, and NMH are synonymous. Syncope need not be present to make the diagnosis of NMH, as many affected individuals with lightheadedness, and other symptoms, sit, or lie down, before fainting.

OH: is defined by a BP reduction of at least 20 mm Hg systolic or 10 mm Hg diastolic within the first 3 min of upright posture (124). This problem is rarely seen in pediatric patients except at times of hypovolemia, febrile illness, acute dehydration, or hemorrhage.

TABLE 10. ORTHOSTATIC TESTING

In-office standing tests

Five minutes supine, then at least 10 minutes of quiet standing, leaning against a wall, with instructions to the young person to remain still, not fidget or shift her/his weight. Changes in HR and BP should be recorded each minute, supine and upright, along with intensity of orthostatic symptoms and fatigue on a 0-10 scale. The patient must be carefully observed due to the risk of syncope. The development of pallor, warmth, or nausea can be prodromal signs of hypotension or syncope. This test will identify POTS and OH, but is usually not sufficiently prolonged for NMH.

Head-up tilt table tests

HR and BP are measured supine and during 70-degree head-up tilt. POTS or OH can be identified by 10-minute tests. Prolonged testing of 40-45 minutes might be required to identify NMH.

For further details on orthostatic testing, and a standing test data sheet see Appendix G.

MANAGEMENT/TREATMENT

The lack of treatment studies in young people with OI, and the lack of specialists with experience in OI, contribute to difficulties in managing this condition. Some young patients have symptoms of OI, but at the time of testing have a standing HR rise or BP fall which is insufficient to diagnose POTS, NMH, or OH. They might still benefit from treatment.

The first step in management is non-pharmacological and emphasizes four main points: (a) avoid conditions that increase pooling of blood, (b) improve venous return to the heart, (c) avoid depletion of salt and water and other causes of low blood volume, and (d) avoid increasing catecholamines beyond their baseline levels (which can be elevated).

Avoid Pooling of Blood

This involves avoiding prolonged standing or sitting, such as by moving around during longer classroom lectures, standing and stretching periodically to break up study sessions, and shopping at off hours. Patients should avoid saunas, hot-tubs and sunbathing, and take short, cool baths and showers. Large meals and high carbohydrate intake can interfere with orthostatic tolerance by contributing to a shift of blood

volume to the splanchnic circulation. Small, frequent meals are often better tolerated.

Improve Venous Return to the Heart

Adolescents can utilize the muscle pump of the lower limbs by e.g., crossing their legs and shifting from one leg to the other while standing, sitting with their knees higher than their hips, or with their knees to their chests, or by performing leg muscle contraction exercises before standing. Sitting on a high stool with the legs dangling freely should be avoided, as there is no resistance to blood pooling in the legs. Some adolescents find they can sit longer without symptoms if they put their feet on a low foot rest, or sit with one leg folded under the buttocks.

Compression garments such as support hose with 20–30 mm Hg compression can be helpful. (Waist-high garments are more effective than thigh-high, which are more effective than knee-high.) Some adolescents derive benefit from wearing body shaper garments or abdominal binders. A time-honored recommendation to improve blood volume is to elevate the head of the bed slightly by 10–15°. While this is not comfortable for everyone, it can help the body retain fluid at night (125, 126).

Avoid Depletion of Salt and Water

Patients need to drink 2–3 liters of fluid daily and take in adequate sodium. We recommend drinking fluids every 2 h during the day. There is no specific amount of sodium that works for each individual. Food should be salted according to taste

and supplemental, buffered, salt tablets should be considered if needed. Oral rehydration fluids can also be beneficial. Healthy, higher sodium food options include dill pickles, olives, tomato juice, soups, salsa, salted nuts, and soy sauce.

TABLE 11. MEDICATIONS FOR TREATING ORTHOSTATIC INTOLERANCE IN ADOLESCENTS

Medication	Usual dose for orthostatic intolerance	Comments
Vasoconstrictors:		
Midodrine	Start at 2.5 mg q 4 h while awake. Increase every 3-7 days by 2.5 mg to optimal dose or max. of 10 mg q 4h while awake.	First-line therapy for those with low BP (SBP < 100 or low normal BP). Monitor BP as supine hypertension can occur. Avoid prior to bedtime.
Methylphenidate	Immediate-release form: 5-10 mg bid, increasing gradually to 15-40 mg/day.	First-line therapy for those with prominent cognitive dysfunction, personal or family history of ADHD, joint hypermobility.
Dextroamphetamine	Sustained release form: 5-10 mg q AM. Increase by 5-10 mg q AM weekly until optimal dose or 10-30 mg daily.	As a rule of thumb, the optimum dosage of dextro-amphetamine is approximately half the optimum dose of methylphenidate.
Volume expanders:		
Sodium chloride	Oral: 1-gram tablets with meals IV: 1-2 liters over 1-2 hours.	IV saline is seldom practical over the longer term, but can help restore baseline function after illnesses or as emergency “rescue” therapy.
Fludrocortisone	0.05 mg daily for 1 week, then 0.1 mg daily. Increase gradually to maximum of 0.2 mg daily.	First-line therapy in those with baseline hypotension or increased salt appetite. Add KCl 10 mEq for every 0.1 mg fludrocortisone to prevent hypokalemia.
Hormonal contraceptives, Medroxyprogesterone	Most are fine. Conventional dosage or continuous pills for 84 days (one period every 3 months).	First line therapy for females with dysmenorrhea or when symptoms worsen with menses. Drospirenone containing pills can have diuretic effect.
Desmopressin acetate	0.1 mg at bedtime, increasing to 0.2 mg daily.	Useful for those with nocturia. Monitor for hyponatremia.
Sympathetic tone modifiers		
Beta blockers: Atenolol	12.5-25 mg daily, increase by 12.5 mg increments until optimal effect. Usual dose, 0.5-1 mg/kg body weight.	First-line therapy for those with resting HR > 100, anxiety, or prominent headache. Higher doses can aggravate fatigue and lightheadedness.
Propranolol	10-20 mg 3-4 times daily.	
Pyridostigmine bromide	Rapid release: 30 mg daily, increase by 30 mg every 3-7 days to 60 mg BID or TID. Sustained-release: 180 mg daily.	Effective in both POTS and NMH. Can also help with GI motility problems.
Clonidine	0.05 mg at bedtime. Increase after 1 week to 0.1 mg nightly. Occasionally higher doses tolerated.	Consider in those with anxiety, problems with attention or insomnia. Reported to improve blood volume.
Selective serotonin and norepinephrine reuptake inhibitors (SSRIs/ SNRIs)		
Escitalopram	5 mg daily for 2-4 weeks, increase to 10 mg daily up to max. of 40 mg daily.	Consider for comorbid dysthymia, depression, or anxiety.
Duloxetine	20-30 mg daily for 2 weeks, increase to max of 60-90 mg daily.	Consider if myalgias are prominent.
Sertraline	25-100mg daily	

Avoid Increasing Catecholamines

Epinephrine and norepinephrine levels are increased in those with OI and worsen with upright posture. Physiological stressors, including pain and emotional distress, can elevate catecholamine levels even higher. Stress avoidance can help with symptom management.

Examine whether medications are helping or making symptoms worse. For example, in those with asthma, beta-adrenergic agonists such as albuterol and salbutamol mimic the effects of epinephrine and can contribute to tremulousness and lightheadedness in patients with OI. While beta-agonists are not completely contraindicated, we try to use inhaled glucocorticoids, sodium chromoglycate, or montelukast for asthma control. Medications that promote vasodilation, such as niacin, phenothiazine anti-emetics and narcotic analgesics are better avoided or minimized. Although low doses of tricyclic antidepressants used for headache, pain, and insomnia might be tolerated, higher doses can aggravate hypotension.

Caffeine intake (including soft drinks or coffee) can help symptoms by acting as a vasoconstrictor, but some patients experience adverse effects. Alcohol consumption usually aggravates OI symptoms.

Treat other ME/CFS symptoms and comorbid conditions

Treating symptoms, especially pain and sleep problems, can improve OI symptoms.

Pharmacological intervention

Pharmacological intervention should aim for monotherapy, but often rational polytherapy is needed to produce optimal symptom control. All medications should be started at low doses and increased very slowly. Some medications are listed in **Table 11**. Some physicians recommend a low-dose beta blocker or midodrine as the first-line agents. Alternatively, an initial medication can be selected from **Table 11** depending on the specifics of the patient's condition and existing comorbidities. For example: beta blockers might be chosen for those with elevated supine HRs, whereas fludrocortisone might be chosen if there is a low resting BP or an increased salt appetite. Midodrine is efficacious in treating syncope, but taking a dose every 4 hours makes it less convenient to take when in school. Stimulants can be helpful for those experiencing fatigue and prominent cognitive symptoms.

Adolescent girls with dysmenorrhea, acne or perimenstrual exacerbation of OI symptoms can benefit from hormonal contraceptive therapy (127). Sometimes the young patient fares better when treated with continuous, combined hormonal regimens that bring one menstrual period every 90 days. A long-acting injectable progesterone can be considered. The mechanism by which hormones improve OI is not entirely clear.

Improvements in symptoms and in responses to upright tilt have been reported after treatment with selective serotonin reuptake inhibitors (SSRIs) in non-depressed patients with NMH refractory to other therapies (128). In those with fibromyalgia, duloxetine (an SNRI) can be effective for pain, independent of its effect on mood. When

symptoms such as anxiety, pain, dysthymia, or premenstrual syndrome are present, these medications might also be chosen.

The concurrent use of several medications with different pharmacologic effects, e.g., a vasoconstrictor, a mineralocorticoid, and a beta blocker might be necessary for the improvement of severe OI. Among those refractory to treatment, it is important to question whether the OI is exacerbated by another comorbid condition.

Selected individuals with OI, whom medications have failed to help, have occasionally been managed with weekly infusions of IV saline until symptoms stabilize. Some clinicians also utilize IV saline infusions as "rescue therapy" when orthostatic symptoms become more intense (such as after an infection). Because individuals with OI are usually hypovolemic, they can withstand a rapid infusion of 2 L of normal saline over 1–2 h. Infusions provide a more rapid restoration of intravascular volume and a larger intake of sodium than is possible orally. Peripheral IV lines are preferred, as the placement of PICC or central lines poses a risk of local infection or bacteremia (129). The efficacy of this practice has not been studied in a randomized trial and more formal study is needed.

6:2 JOINT HYPERMOBILITY, CONNECTIVE TISSUE LAXITY, EHLERS-DANLOS SYNDROME

Some 60% of young patients who meet the criteria for ME/CFS also have joint hypermobility, compared with about 20% of healthy adolescents (32). Although joint hypermobility is a physical trait that can confer advantages in athletics and dance, some patients with joint hypermobility also have constitutional symptoms including tiredness, difficulty sleeping, gastrointestinal symptoms, arthralgias, myalgias, lightheadedness, and OI, suggestive of undiagnosed comorbid ME/CFS.

Joint hypermobility is one of the clinical features of Ehlers-Danlos syndrome (EDS) (130). Other features of this heritable connective tissue disorder can include stretchy or fragile skin, delayed wound healing, easy bruising, unusually wide or thin scars, striae in the absence of marked weight changes, blue sclerae, easy eversion of the upper eyelids, and a positive Gorlin's sign (the ability to touch the tongue to the tip of the nose). Some with EDS develop early onset of varicose veins. In the classical form of EDS there can be hemosiderin deposition around the knees and shins. Those with the hypermobile form of EDS are more likely than those with other forms of EDS to have OI (131, 132). Constitutional symptoms that overlap with symptoms of ME/CFS are common in EDS. Fatigue and pain are substantial contributors to impaired quality of life in EDS (133, 134). The mechanism for the overlap of ME/CFS and joint hypermobility or EDS has not been explained.

Clinicians can have an increased index of suspicion for joint hypermobility if their patients have been swimmers, dancers, and gymnasts. In taking the history, the clinician

should ask whether the patient has had subluxations or dislocations (including “nursemaid’s elbow” in early childhood), and whether the patient can perform “tricks” with their joints. Joint hypermobility can be overlooked unless the clinician performs specific measurements such as the Beighton score, a nine-point measure in which scores of 4 or higher indicate joint hypermobility. To obtain a Beighton score, the examiner needs a goniometer to measure joint angle, assigning one point for the ability to dorsiflex each fifth finger past 90°, one point on each side for bringing the thumb to the forearm, one for more than 190° of hyperextension at each elbow, one point for more than 10° of hyperextension of each knee, and the ninth point is for the ability to place the palms on the floor bending over at the waist, with the legs straight. Some with joint hypermobility can have associated postural dysfunctions such as thoracic kyphosis, scoliosis, a head-forward posture, lumbar lordosis, and pes planus.

Diagnosing joint hypermobility is important, as the condition can be associated with pain, add to the burden of illness in ME/CFS, and requires different approaches in physical therapy. The evaluation and management of these patients is often helped by consultation with a physical therapist. For the treatment/management of pain see section 5:4, “Pain”.

6:3 GYNECOLOGICAL ISSUES

Common problems for adolescent females with ME/CFS are the exacerbation of ME/CFS symptoms (especially OI) in the week before and during the menses, and the onset of, or an increase in severity of, gynecological symptoms, including dysmenorrhea, menorrhagia, pelvic pain, and premenstrual syndrome. An occasional problem is cessation of the menses following the onset of ME/CFS (section 3, “Adolescent Development”). In older adolescents, sexual activity can cause post-exertional symptom exacerbation.

DISMENORRHEA

Clinical experience has shown that in some adolescents, the onset of dysmenorrhea may be concurrent with the onset of ME/CFS and menstrual symptoms can improve as ME/CFS symptoms improve.

ENDOMETRIOSIS

In adolescents with ME/CFS who have comorbid endometriosis, pelvic pain and associated gastrointestinal or urinary symptoms are typically worse during the menstrual cycle. Adolescents with endometriosis are more likely than their adult counterparts to report pelvic pain that is also (or only) non-cyclical. The pain is often minimally responsive to oral contraceptive pills (OCPs) and NSAIDs. Associated symptoms can include constipation, pain with defecation, and urinary symptoms such as dysuria, urgency, frequency, and hematuria. Dyspareunia can also be present.

PELVIC CONGESTION SYNDROME (PCS)

A less well recognized problem that can cause chronic pelvic pain, associated with low BP and chronic fatigue, is PCS (135–137). While this condition is more common in multiparous

women, it can occasionally be present in adolescents with ME/CFS. It is associated with varicose ovarian and internal iliac veins. Symptoms include chronic, non-cyclical pelvic pain and perineal heaviness, occasionally associated with lower back pain. Pain is usually present throughout the month, but often worsens with the menses. Unlike endometriosis, this form of pelvic pain worsens at the end of the day or with prolonged standing due to progressive distention of varicosities in the pelvis. Also, in contrast to endometriosis, PCS symptoms improve with prolonged supine posture or after a night in bed. Vulvar and thigh varices are less common in adolescents with PCS than in adults.

TREATMENT

Adolescents with dysmenorrhea and/or peri-menstrual symptoms often feel better on an OCP, and OI symptoms can also improve (127). The OCP can be given in monthly cycles, but for peri-menstrual symptoms, patients often do better when the pill is taken continuously for 3 months, e.g., an active pill daily for 84 days followed by one week of placebo pills to induce menstrual periods every 90 days. Intra-muscular Depoprovera (medroxyprogesterone) can also be effective. For menorrhagia, the patient should be tested for the presence of iron deficiency anemia and this should be treated if present. The menorrhagia might respond to an OCP or to cyclokapron (tranexamic acid), 1 g tid during the period. For persisting pelvic pain, consultation with a gynecologist is often helpful.

6:4 GASTROINTESTINAL ISSUES

Some young people severely affected by ME/CFS and mostly bedbound might be unable to maintain hydration and adequate nourishment orally. These patients require tube feeding (section 7:1, Severely Affected and Very Severely Affected Young Patients).

Abdominal pain, nausea, and reduced appetite are common in young patients with ME/CFS. Gastrointestinal conditions which can be present include: gastroesophageal reflux, gastrointestinal motility disorders, celiac disease and non-celiac gluten sensitivity, lactose intolerance, food allergies (e.g., nut, milk, eggs, and wheat), post-infectious or irritable bowel syndrome, and constipation. These conditions should be considered in the differential diagnosis of gastrointestinal complaints and, if present, should be treated appropriately.

Another recently recognized gastrointestinal problem that can be present in up to a third of adolescents with ME/CFS is intolerance of specific food proteins (138). Milk protein is the most common offending food, but soy, wheat, and egg proteins can also cause symptoms. Many young patients are unaware that milk or other specific proteins are a problem, because immediate reactions are absent, and symptoms can be delayed for several hours after ingestion.

Symptoms that indicate the possibility of a non-IgE-mediated allergy or an intolerance of a food protein are: (a) epi-

gastric or abdominal pain, (b) gastroesophageal reflux symptoms (heartburn, retro-sternal discomfort, acid taste in the mouth, sometimes a mucousy form of vomiting), and (c) appetite disturbance (early satiety, picky appetite) (138, 139).

Other associated symptoms can include recurrent aphthous ulcers, intermittent fevers, headaches (including migraines), worsening lightheadedness, myalgias, sinusitis, and either constipation or diarrhea. Skin testing in people with delayed gastrointestinal hypersensitivities is usually negative. Unless delayed food protein hypersensitivities are adequately addressed, they can obscure any improvements that might accompany otherwise effective treatments.

A history of suspected food intolerances should be taken. If the specific symptoms mentioned above are present, and intolerance to a specific food is suspected, a trial of strict dietary elimination of the offending food for 2–4 weeks can be undertaken. Provided that the initial food that has been restricted based on the history is indeed the culprit, and the elimination diet is strict enough, intestinal symptoms usually begin to resolve after 10–14 days (sometimes sooner). If allergic individuals have already been restricting the offending food and then are inadvertently re-exposed, their symptoms will return. This recurrence provides support for the diagnosis. For persisting abdominal symptoms, consultation with a gastroenterologist can be helpful.

6:5 ALLERGIES

Allergies are more common in young patients with ME/CFS than in otherwise healthy young people and they often predate the onset of ME/CFS (140). In contrast to non-IgE-mediated allergies (section 6:4, “Gastrointestinal Issues”), IgE-mediated allergies are recognized by the presence of immediate allergic symptoms, including wheezing, pruritus, urticaria, lip and tongue swelling, and more severe features of anaphylaxis. Skin prick tests and RAST blood tests are abnormal in those with IgE-mediated allergies. A mast cell activation syndrome (MCAS) might be present.

The importance of MCAS has likely been underappreciated in the past. Symptoms can include fatigue, lightheadedness, facial flushing, rashes, itching, hives, bone and muscle pain, nausea, vomiting, abdominal pain, diarrhea, brain fog, migraines, and intolerance to multiple medications (141, 142). Joint hyper-mobility is also associated with MCAS, and a subset of POTS patients have MCAS (143). Some of these symptoms overlap with symptoms of ME/CFS. Recent work has identified hereditary elevations in tryptase (an enzyme released after mast cell activation) among those with POTS, joint hypermobility, and atopic disorders (144). Clinicians should have a higher index of suspicion for MCAS in those diagnosed with ME/CFS who report the symptoms listed above. Treatment of MCAS involves antihistamines and medications to stabilize the mast cell membrane such as cromolyn, quercetin and the leukotriene receptor antagonists zafirlukast and montelukast. Several detailed reviews of the clinical features, diagnostic tests and treatments of MCAS are available (141–143, 145).

6:6 NEURO-ANATOMIC ABNORMALITIES

Some reports have shown an overlap of symptoms between ME/CFS and anatomic abnormalities such as Chiari I malformations, congenital cervical stenosis, cervical instability, tethered spinal cord, and thoracic outlet syndrome (146, 147). Taken together, these disorders represent a very small proportion of those with ME/CFS, but their prevalence can be higher among more severely affected patients or those unresponsive to the usual interventions. Symptoms of these various abnormalities can include suboccipital headaches, made worse by neck flexion or extension, coughing, or straining; back and leg pain, problems swallowing, weakness, coordination difficulties, numbness in the face and limbs, and/or frequent urination. A neurological examination might reveal nystagmus, diplopia, absence of the gag reflex, hyperreflexia and decreased sensation in the pelvis and lower limb. In those with prominent symptoms including headache, evaluation must exclude intracranial hypertension and intracranial hypotension. Referral to a neurologist can be helpful.

6:7 ORAL AND DENTAL ISSUES

Major contributions to this section by Evan Spivack, DDS.

Dental and orofacial problems are found in many young people with ME/CFS, but are often neglected because the young patient is too ill to make dental office visits. Correction of dental problems can improve overall health. Commonly reported problems are xerostomia (dry mouth), dental caries, periodontal disease, bruxism, temporomandibular joint disorder (TMD) and impacted third molar teeth.

Dental visits can be stressful, and result in lingering discomfort, debilitating fatigue, and prolonged recovery. Young patients with ME/CFS and orthostatic problems might not tolerate prolonged sitting in the dental chair and some young patients have difficulty in maintaining an open mouth for the duration of dental treatment.

During dental procedures, discomfort can be minimized by the use of a mouth prop to maintain an open posture of the mouth. The smallest size mouth prop that is effective should be used. Dentists also need to be familiar with the clinical features of OI and be prepared to treat patients at risk of developing syncope. Treatment planning of elective dentistry in more extensive cases should allow time between appointments to recover from fatigue.

Dry mouth can exist on its own, result from the effects of medications or from comorbid medical conditions. It can lead to rampant dental caries, exacerbation of periodontal disease, or oral candidiasis. Standard treatment includes increasing oral moistness with regular fluid intake, fluoride supplementation for home use, and professional dental prophylaxis.

Treatment for dental caries and periodontal disease follows standard dental practice. For those who might be concerned about whether mercury amalgam fillings should be avoided, all scientific and medical/dental organizations support the safety of amalgam.

Local anesthetics for pain relief in dental work are well-tolerated, but many young patients with ME/CFS and comorbid OI can develop serious side effects (syncope) from the use of the epinephrine/adrenalin which is included with local anesthetic agents. In these patients, a local anesthetic can be used without epinephrine. If a local anesthetic with added epinephrine is required, it should be administered with caution.

Temporomandibular joint disorders (TMD) and bruxism (tooth grinding) are more prevalent in ME/CFS patients than in the population at large and joint hypermobility comorbid with ME/CFS is a risk factor. Bruxism often results in loss of tooth structure and can exacerbate TMD. These conditions can cause significant TM joint pain and/or headache. They should be considered in the differential diagnosis of headache in patients with ME/CFS. For bruxism, an occlusal

guard can be prescribed to protect the dentition and to help alleviate TMD symptoms.

The overall approach to the management of impacted third molars (wisdom teeth) in young patients with ME/CFS is conservative: Asymptomatic, impacted, teeth that appear as if they will not erupt, or where there is room for proper eruption, are monitored. If the teeth are partially erupted, symptomatic, and/or, are affecting (or will potentially affect) the existing oral/dental condition, the third molars are generally removed. The impact on the patient of tooth removal is related to the difficulty of the extraction. In those patients who would be most affected by long, difficult, procedures and the possible need for IV or general anesthesia with a significant post-operative recovery time, we would recommend a more conservative approach. Each case must be evaluated individually.

7 AREAS OF SPECIAL CLINICAL CONCERN

7:1 SEVERELY AFFECTED AND VERY SEVERELY AFFECTED YOUNG PATIENTS

Some young patients with ME/CFS are severely ill and are wheelchair dependent, housebound, or bedridden, sometimes for months or years. Many are too debilitated to be brought to a doctor's office. A visit to a hospital emergency room can result in severe post-exertional symptoms. Published data on the characteristics of this group are lacking. Our clinicians estimate that about 5–10% of patients may be severely affected, and 2–5% may be very severely affected and bedridden at some time during the course of the illness, but no studies have confirmed these numbers. The course of the severe form of the illness is unpredictable. Many severely affected young patients do show varying degrees of improvement with time and some manage to return to full activities. A few remain severely affected.

ME/CFS in severely ill young patients is often difficult to manage and frequently these patients have received little help from medical practitioners. They can be socially isolated and frequently have to confront disbelief in the reality of their illness from family members, school personnel, social workers and physicians. They are in need of a great deal of practical help, emotional support, and comfort. In addition to medical supervision, they may require support from home health services and aides, perhaps overseen by a nurse manager. Patients' caregivers might also require support. They are under great stress and can sometimes benefit from counseling.

A vital part of management is to gain the trust of the young patient and caregivers by reassuring them that the illness is recognized as a physical illness, that it is taken very seriously, that the autonomy of the young patient will be respected, that all management/treatment options to be offered will be fully discussed with the patient and caregivers, and that informed consent will be requested prior to implementation of any therapy. The patient can be reassured that improvement is common, even if it takes months or years, and that recovery is possible, but cannot be guaranteed.

VERY SEVERELY AFFECTED PATIENTS

At the far end of the illness spectrum are the very severely affected patients. Although formal epidemiologic studies of this group have not been conducted, we believe these patients are relatively rare. Consequently, the average practitioner can be quite unprepared when confronted by a patient who is extremely ill with ME/CFS. These young patients are in an exceedingly unpleasant situation. Not only are the symptoms very distressing in their own right, but the patient often feels helpless and afraid, and is totally dependent on her/his caretakers.

CLINICAL FEATURES OF THE VERY SEVERELY AFFECTED CAN INCLUDE:

- A very high degree of symptom severity.
- Bedridden with profound weakness.
- Severe body pain and hyperesthesia.
- Marked sensitivity to sound, light, touch, odors, some foods, and/or medications.
- Hyper-somnolence in the early stages.
- Severe nausea, difficulty swallowing, occasionally requiring tube feeding.
- Difficulty getting to a toilet, requiring the use of a bottle, bedpan, diapers, and/or indwelling catheter.
- Difficulty communicating their needs to a caregiver, due to speech difficulties or exhaustion.
- Severe limitations of mental activity, including short-term memory impairment.
- Severe OI; might be unable to tolerate sitting up in bed.
- Difficulty tolerating being washed in bed due to hyperesthesia.
- Emotional changes secondary to the illness: patients can be very frightened and struggle with feelings of frustration, despair, and anger.
- Vitamin D deficiency in housebound patients and prolonged bed rest can lead to osteopenia.

MANAGEMENT OF THE VERY SEVERELY AFFECTED

Our advice is based on clinical experience, as there is little literature on this subject. Ideally, one physician should accept responsibility for the patient's care for the duration of the severe stage of the illness. If the patient is cared for at home, home visits are necessary. Further advice can also be given by telephone consultations or by e-mail. If the patient is very severely affected from the outset, confirmation of the diagnosis is first necessary. Where there is a marked deterioration in a moderately severely affected patient, the practitioner might need to exclude other illnesses. Consultation with physicians from other disciplines who are familiar with ME/CFS can be helpful. While remaining optimistic, the physician might find that she/he will need to accept the continuing severity of the illness. Likewise, the patient and the family might need to adjust their expectations to very modest levels. Although there are therapeutic options (see below), results of therapy are variable. Therefore, targets or predictions for recovery should be avoided.

The two best environments in which to care for the very severely affected patient are (a) the home and (b) an institution where long-term supportive care and symptom relief are the priorities and where the staff are familiar with the illness. Because of noise and bustle, a general hospital might be unsuitable. However, if general hospital care becomes necessary, attempts should be made to find a facility where the patient can be nursed in a very quiet location. We should caution that well-meaning attempts by hospital staff at too rapid "rehabilitation" (forcing the young patient to increase her/his activities too quickly) can lead to serious deterioration.

The best people to take care of the young patient are usually the parents. If the patient has to be admitted to an institution, attempts should be made to have one or two individual nurses be assigned to the patient.

MANAGEMENT GUIDELINES

- Protect the patient from undue physical, cognitive, and emotional stress.
- A very quiet environment that might include a darkened room.
- The use of patient eye pads can allow the physician to examine the patient in a low ambient light.
- Maintain fluid and nutritional intake by early recourse to tube feeding.
- General nursing care to consist of gentle help with turning, skin care and toileting. Diapers might be necessary.
- Prevention of venous thrombosis by passive physiotherapy.

More detailed information on further management strategies is available (148).

SYMPTOMATIC TREATMENT

Medications should be limited to those absolutely necessary, and initially prescribed in very low doses. They should be increased slowly, as tolerated.

- Provide generous pain relief (including opioids if necessary).

- Treat problems such as migraine, dysmenorrhea and orthostatic symptoms.
- Consider vitamin D supplementation in view of lack of exposure to sunlight.
- In rare cases that remain bedbound for prolonged periods, consider bisphosphonates for prevention of osteoporosis.

THERAPEUTIC OPTIONS

- Immunoglobulin therapy has shown some benefit in two randomized trials (section 5:7, "Immune System Support"). It can be given IV or IM. The IM injection can be painful.
- Regular use of IV saline can be helpful (section 6:1, "Orthostatic Intolerance").

PROGNOSIS OF VERY SEVERE ME/CFS

There is no published literature on prognosis in very severely affected young patients with ME/CFS. One follow-up study for a period of 7–10 years, of 24 young patients classified as having severe ME/CFS, found that 7 remained severely affected, 15 improved and were no longer classified as severe, and 2 patients had recovered (149).

ACTIVITY MANAGEMENT FOR THE HOMEBOUND PATIENT

While cognitive behavioral therapy (CBT) and graded exercise therapy (GET) have been promoted as of value in mild and moderate ME/CFS, there is no evidence that they are of therapeutic value in very severely affected patients. Inflexible GET is often harmful and leads to exacerbation of symptoms in severe cases. However, movement is important to help reduce stiffness, maintain range of motion and prevent contractures. In very severely affected patients who are confined to bed, movement is limited to tolerated activities of daily living. For those who can tolerate touch, a knowledgeable physical therapist can provide gentle, passive range-of-motion activity and gentle, passive stretching for brief periods of time (1 min at a time followed by a rest).

Any increase of activity, including moving around in bed, needs to be determined by the young patient her/himself. When possible, the gradual resumption of some activities of daily living can be encouraged, but the patient should not be pressured into this. Orthostatic symptoms might need to be treated before the patient is able to sit up for very long. Even when the patient can sit up, activity/physical therapy is usually easier when lying flat. Further progress is shown when the patient can tolerate sitting out of bed in a chair. When there is progress to the point that standing up is possible, minimal leisurely walking, for a few minutes daily, can be tried. Any activity program should allow severely ill patients to pace themselves and stay within their energy envelope, however small that might be.

7:2 THE POSSIBLE IMPACT OF ME/CFS ON THE FAMILY

ME/CFS in a child or adolescent presents challenges for the entire family. The challenges are similar to those faced by

families of children with other chronic illnesses such as leukemia or juvenile rheumatoid arthritis, but with the additional challenges of widespread disbelief in the authenticity of the illness, the pervasive social stigma associated with a diagnosis of ME/CFS, and a paucity of medical professionals who are knowledgeable about the illness.

In our experience, the majority of families draw on their strengths. The parents are usually able to provide the necessary care, and siblings learn to cope with diminished parental attention. When families cope well with their child's illness, the risk of emotional damage to siblings is minimized.

Difficulties can arise when family members are ill-informed about the illness, when they do not believe that the young patient has a physical illness, when one parent needs to cease working in order to take care of the sick, young person, when there is only one parent and the young person is too ill to go to school and has to be left at home alone, or when the school system is unable, or unwilling, to provide suitable education for the patient. As with other chronic illnesses, pre-existing marital difficulties can be compounded by the strain of dealing with a sick child. Sometimes disbelief in the authenticity of their child's illness has led the non-custodial parent to report the custodial parent to social services as a potential case of child neglect or factitious and induced illness/Munchausen's syndrome by proxy. Members of the wider extended family who show disbelief in the illness can also cause problems, even from a distance.

Research has shown that siblings of young patients with ME/CFS are more anxious than normal adolescents. Siblings identified factors having a negative impact on their lives, as lack of knowledge about the illness, change in their role in the family, lack of communication within the family, new restrictions placed on family life, change of parental focus, emotional reaction to having a sick sibling, and the social stigma of being the sibling of a young person with ME/CFS.

Communication within the family, social support, and extra activities, were found to have a positive impact (150).

Helpful strategies to support the family can include:

- Participation of both parents in the evaluation and management of the patient.
- Educating the immediate family about the illness and ensuring that siblings receive age-appropriate information.
- Enabling extended family members to be informed about ME/CFS, with the goal of fostering their support of the nuclear family.
- Encouraging communication between family members about management of the illness.
- Having the treating physician serve as an advocate for the patient with her/his school system.

7:3 IMMUNIZATIONS

Most young patients with ME/CFS tolerate standard immunizations. Immunization against human papilloma virus and hepatitis B are important for long-term health. Yearly immunization against influenza will prevent the serious relapse that can follow this illness. If possible, it should be administered when the patient is relatively well and it should be followed by 2–3 days of rest. Post immunization relapse has been reported, but is uncommon. Immunization of other family members can also help to protect the patient.

7:4 CONSIDERATIONS REGARDING SURGERY

In general, young patients with ME/CFS requiring surgery tolerate anesthesia well. Prior discussion with the surgeon and anesthesiologist/anesthetist about this illness and issues such as OI, pain control, and possible extended recovery times should be addressed. Further recommendations are given in Appendix F

8 THE SCHOOL SYSTEM

Major contributions by Faith Newton, Ed. D.

Myalgic encephalomyelitis/chronic fatigue syndrome is the most common cause of prolonged school absence due to illness (9, 13–16), and undiagnosed ME/CFS is also a frequent cause of poor school attendance. Absence from school is usually due to poor physical and cognitive function.

Sometimes, a knowledgeable teacher or a school nurse has been the first to suspect the illness in a student with undiagnosed ME/CFS. Some educators, however, have less understanding of ME/CFS and view ME/CFS as a behavioral issue (151).

Teachers, school nurses, and education officials need to be educated about ME/CFS and how it affects young people and their schooling. An educational fact sheet, giving information about the disease and its impact on education, is included in Appendix D.

It is helpful for school personnel to be aware that the ill

ness is very unpredictable, and that symptoms vary widely between patients and wax and wane. Large fluctuations in illness severity can occur, making planning and school attendance a challenge. Some students are able to attend school daily. Others can only manage a part-time schedule, while others are homebound or bedbound. Early in the illness, students might be too ill to attend school and this situation can sometimes persist for months or years. Sometimes a student who is able to attend school might appear fine one day and the next day be unable to go to school, and that inability to attend might continue for several weeks. Sometimes the student may be able to attend school in the early part of the week, but can't manage Thursday and Friday. A common pattern of absence is that following the summer break, students with ME/CFS are able to start the school term enthusiastically, but are incapable of keeping up with the increased activity involved in maintaining their school schedule over time. They "run out of steam," which can result in a prolonged

absence from school. While this might raise suspicions of truancy or school refusal in some school personnel, the student usually wants to attend school but is too ill to do so.

THE IMPORTANCE OF EDUCATION

The physician might need to take an active role in supporting young people with ME/CFS, ensuring that they receive an education that is appropriate for their physical condition. Long-term follow-up of young people with ME/CFS shows that engagement in education is a key issue that improves their ability to function regardless of whether or not they recover (23, 42). Students can become demoralized if they are asked to withdraw from school. Education helps students to fulfill their aspirations and allows important aspects of their lives, such as socializing with their peer group, to develop (152). It widens the range of possible occupations in later life. Work that is low-skilled is usually more physically demanding. Although students with ME/CFS have cognitive dysfunction and reduced energy reserves, intellectual reasoning is frequently retained and most students with ME/CFS are capable of keeping up with their peers in some academic classes provided that the number of their classes is strictly limited (153).

RELATIONSHIP BETWEEN THE SCHOOL, THE STUDENT, THE FAMILY, AND THE TREATING PHYSICIAN

During regular appointments with the young patient, the physician should ask how school is going. The clinician needs to be sensitive to the relationship between the young person, her/his parents, and the school. Many families have followed a long and circuitous route to a diagnosis and the young patient can be months, or years, behind in school by the time a diagnosis is reached. The young patient and parents often perceive dealing with the school to be very stressful, especially when they face disbelief about their “invisible” illness from teachers, other parents, and the young patient’s classmates (153). Compounding these stresses, parents see that their child’s academic performance has deteriorated and they might fear that she/he will not receive an education that eventually allows for employment and independent living. Many parents need to place their own lives and/or careers “on hold” in order to stay at home and take care of the young person. If both parents need to work, that can be problematic for the young patient at home alone.

Students who have understanding teachers, a flexible program, and assistance from sympathetic advocates often need less help from medical and psychological professionals. Schools differ in their response to a student with ME/CFS. Some schools are cooperative from the outset, while others resist the diagnosis, ignore the treating physician’s letters, do not follow the physician’s recommendations and may reach the point of becoming adversarial. Other schools might appear to agree with the recommendations, yet never follow through with implementation. Some schools might try to make a homebound student with ME/CFS return to school too early in order to save money on services such as homebound teaching. Some educators view ME/CFS as a behavioral issue and, in some instances have instituted legal proceedings because they have

wrongly believed that school absence in a student with ME/CFS was due to psychological factors such as school refusal, or the extremely rare condition of factitious disorder by proxy (Munchausen’s syndrome by proxy). As a result, young people seriously ill with ME/CFS have been removed from the care of their parents, sometimes for years.

IMPACT OF ME/CFS SYMPTOMS ON LEARNING

Several prominent ME/CFS symptoms affect the student’s ability to learn. Cognitive problems (often described as “brain fog”) are evident in most students even if they are less severely affected. Students experience mental confusion, forgetfulness, difficulty concentrating, a short attention span and a slowing of mental processing speed. Working memory can be significantly reduced and there is often increased distractibility, which can be exacerbated by noise in the classroom (85–87). There is no evidence of lower innate intelligence in ME/CFS. IQ scores are usually normal, but can be lower than the scores of healthy peers (154), likely related to processing and concentration problems during testing. Cognitive problems can sometimes mimic attention deficit disorder without hyperactivity. For those with more severe illness, cognitive problems are very limiting. Generally, if students are homebound, the most that they can manage are one or two essential or core subjects. Although not easy and requiring a real commitment, completing school work can give the student a real sense of achievement, which is important. The homebound student usually needs regular help from someone such as a Visiting/Homebound Teacher.

Students with ME/CFS are often unable to handle simple math calculations. They might be able to complete the steps to solve a complex problem correctly, but can make simple addition, subtraction, or multiplication mistakes. Teachers should be aware of this problem when grading tests (153).

Many young people with ME/CFS also experience orthostatic intolerance. Educators need to be aware that it is difficult for these students to stand or even sit for prolonged periods of time. These students might need to move around during lessons. They might also need access to drinks and salty snacks especially during testing. They might also be physically unable to complete long exams in one sitting.

Returning to school after a long absence can be a challenge. The illness might have occurred at a time when the student is transitioning to a new school and she/he might not be familiar with how the new school functions. The student might also have lost touch with her/his peer group. If the student needs to travel long distances to school, this is very tiring. The situation needs to be handled with understanding and patience.

EDUCATIONAL PLAN

Students with ME/CFS often need a personalized school schedule. The legal and procedural requirements for students to receive services for their disabilities vary significantly from place to place and are beyond the scope of this Primer.

Ideally, young people with ME/CFS will undergo an evaluation process, and an educational plan should be developed by the school after consultation with the student, the student's parents, and the student's physician. Neuropsychological testing is not routinely recommended to investigate the cognitive symptoms of ME/CFS for several reasons. First, affected ME/CFS patients often do not tolerate testing when they are at their most symptomatic, when cognitive problems might be identified. If tested on a relatively good day, they might not have scores that differ from healthy individuals. Second, neuropsychological testing in adolescents with ME/CFS is often only abnormal if the study sample is enriched with those who are reporting more difficulty with attention and memory (85, 86), or in the setting of concurrent physiological challenges such as during head-up tilt testing (50, 56). Third, this kind of testing is often not covered by insurance, and can be costly. At a practical level, the testing usually does not alter the suggested management, which most often is to decrease the volume of academic work.

Because ME/CFS symptom severity varies widely, clinicians should, whenever possible, recommend specific educational accommodations (see later) that are appropriate for the severity of symptoms. A sample physician's letter that can be used in the evaluation process can be found in Appendix E.

Regular communication with the school is helpful. For example, a supplemental doctor's note given to the parents can forewarn the school that a change in medication can have an adverse effect on the student's ability to function under the provisions of his or her educational plan. When the clinician can be seen by teachers and school administrators as a partner and a valuable resource, the process of accommodating a student with ME/CFS leads to better results.

EDUCATIONAL ACCOMMODATIONS

Any of the following can be recommended, depending on the student's physical condition:

In the school:

- A person designated as a single point of contact for both teachers and the family.
- A shortened day/shortened week; the student might arrive late, leave early, attend school for only part of the day and/or only 2 or 3 days a week; students with sleep reversal might not be able to manage morning classes.
- A reduction in course load and flexible scheduling where only classes in selected subjects are attended.
- A quiet place to rest if fatigue is evident to the student or the teacher.
- Use of the elevator to access different floors.

- Exemption from or modification of the physical education program.
- Provide homebound instruction or Distance Education for students who are partly or completely homebound.

In the classroom:

- Provide two sets of textbooks—one for school and one for home.
- Use the buddy system, so that someone can take notes in class, allow taping of classes, and/or give the student an outline of material taught.
- Permit the use of electronic devices such as a laptop or tablet and allow work to be completed and submitted online.
- Permit a student with orthostatic intolerance to move around during classes.
- Allow salty snacks and a water bottle for use in the classroom and especially during long tests.
- Provide tutorial or homebound instruction for work missed, or if the student is too ill to attend school.

Assessments/Testing:

- Allow flexibility with assignments and deadlines as well as modifications of the number of problems and/or assignments to be completed.
- Significant extended time might be needed for testing as well as adjusted time of day for assessments, depending on the time when the student functions best.
- Tests/Final Exams might need to be given over several days and/or sessions with water and snacks available.

SPORTS

Symptoms of ME/CFS frequently worsen after physical exertion. Some students might be able to participate in a short physical activity, but not an activity that requires stamina. Students need to be able to recognize and to inform the teacher when they are experiencing the onset of fatigue. When this occurs, the student *must* stop and rest. The student might want to continue, but failure to stop and rest at the onset of increased fatigue often causes a serious and prolonged relapse of symptoms. Students with ME/CFS should never be pressured to push themselves to their limits.

SOCIAL DEVELOPMENT

The classroom and the school lunchroom might be the only place where the student with ME/CFS is able to socialize with her/his peers. When possible, these opportunities should be facilitated (152, 153). Access to extra-curricular activities is also important for social reasons. Students who are unable to attend school often feel isolated at home, and miss their friends.

9 REFERENCES

1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. *Ann Intern Med* (1994) 121(12):953–9. doi:10.7326/0003-4819-121-12-199412150-00009
2. Institute of Medicine. *Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness*. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Washington, DC: The National Academies Press (2015).
3. World Health Organization. *International Classification of Diseases (ICD)*. (2016). Available from: <http://apps.who.int/classifications/icd10/> browse/2016/en#/G90-G99
4. Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. Chronic fatigue syndrome following infectious mononucleosis in adolescents. *Pediatrics* (2009) 124(1):189–93. doi:10.1542/peds.2008-1879
5. Bell KM, Cookfair D, Bell DS, Reese P, Cooper L. Risk factors associated with chronic fatigue syndrome in a cluster of pediatric cases. *Rev Infect Dis* (1991) 13(Suppl 1):S32–8. doi:10.1093/clinids/13.Supplement_1.S32
6. Siggurdsson B, Sigurjonsson J, Siggurdsson JH, Thorkelsson J, Gudmundsson JR. Disease epidemic in Iceland simulating poliomyelitis. *Am J Hyg* (1950) 52(2):222–3.
7. Bakken I, Tveito K, Gunnes N, Ghaderi S, Stoltenberg C, Trostad L, et al. Two age peaks in the incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study from Norway 2008–2012. *BMC Med* (2014) 12(1):167. doi:10.1186/s12916-014-0167-5
8. Davies S, Crawley E. Chronic fatigue syndrome in children aged 11 years old and younger. *Arch Dis Child* (2008) 93:419–22. doi:10.1136/adc.2007.126649
9. Nijhof SL, Maijer K, Bleijenberg G, Uiterwaal C, Kimpen JLL, van de Putte EM. Adolescent chronic fatigue syndrome: prevalence, incidence, and morbidity. *Pediatrics* (2011) 127(5):E1169–75. doi:10.1542/peds.2010-1147
10. Rimes KA, Goodman R, Hotopf M, Wessely S, Meltzer H, Chalder T. Incidence, prognosis, and risk factors for fatigue and chronic fatigue syndrome in adolescents: a prospective community study. *Pediatrics* (2007) 119(3):e603–9. doi:10.1542/peds.2006-2231
11. Reyes M, Nisenbaum R, Hoaglin DC, Unger ER, Emmons C, Randall B, et al. Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. *Arch Intern Med* (2003) 163:1530–6. doi:10.1001/archinte.163.13.1530
12. Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, et al. A community-based study of chronic fatigue syndrome. *Arch Intern Med* (1999) 159(18):2129–37. doi:10.1001/archinte.159.18.2129
13. Crawley EM, Emond AM, Sterne JAC. Unidentified chronic fatigue syndrome/ myalgic encephalomyelitis (cfs/me) is a major cause of school absence: surveillance outcomes from school-based clinics. *BMJ Open* (2011) 1(2):e000252. doi:10.1136/bmjopen-2011-000252
14. Dowsett EG, Colby J. Long-term sickness absence due to me/cfs in UK schools: an epidemiological study with medical and educational implications. *J Chronic Fatigue Syndr* (1997) 3(2):29–42. doi:10.1300/J092v03n02_04
15. Crawley EM, Sterne JA. Association between school absence and physical function in paediatric chronic fatigue syndrome/myalgic encephalopathy. *Arch Dis Child* (2009) 94(10):752–6. doi:10.1136/adc.2008.143537
16. Smith MS, Martin-Herz SP, Womack WM, Marsigan JL. Comparative study of anxiety, depression, somatization, functional disability, and illness attribution in adolescents with chronic fatigue or migraine. *Pediatrics* (2003) 111:e376–81. doi:10.1542/peds.111.4.e376
17. Kennedy G, Underwood C, Belch JFF. Physical and functional impact of chronic fatigue syndrome/myalgic encephalomyelitis in childhood. *Pediatrics* (2010) 125(6):e1324–30. doi:10.1542/peds.2009-2644
18. Winger A, Kvarstein G, Wyller VB, Ekstedt M, Sulheim D, Fagermoen E, et al. Health related quality of life in adolescents with chronic fatigue syndrome: a cross-sectional study. *Health Qual Life Outcomes* (2015) 13:96. doi:10.1186/s12955-015-0288-3
19. Rowe KS, Moon J. What is the natural history of chronic fatigue syndrome in young people? Oral presentation IACFS/ME conference Ottawa. *Bull IACFS/ ME Fall* (2011). p. 129.
20. Bell DS, Jordan K, Robinson M. Thirteen-year follow-up of children and adolescents with chronic fatigue syndrome. *Pediatrics* (2001) 107(5):994–8. doi:10.1542/peds.107.5.994
21. Gill AC, Dosen A, Ziegler JB. Chronic fatigue syndrome in adolescents: a follow-up study. *Arch Pediatr Adolesc Med* (2004) 158(3):225–9. doi:10.1001/archpedi.158.3.225
22. Van Geelen SM, Bakker RJ, Kuis W, Van De Putte EM. Adolescent chronic fatigue syndrome: a follow-up study. *Arch Pediatr Adolesc Med* (2010) 164(9):810–4. doi:10.1001/archpediatrics.2010.145
23. Rowe KS, Moon J. What is the natural history of chronic fatigue syndrome in young people? Paper Presented at IACFS/ME Biennial International Conference Ottawa Sept 24–26 2011, *Bulletin IACFS/ME*. Ottawa (2011). Abstract p129.
24. Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. *J Chronic Fatigue Syndr* (2003) 11(1):7–116. doi:10.1300/J092v11n01_02
25. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international consensus criteria. *J Intern Med* (2011) 270(4):327–38. doi:10.1111/j.1365-2796.2011.02428.x
26. Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, et al. Chronic fatigue syndrome: a working case definition. *Ann Intern Med* (1988) 108(3):387–9. doi:10.7326/0003-4819-108-3-387
27. Jason LA, Bell DS, Rowe K, Van Hoof ELS, Jordan K, Lapp C, et al. A pediatric case definition for myalgic encephalomyelitis and chronic fatigue syndrome. *J Chronic Fatigue Syndr* (2006) 13(2–3):1–44. doi:10.1300/J092v13n02_01
28. Knight S, Harvey A, Lubitz L, Rowe K, Reveley C, Veit F, et al. Paediatric chronic fatigue syndrome: complex presentations and protracted time to diagnosis. *J Paediatr Child Health* (2013) 49:919–24. doi:10.1111/jpc.12425
29. Underhill R, O’Gorman R. The prevalence of chronic fatigue syndrome and chronic fatigue among family members of CFS patients. *J Chronic Fatigue Syndr* (2006) 13(1):3–13. doi:10.1300/J092v13n01_02
30. Albright F, Light K, Light A, Bateman L, Cannon-Albright LA. Evidence for a heritable predisposition to chronic fatigue syndrome. *BMC Neurol* (2011) 11:62. doi:10.1186/1471-2377-11-62
31. Buchwald D, Herrell R, Ashton S, Belcourt M, Schmalting K, Sullivan P, et al. A twin study of chronic fatigue. *Psychosom Med* (2001) 63(6):936–43.
32. Barron DF, Cohen BA, Geraghty MT, Violand R, Rowe PC. Joint hypermobility is more common in children with chronic fatigue syndrome than in healthy controls. *J Pediatr* (2002) 141:421–5. doi:10.1067/mpd.2002.127496
33. Jason LA, Katz BZ, Shiraishi Y, Mears C, Im Y, Taylor RR. Predictors of post-infectious chronic fatigue syndrome in adolescents. *Health Psychol Behav Med* (2014) 2(1):41–51. doi:10.1080/21642850.2013.869176
34. Sulheim DE, Fagermoen E, Winger A, Andersen AM, Godang K, Muller F, et al. Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome: a combined cross-sectional and randomized clinical trial. Supplementary Online Content. *JAMA Pediatr* (2014) 168(Suppl eTable 8):22–3. doi:10.1001/jamapediatrics.2013.4647

35. Straus SE, Dale JK, Tobi M, Lawley T, Preble O, Blaese RM, et al. Acyclovir treatment of the chronic fatigue syndrome: lack of efficacy in a placebo-controlled trial. *N Engl J Med* (1988) 319:1692–8. doi:10.1056/NEJM198812293192602
36. Montoya JG, Kogelnik AM, Bhargoo M, Lunn MR, Flamand L, Merrihew LE, et al. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. *J Med Virol* (2013) 85:2101–9. doi:10.1002/jmv.23713
37. Diaz-Mitoma F, Turgonyi E, Kumar A, Lim W, Larocque L, Hyde BM. Clinical improvement in chronic fatigue syndrome is associated with enhanced natural killer cell-mediated cytotoxicity: the results of a pilot study with Isoprinosine. *J Chronic Fatigue Syndr* (2003) 11:71–95. doi:10.1300/J092v11n02_06
38. Natelson BH, Haghighi MH, Ponzio NM. Evidence for the presence of immune dysfunction in chronic fatigue syndrome. *Clin Diagn Lab Immunol* (2002) 9(4):747–52. doi:10.1128/CDLI.9.4.747-752.2002
39. Hardcastle SL, Brenu EW, Johnston S, Nguyen T, Huth T, Ramos S, et al. Longitudinal analysis of immune abnormalities in varying severities of chronic fatigue syndrome/myalgic encephalomyelitis patients. *J Transl Med* (2015) 13:299. doi:10.1186/s12967-015-0653-3
40. Klimas N, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. *J Clin Microbiol* (1990) 28(6):1403–10.
41. Itoh Y, Shigemori T, Igarashi T, Fukunaga Y. Fibromyalgia and chronic fatigue syndrome in children. *Pediatr Int* (2012) 54(2):266–71. doi:10.1111/j.1442-200X.2011.03514.x
42. Rowe KS. Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents. *J Psychiatr Res* (1997) 31(1):133–47. doi:10.1016/S0022-3956(96)00047-7
43. Kennedy G, Khan F, Hill A, Underwood C, Belch JFF. Biochemical and vascular aspects of pediatric chronic fatigue syndrome. *Arch Pediatr Adolesc Med* (2010) 164(9):817–23. doi:10.1001/archpediatrics.2010.157
44. Kavelaars A, Kuis W, Knook L, Sinnema G, Heijnen CJ. Disturbed neuroendocrine-immune interactions in chronic fatigue syndrome. *J Clin Endocrinol Metab* (2000) 85(2):692–6. doi:10.1210/jc.85.2.692
45. Broderick G, Katz BZ, Fernandes H, Fletcher MA, Klimas N, Smith FA, et al. Cytokine expression profiles of immune imbalance in post-mononucleosis chronic fatigue. *J Transl Med* (2012) 10:191. doi:10.1186/1479-5876-10-191
46. Wyller VB, Sørensen O, Sulheim D, Fagermoen E, Ueland T, Mollnes TE. Plasma cytokine expression in adolescent chronic fatigue syndrome. *Brain Behav Immun* (2015) 46:80–6. doi:10.1016/j.bbi.2014.12.025
47. Fluge O, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, et al. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. *PLoS One* (2011) 6:e26358. doi:10.1371/journal.pone.0026358
48. Rowe PC, Bou-Halaigh I, Kan JS, Calkins H. Is neurally mediated hypotension an unrecognized cause of chronic fatigue? *Lancet* (1995) 345:623–4. doi:10.1016/S0140-6736(95)90525-1
49. Stewart JM, Gewitz MH, Weldon A, Arlievsky N, Li K, Munoz J. Orthostatic intolerance in adolescent chronic fatigue syndrome. *Pediatrics* (1999) 103(1):116–21. doi:10.1542/peds.103.1.116
50. Stewart JM, Medow MS, Messer ZR, Baugham IL, Terilli C, Ocon AJ. Postural neurocognitive and neuronal activated cerebral blood flow deficits in young chronic fatigue syndrome patients with postural tachycardia syndrome. *Am J Physiol Heart Circ Physiol* (2012) 302:H1185. doi:10.1152/ajpheart.00994.2011.
51. Bou-Halaigh I, Rowe PC, Kan J, Calkins H. Relationship between neurally mediated hypotension and the chronic fatigue syndrome. *JAMA* (1995) 274:961–7. doi:10.1001/jama.1995.03530120053041
52. Galland BC, Jackson PM, Sayers RM, Taylor BJ. A matched case control study of orthostatic intolerance in children/adolescents with chronic fatigue syndrome. *Pediatr Res* (2008) 63(2):196–202. doi:10.1203/PDR.0b013e31815ed612
53. Katz BZ, Stewart JM, Shiraishi Y, Mears CJ, Taylor R. Orthostatic tolerance testing in a prospective cohort of adolescents with chronic fatigue syndrome and recovered controls following infectious mononucleosis. *Clin Pediatr* (2012) 51:835–9. doi:10.1177/0009922812455094
54. Tanaka H, Matsushima R, Tamai H, Kajimoto Y. Impaired postural cerebral hemodynamics in young patients with chronic fatigue with and without ortho-static intolerance. *J Pediatr* (2002) 140:412–7. doi:10.1067/mpd.2002.122725
55. Wyller VB, Due R, Saul JP, Amlie JP, Thaulow E. Usefulness of an abnormal cardiovascular response during low-grade head-up tilt-test for discriminating adolescents with chronic fatigue from healthy controls. *Am J Cardiol* (2007) 99:997–1001. doi:10.1016/j.amjcard.2006.10.067
56. Ocon AJ, Messer ZR, Medow MS, Stewart JM. Increasing orthostatic stress impairs neurocognitive functioning in chronic fatigue syndrome with postural tachycardia syndrome. *Clin Sci* (2012) 122(5):227–38. doi:10.1042/CS20110241
57. Hurwitz BE, Coryell VT, Parker M, Martin P, Laperriere A, Klimas NG, et al. Chronic fatigue syndrome: illness severity, sedentary lifestyle, blood volume and evidence of diminished cardiac function. *Clin Sci* (2010) 118(2):125–35. doi:10.1042/CS20090055
58. Okamoto LE, Raj SR, Peltier A, Gamboa A, Shibao C, Diedrich A, et al. Neurohumoral and haemodynamic profile in postural tachycardia and chronic fatigue syndromes. *Clin Sci* (2012) 122(4):183–92. doi:10.1042/CS20110200
59. Streeten DHP, Bell DS. Circulating blood volume in chronic fatigue syndrome. *J Chronic Fatigue Syndr* (1998) 4(1):3–11. doi:10.1300/J092v04n01_02
60. Streeten DHP, Thomas D, Bell DS. The roles of orthostatic hypotension, ortho-static tachycardia, and subnormal erythrocyte volume in the pathogenesis of the chronic fatigue syndrome. *Am J Med Sci* (2000) 320(1):1–8. doi:10.1016/S0002-9629(15)40790-6
61. Nijhof SL, Rutten JMTM, Uiterwaal C, Bleijenberg G, Kimpen JLL, van de Putte EM. The role of hypocortisolism in chronic fatigue syndrome. *Psychoneuroendocrinology* (2014) 42:199–206. doi:10.1016/j.psyneuen.2014.01.017
62. Segal TY, Hindmarsh PC, Viner RM. Disturbed adrenal function in adolescents with chronic fatigue syndrome. *J Pediatr Endocrinol Metab* (2005) 18(3):295–301. doi:10.1515/JPEM.2005.18.3.295
63. Tomoda A, Jhodoi T, Miike T. Chronic fatigue syndrome and abnormal biological rhythms in school children. *J Chronic Fatigue Syndr* (2001) 8(2):29–37. doi:10.1300/J092v08n02_03
64. McKenzie R, O'Fallon A, Dale J, Demitrac M, Sharma G, Deloria M, et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. *JAMA* (1998) 280:1061–6. doi:10.1001/jama.280.12.1061
65. Nakatomi Y, Mizuno K, Ishii A, Wada Y, Tanaka M, Tazawa S, et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: an 11c-(r)-pk11195 pet study. *J Nucl Med* (2014) 55:945–50. doi:10.2967/jnumed.113.131045
66. Barnden LR, Crouch B, Kwiatek R, Burnet R, Mernone A, Chrysosidis S, et al. A brain MRI study of chronic fatigue syndrome: evidence of brainstem dysfunction and altered homeostasis. *NMR Biomed* (2011) 24(10):1302–12. doi:10.1002/nbm.1692
67. PuriBK, Jakeman PM, AgourM, GunatillakeKD, Fernando KA, GurusingeAl, et al. Regional grey and white matter volumetric changes in myalgic encephalomyelitis (chronic fatigue syndrome): a voxel-based morphometry 3 t mri study. *Br J Radiol* (2012) 85(1015):e270–3. doi:10.1259/bjr/93889091
68. Yoshiuchi K, Farkas J, Natelson BH. Patients with chronic fatigue syndrome have reduced absolute cortical blood flow.

- Clin Physiol Funct Imaging* (2006) 26:83–6. doi:10.1111/j.1475-097X.2006.00649.x
69. Murrough JW, Mao X, Collins KA, Kelly C, Andrade G, Nestadt P, et al. Increased ventricular lactate in chronic fatigue syndrome measured by 1h mrs imaging at 3.0 t. II: comparison with major depressive disorder. *NMR Biomed* (2010) 23(6):643–50. doi:10.1002/nbm.1512
70. Shungu DC, Weiduschat N, Murrough JW, Mao X, Pillemer S, Dyke JP, et al. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. *NMR Biomed* (2012) 25(9):1073–87. doi:10.1002/nbm.2772
71. Cook DB, O'Connor PJ, Lange G, Steffener J. Functional neuroimaging correlates of mental fatigue induced by cognition among chronic fatigue syndrome patients and controls. *Neuroimage* (2007) 36(1):108–22. doi:10.1016/j.neuroimage.2007.02.033
72. Mizuno K, Tanaka M, Tanabe HC, Joudoi T, Kawatani J, Shigihara Y, et al. Less efficient and costly processes of frontal cortex in childhood chronic fatigue syndrome. *Neuroimage Clin* (2015) 9:355–68. doi:10.1016/j.nicl.2015.09.001
73. Schmalzing KB, Lewis DH, Fiedelak JL, Mahurin R, Buchwald DS. Single-photon emission computerized tomography and neurocognitive function in patients with chronic fatigue syndrome. [Erratum appears in psychosom med. 2003 Mar–Apr; 65(2):210]. *Psychosom Med* (2003) 65(1):129–36. doi:10.1097/01.PSY.0000038942.33335.9B
74. Medow MS, Sood S, Messer Z, Dzagbeta S, Terilli C, Stewart JM. Phenylephrine alteration of cerebral blood flow during orthostasis: effect on N-back performance in chronic fatigue syndrome. *J Appl Physiol* (2014) 117:1157–64. doi:10.1152/jappphysiol.00527.2014
75. Jones DE, Hollingsworth KG, Jakovljevic DG, Fattakhova G, Pairman J, Blamire AM, et al. Loss of capacity to recover from acidosis on repeat exercise in chronic fatigue syndrome: a case-control study. *Eur J Clin Invest* (2012) 42(2):186–94. doi:10.1111/j.1365-2362.2011.02567.x
76. Van Ness JM, Snell CR, Stevens SR. Diminished cardiopulmonary capacity during post-exertional malaise. *J Chronic Fatigue Syndr* (2007) 14:77–85. doi:10.1300/J092v14n02_07
77. Keller BA, Pryor JL, Giloteaux L. Inability of myalgic encephalomyelitis/ chronic fatigue syndrome patients to reproduce VO2peak indicates functional impairment. *J Transl Med* (2014) 12(1):104. doi:10.1186/1479-5876-12-104
78. Snell CR, Stevens SR, Davenport TE, Van Ness JM. Discriminative validity of metabolic and workload measurements for identifying people with chronic fatigue syndrome. *Phys Ther* (2013) 93(11):1484–92. doi:10.2522/ptj.20110368
79. Katz BZ, Boas S, Shiraiishi Y, Mears CJ, Taylor R. Exercise tolerance testing in a prospective cohort of adolescents with chronic fatigue syndrome and recovered controls following infectious mononucleosis. *J Pediatr* (2010) 157(3):468–472,472.e461. doi:10.1016/j.jpeds.2010.03.025
80. Booth NE, Myhill S, McLaren-Howard J. Mitochondrial dysfunction and the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *Int J Clin Exp Med* (2012) 5(3):208–20.
81. Wallace DC. A mitochondrial bioenergetic etiology of disease. *J Clin Invest* (2013) 123(4):1405–12. doi:10.1172/JCI61398
82. Kerr J, Petty R, Burke B, Gough J, Fear D, Sinclair LJ, et al. Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. *Infect Dis* (2008) 197(8):1171–84. doi:10.1086/533453
83. Light AR, White AT, Hughes RW, Light KC. Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. *J Pain* (2009) 10(10):1099–112. doi:10.1016/j.jpain.2009.06.003
84. de Vega WC, Vernon SD, McGowan PO. DNA methylation modifications associated with chronic fatigue syndrome. *PLoS One* (2014) 9:e104757. doi:10.1371/journal.pone.0104757
85. Haig-Ferguson A, Tucker P, Eaton N, Hunt L, Crawley E. Memory and attention problems in children with chronic fatigue syndrome or myalgic encephalopathy. *Arch Dis Child* (2009) 94(10):757–62. doi:10.1136/adc.2008.143032
86. Tucker P, Haig-Ferguson A, Eaton N, Crawley E. What to do about attention and memory problems in children with CFS/ME: a neuropsychological approach. *Clin Child Psychol Psychiatry* (2011) 16(2):215–23. doi:10.1177/1359104511403585
87. Cockshell SJ, Mathias JL. Cognitive functioning in chronic fatigue syndrome: a meta-analysis. *Psychol Med* (2010) 40:1253–67. doi:10.1017/S0033291709992054
88. Rowe KS. Does depression at presentation impact on outcomes for young people with CFS? *IACFS/ME Conference*. San Francisco (2014).
89. Shaw RJ, Dayal S, Hartman JK, DeMaso DR. Factitious disorder by proxy: pediatric condition falsification. *Harv Rev Psychiatry* (2008) 16(4):215–24. doi:10.1080/10673220802277870
90. M.E. Parents Fury at Child Abuse Claims. (2015). Available from: www.meassociation.org.uk/2015/06/m-e-parents-fury-at-child-abuse-claims-sunday-express-21-june-2015/
91. Fremont WP. School refusal in children and adolescents. *Am Fam Physician* (2003) 68(8):1555–60.
92. Walker LS, Greene JW. The functional disability inventory: measuring a neglected dimension of child health status. *J Pediatr Psychol* (1991) 16:39–58. doi:10.1093/jpepsy/16.1.39
93. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. *Med Care* (2001) 39:800–12. doi:10.1097/00005650-200108000-00006
94. Bentall RP, Wood GC, Marrinan T, Deans C, Edwards RHT. A brief mental fatigue questionnaire. *Br J Clin Psychol* (1993) 32:375–9. doi:10.1111/j.2044-8260.1993.tb01070.x
95. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* (1991) 14(6):540–5. doi:10.1093/sleep/14.6.540
96. Peuhkuri K, Sihvola N, Korpela R. Diet promotes sleep duration and quality. *Nutr Res* (2012) 32(5):309–19. doi:10.1016/j.nutres.2012.03.009
97. Bell DS. Chronic fatigue syndrome in children. *J Chronic Fatigue Syndr* (1995) 1:9–33. doi:10.1300/J092v01n01_03
98. Bell DS, Bell KM, Cheney PR. Primary juvenile fibromyalgia syndrome and chronic fatigue syndrome in adolescents. *Clin Infect Dis* (1994) 18(Suppl 1):S21–3. doi:10.1093/clinids/18.Supplement_1.S21
99. Rowe KS, Rowe KJ. Symptom patterns of children and adolescents with chronic fatigue syndrome. In: Nirbhay THO, Singh N, Ashvind NS, editors. *International Perspectives on Child and Adolescent Mental Health*. (Vol. 2), Kuala Lumpur: Elsevier (2002). p. 395–421.
100. Vermeulen RC, Kurk RM, Visser FC, Sluiter W, Scholte HR. Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. *J Transl Med* (2010) 8:93. doi:10.1186/1479-5876-8-93
101. Twisk FN, Maes M. A review on cognitive behavioral therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME)/ chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. *Neuro Endocrinol Lett* (2009) 30(3):284–99.
102. Takenaka KY, Suzuki Y, Uno K, Sato M, Komuro T, Haruna Y, et al. Effects of rapid saline infusion on orthostatic intolerance and autonomic tone after 20 days bed rest. *Am J Cardiol* (2002) 89:557–61. doi:10.1016/S0002-9149(01)02296-2
103. Jason LA, Muldowney K, Torres-Harding S. The energy envelope theory and myalgic encephalomyelitis/chronic fatigue syndrome. *AAOHN J* (2008) 56(5):189–95. doi:10.3928/08910162-20080501-06
104. Rowe PC, Marden CL, Flaherty MAK, Jasione SE, Cranston EM, Johns AS, et al. Impaired range of motion of limbs and spine in chronic fatigue syndrome. *J Pediatr* (2014) 165:360–6. doi:10.1016/j.jpeds.2014.04.051

105. Olson LG, Ambrogetti A, Sutherland DC. A pilot randomized controlled trial of dexamphetamine in patients with chronic fatigue syndrome. *Psychosomatics* (2003) 44:38–43. doi:10.1176/appi.psy.44.1.38
106. Blockmans D, Persoons P, van Houdenhove B, Bobbaers H. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? *Am J Med* (2006) 119:167.e23–30. doi:10.1016/j.amjmed.2005.07.047
107. Young JL. Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: a double blind, placebo-controlled study. *Psychiatry Res* (2013) 207:127–33. doi:10.1016/j.psychres.2012.09.007
108. Randall DC, Cafferty FH, Shneerson JM, Smith IE, Llewelyn MB, File SE. Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. *J Psychopharmacol* (2005) 19:647–60. doi:10.1177/0269881105056531
109. Regland B, Forsmark S, Halaouate L, Matousek M, Peilot B, Zachrisson O, et al. Response to vitamin B12 and folic acid in myalgic encephalomyelitis and fibromyalgia. *PLoS One* (2015) 10(4):e0124648. doi:10.1371/journal.pone.0124648
110. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. *J Allergy Clin Immunol* (2008) 122:1238–9. doi:10.1016/j.jaci.2008.08.033
111. Rimes KA, Wingrove J. Mindfulness-based cognitive therapy for people with chronic fatigue syndrome still experiencing excessive fatigue after cognitive behaviour therapy: a pilot randomized stud. *J Clin Psychol Psychotherapy* (2013) 20(2):107–17. doi:10.1002/cpp.793
112. Knight SJ, Scheinberg A, Harvey AR. Interventions in pediatric chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review. *J Adolesc Health* (2013) 53(2):154–65. doi:10.1016/j.jadohealth.2013.03.009
113. Knoop H, Stulemeijer M, de Jong LW, Fiselier TJ, Bleijenberg G. Efficacy of cognitive behavioral therapy for adolescents with chronic fatigue syndrome: long-term follow-up of a randomized, controlled trial. *Pediatrics* (2008) 121(3):e619–25. doi:10.1542/peds.2007-1488
114. Nijhof SL, Priesterbach LP, Uiterwaal CS, Bleijenberg G, Kimpen JL, van de Putte EM. Internet-based therapy for adolescents with chronic fatigue syndrome: long-term follow-up. *Pediatrics* (2013) 131(6):e1788–95. doi:10.1542/peds.2012-2007
115. Stulemeijer M, de Jong LW, Fiselier TJ, Hoogveld SW, Bleijenberg G. Cognitive behaviour therapy for adolescents with chronic fatigue syndrome: randomised controlled trial. *BMJ* (2005) 330(7481):14; Erratum in: *BMJ* (2005) 330(7495):820. doi:10.1136/bmj.38301.587106.63
116. O'Dowd H, Gladwell P, Rogers CA, Hollinghurst S, Gregory A. Cognitive behavioural therapy in chronic fatigue syndrome: a randomised controlled trial of an outpatient group programme. *Health Technol Assess* (2006) 10(37):iii–iv,ix–x,1–121. doi:10.3310/hta10370
117. Price JR, Mitchell E, Tidy E, Hunot V. Cognitive behavioural therapy for chronic fatigue syndrome in adults. *Cochrane Database Syst Rev* (2008) 3:CD001027. doi:10.1002/14651858.CD001027
118. Lloyd AR, Hickie I, Brockman A, Hickie C, Wilson A, Dwyer J, et al. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. *Am J Med* (1993) 94(2):197–203. doi:10.1016/0002-9343(93)90183-P
119. Friedberg F, Sohl S. Cognitive-behavior therapy in chronic fatigue syndrome: is improvement related to increased physical activity? *J Clin Psychol* (2009) 65:423–42. doi:10.1002/jclp.20551
120. Nijhof SL, Bleijenberg G, Uiterwaal CS, Kimpen JL, van de Putte EM. Effectiveness of internet-based cognitive behavioural treatment for adolescents with chronic fatigue syndrome (FITNET): a randomised controlled trial. *Lancet* (2012) 379(9824):1412–8. doi:10.1016/S0140-6736(12)60025-7
121. Van Houdenhov B, Luyten P. Treatment of chronic fatigue syndrome: how to find a 'new equilibrium'? *Patient Educ Couns* (2009) 77:153–4. doi:10.1016/j.pec.2009.09.001
122. Alraek T, Lee MS, Choi TY, Cao H, Liu J. Complementary and alternative medicine for patients with chronic fatigue syndrome: a systematic review. *BMC Complement Altern Med* (2011) 11:87. doi:10.1186/1472-6882-11-87
123. Porter NS, Jason LA, Boulton A, Bothne N, Coleman B. Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia. *J Altern Complement Med* (2010) 16(3):235–49. doi:10.1089/acm.2008.0376
124. Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. *Clin Auton Res* (2011) 21:69–72. doi:10.1007/s10286-011-0119-5
125. MacLean AR, Allen EV. Orthostatic hypotension and orthostatic tachycardia: treatment with the "head-up" bed. *JAMA* (1940) 115:2162–7. doi:10.1001/jama.1940.02810510038010
126. Van Lieshout JJ, ten Harkel ADJ, Wieling W. Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. *Clin Auton Res* (2000) 10:35–42. doi:10.1007/BF02291388
127. Boehm KE, Kip KT, Grubb BP, Kosinski DJ. Neurocardiogenic syncope: response to hormonal therapy. *Pediatrics* (1997) 99:623–5. doi:10.1542/peds.99.4.623
128. Grubb BP, Samoil D, Kosinski D, Kip K, Brewster P. Use of sertraline chloride in the treatment of refractory neurocardiogenic syncope in children and adolescents. *J Am Coll Cardiol* (1994) 24:480–4. doi:10.1016/0735-1097(94)90308-5
129. Moak JP, Leong D, Fabian R, Freedenberg V, Jarosz E, Toney C, et al. Intravenous hydration for management of medication-resistant orthostatic intolerance in the adolescent and young adult. *Pediatr Cardiol* (2015) 37(2):278–82. doi:10.1007/s00246-015-1274-6
130. Malfait F, De Paepe A. The Ehlers-Danlos syndrome. *Adv Exp Med Biol* (2014) 802:129–43.
131. Rowe PC, Barron DF, Calkins H, Maumenee IH, Tong PY, Geraghty MT. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. *J Pediatr* (1999) 135:494–9. doi:10.1016/S0022-3476(99)70173-3
132. De Wande I, Calders P, Peersman W, Rimbaut S, De Backer T, Malfait F, et al. Autonomic symptom burden in the hypermobility type of Ehlers-Danlos syndrome: a comparative study with two other EDS types, fibromyalgia, and healthy controls. *Semin Arthritis Rheum* (2014) 44(3):353–61. doi:10.1016/j.semarthrit.2014.05.013
133. Rombaut L, Malfait F, Cool A, de Paepe A, Calders P. Musculoskeletal complaints, physical activity and health-related quality of life among patients with the Ehlers-Danlos syndrome hypermobility type. *Disabil Rehabil* (2010) 32(16):1339–45. doi:10.3109/09638280903514739
134. Voermans NC, Knoop H, van de Kamp N, Hamel BC, Bleijenberg G, van Engelen BG. Fatigue is a frequent and clinically relevant problem in Ehlers-Danlos Syndrome. *Semin Arthritis Rheum* (2010) 40:267–267. doi:10.1016/j.semarthrit.2009.08.003
135. Beard RW, Reginal PW, Wadsworth J. Clinical features of women with chronic lower abdominal pain and pelvic congestion. *Br J Obstet Gynaecol* (1988) 95:153–61. doi:10.1111/j.1471-0528.1988.tb06845.x
136. Venbrux AC, Lambert DL. Embolization of the ovarian veins as a treatment for patients with chronic pelvic pain caused by pelvic vein incompetence (pelvic congestion syndrome). *Curr Opin Obstet Gynecol* (1999) 11:395–9. doi:10.1097/00001703-199908000-00006
137. Venbrux AC, Chang AH, Kim HS, Montague BJ, Hebert JB, Arepally A, et al. Pelvic congestion syndrome (pelvic venous

- incompetence): impact of ovarian and internal iliac vein embolotherapy on menstrual cycle and chronic pelvic pain. *J Vasc Interv Radiol* (2002) 13:171–8. doi:10.1016/S1051-0443(07)61935-6
138. Rowe PC, Marden CL, Jasion SE, Cranston EM, Flaherty MA, Kelly KJ. Cow's milk protein intolerance in adolescents and young adults with chronic fatigue syndrome. *Acta Paediatr* (2016) 105(9):e412–8. doi:10.1111/apa.13476
139. Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. *Gastroenterology* (1995) 109:1503–12. doi:10.1016/0016-5085(95)90637-1
140. Evans M, Barry M, Im Y, Brown A, Jason LA. An investigation of symptoms predating CFS onset. *J Prev Interv Community* (2015) 43(1):54–61. doi:10.1080/10852352.2014.973240
141. Afrin LB. Presentation, diagnosis, and management of mast cell activation syndrome. In: Murray DB, editor. *Mast Cells*. Hauppauge, NY: Nova Science Publishers, Inc. (2013). p. 155–232.
142. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. *J Allergy Clin Immunol* (2010) 126:1099–104. doi:10.1016/j.jaci.2010.08.035
143. Shibao C, Arzubiaga C, Jackson Roberts L, Raj S, Black B, Harris P, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. *Hypertension* (2005) 45:385–90. doi:10.1161/01.HYP.0000158259.68614.40
144. Lyons JJ, Sun G, Stone KD, Nelson C, Wisch L, O'Brien M, et al. Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. *J Allergy Clin Immunol* (2014) 133:1471–4. doi:10.1016/j.jaci.2013.11.039
145. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. *J Hematol Oncol* (2011) 4:10. doi:10.1186/1756-8722-4-10
146. Heffez DS, Ross RE, Shade-Zeldow Y, Kostas K, Shah S, Gottschalk R, et al. Clinical evidence for cervical myelopathy due to Chiari malformation and spinal stenosis in a non-randomized group of patients with the diagnosis of fibromyalgia. *Eur Spine J* (2004) 13:516–23. doi:10.1007/s00586-004-0672-x
147. Milhorat TH, Chou MW, Trinidad EM, Kula RW, Mandell M, Wolpert C, et al. Chiari I malformation redefined: clinical and radiographic findings for 364 symptomatic patients. *Neurosurgery* (1999) 44:1005–17. doi:10.1097/00006123-199905000-00042
148. Collingridge E. *Severe ME/CFS: A Guide to Living*. Great Britain: AYME (2010). p. 1–140.
149. Speight AN, Kumar P, Sabai J. *Paediatric Chronic Fatigue Syndrome in One Health Authority—Epidemiology, Spectrum of Severity and Natural History*. Alison Hunter Memorial Foundation Clinical and Scientific Meeting. Cardiff (2001). Available from: http://adc.bmj.com/content/archdischild/82/suppl_1/A55.full.pdf (accessed May 21, 2017).
150. Velleman S, Collins SM, Beasant L, Crawley E. Psychological wellbeing and quality-of-life among siblings of paediatric CFS/ME patients: a mixed-methods study. *Clin Child Psychol Psychiatry* (2016) 21(4):618–33. doi:10.1177/1359104515602373
151. Newton F. *Chronic Fatigue Syndrome*. National Association of Special Education Teachers. (2014). Available from: www.naset.org/3349.0.html
152. Bell DS, Carruthers BM. *Teach-me: A Sourcebook for Teachers of Young People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia Syndrome*. 2nd ed. Nepean, ON: National ME/FM Action Network (2005). Available from: http://mefmaction.com/images/stories/Support/Teach_Me_Eng.pdf
153. Newton F. Improving Academic Success for students with myalgic encephalomyelitis/chronic fatigue syndrome. *Fatigue Biomed Health Behav* (2015) 3(2):97–103. doi:10.1080/21641846.2015.1004831
154. Nijhof LN, Nijhof SL, Bleijenberg G, Stellato RK, Kimpen JL, Hulshoff Pol HE, et al. The impact of chronic fatigue syndrome on cognitive functioning in adolescents. *Eur J Pediatr* (2016) 175(2):245–52. doi:10.1007/s00431-015-2626-1
155. Ang-Lee MK, Moss J, Yuan CS. Herbal medications and perioperative care. *JAMA* (2001) 286(2):208–16.
156. Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS). *J Cardiovasc Electrophysiol* (2009) 20:352–8. doi:10.1111/j.1540-8167.2008.01407.x
157. Rowe PC, Bou-Holaigah I, Kan JS, Calkins H. Is neurally mediated hypotension an unrecognized cause of chronic fatigue? *Lancet* (1995) 345:623–4. doi:10.1016/S0140-6736(95)90525-1
158. Stewart J, Weldon A, Arlievsky N, Li K, Munoz J. Neurally mediated hypotension and autonomic dysfunction measured by heart rate variability during head-up tilt testing in children with chronic fatigue syndrome. *Clin Auton Res* (1998) 8:221–30. doi:10.1007/BF02267785
159. Wyller VB, Saul JP, Amlie JP, Thaulow E. Sympathetic predominance of cardiovascular regulation during mild orthostatic stress in adolescents with chronic fatigue. *Clin Physiol Funct Imaging* (2007) 27:231–8. doi:10.1111/j.1475-097X.2007.00743.x
160. Wyller VB, Saul JP, Walloe L, Thaulow E. Sympathetic cardiovascular control during orthostatic stress and isometric exercise in adolescent chronic fatigue syndrome. *Eur J Appl Physiol* (2008) 102:623–32. doi:10.1007/s00421-007-0634-1
161. Wyller VB, Thaulow E, Amlie JP. Treatment of chronic fatigue and orthostatic intolerance with propranolol. *J Pediatr* (2007) 150:654–5. doi:10.1016/j.jpeds.2007.03.012
162. Rowell L. *Human Cardiovascular Control*. New York: Oxford University Press (1992)
163. Medow MS, Stewart JM, Sanyal S, Mumtaz A, Sica D, Frishman WH. Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasovagal syncope. *Cardiol Rev* (2008) 16:4–20. doi:10.1097/CRD.0b013e31815c8032
164. Weiling W, Shepherd JT. Initial and delayed circulatory responses to ortho-static stress in normal humans and in subjects with orthostatic intolerance. *Int Angiol* (1992) 11:69–82.
165. Wyller VB, Evang JA, Godang K, Solhjell KK, Bollerslev J. Hormonal alterations in adolescent chronic fatigue syndrome. *Acta Paediatr* (2010) 99:770–3. doi:10.1111/j.1651-2227.2010.01701.x
166. Fortney SM, Schneider VS, Greenleaf JE. The physiology of bed rest. In: Fregley MJ, Blatters CM, editors. *Handbook of Physiology. Section 4: Environmental Physiology*. (Vol. II), New York: Oxford University Press (1996). p. 889–939.
167. Hyatt KH, Jacobson LB, Schneider VS. Comparison of 70° tilt, LBNP, and passive standing as measures of orthostatic tolerance. *Aviat Space Environ Med* (1975) 46:801–8.
168. Rosen SG, Cryer PE. Postural tachycardia syndrome: reversal of sympathetic hyperresponsiveness and clinical improvement during sodium loading. *Am J Med* (1982) 72:847–50. doi:10.1016/0002-9343(82)90559-9
169. Benditt DG, Ermie C, Padamilan B, Samniah N, Sakaguchi S. Catecholamine response during hemodynamically stable upright posture in individuals with and without tilt-table induced vasovagal syncope. *Europace* (2003) 5:65–70. doi:10.1053/eupc.2002.0271
170. Goldstein DS, Eldadah B, Holmes C, Pechnik S, Moak J, Sharabi Y. Neurocirculatory abnormalities in chronic orthostatic intolerance. *Circulation* (2005) 111:839–45. doi:10.1161/01.CIR.0000155613.20376.CA
171. Sandroni P, Opfer-Gehrking TL, Benarroch EE, Shen WK, Low PA. Certain cardiovascular indices predict syncope in the postural tachycardia syndrome. *Clin Auton Res* (1996) 6:225–31. doi:10.1007/BF02291138
172. Rowe PC, Calkins H, DeBusk K, McKenzie R, Anand R, Sharma G, et al. Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. *JAMA* (2001) 285:52–9. doi:10.1001/jama.285.1.52

173. Kanjwal K, Sheikh M, Karabin B, Kanjwal Y, Grubb BP. Neurocardiogenic syncope coexisting with postural orthostatic tachycardia syndrome in patients suffering from orthostatic intolerance: a combined form of autonomic dysfunction. *Pacing Clin Electrophysiol* (2011) 34:549–54. doi:10.1111/j.1540-8159.2010.02994.x
174. Stewart JM, Clarke D. “He’s dizzy when he stands up”: an introduction to initial orthostatic hypotension. *J Pediatr* (2011) 158(3):499–504. doi:10.1016/j.jpeds.2010.09.004
175. Tanaka H, Fujita Y, Takenaka Y, Kajiura S, Masutani S, Ishizaki Y, et al. Japanese clinical guidelines for juvenile orthostatic dysregulation version 1. *Pediatr Int* (2009) 51:169–79. doi:10.1111/j.1442-200X.2008.02783.x
176. Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? *Neurology* (1993) 43:132–7. doi:10.1212/WNL.43.1_Part_1.132
177. Raj SR. Postural tachycardia syndrome (POTS). *Circulation* (2013) 127:2336–42. doi:10.1161/CIRCULATIONAHA.112.144501
178. Stewart JM. Common syndromes of orthostatic intolerance. *Pediatrics* (2013) 131:1–13. doi:10.1542/peds.2012-2610
179. Singer W, Sletten DM, Opfer-Gehrking TL, Brands CK, Fischer PR, Low PA. Postural tachycardia syndrome in children and adolescents: what is abnormal? *J Pediatr* (2012) 160:222–6. doi:10.1016/j.jpeds.2011.08.054
180. Grubb BP. Neurocardiogenic syncope. *N Engl J Med* (2005) 352:1004–10. doi:10.1056/NEJMc042601
181. Wieling W, Ganzeboom KS, Saul JP. Reflex syncope in children and adolescents. *Heart* (2004) 90:1094–100. doi:10.1136/hrt.2003.022996
182. Jhanjee R, Can I, Benditt DG. Syncope. *Dis Mon* (2009) 55:532–85. doi:10.1016/j.disamonth.2009.04.004
183. van Lieshout JJ, Wieling W, Karemaker JM, Eckberg DL. The vasovagal response. *Clin Sci* (1991) 81:575–86. doi:10.1042/cs0810575
184. Jardine DL, Melton IC, Crozier IG, Bennett SI, Donald RA, Ikram H. Neurohormonal response to head-up tilt and its role in vasovagal syncope. *Am J Cardiol* (1997) 79:1302–6. doi:10.1016/S0002-9149(9X)00084-9
185. Rose MS, Koshman ML, Spreng S, Sheldon R. The relationship between health-related quality of life and frequency of spells in patients with syncope. *J Clin Epidemiol* (2000) 53:1209–16. doi:10.1016/S0895-4356(00)00257-2
186. Kenney RA, Graham LA. Chronic fatigue syndrome symptoms common in patients with vasovagal syncope. *Am J Med* (2001) 110:242–3. doi:10.1016/S0002-9343(00)00704-X
187. Legge H, Norton M, Newton JL. Fatigue is significant in vasovagal syncope and is associated with autonomic symptoms. *Europace* (2008) 10:1095–101. doi:10.1093/europace/eun164
188. Martinez-Lavin M. Biology and therapy of fibromyalgia. Stress, the stress response system, and fibromyalgia. *Arthritis Res Ther* (2006) 9:216. doi:10.1186/ar2146
189. Stewart JM, Gewitz MH, Weldon A, Munoz J. Patterns of orthostatic intolerance: the orthostatic tachycardia syndrome and adolescent chronic fatigue. *J Pediatr* (1999) 135:218–25. doi:10.1016/S0022-3476(99)70025-9
190. Benditt DG, Ferguson DW, Grubb BP, Kapoor WN, Kugler J, Lerman BB, et al. Tilt table testing for assessing syncope. *J Am Coll Cardiol* (1996) 28:263–75. doi:10.1016/0735-1097(96)00236-7
191. Moya A, Sutton R, Ammirati F, Blanc JJ, Brignole M, Dahm JB, et al. Guidelines for the diagnosis and management of syncope (version 2009). *Eur Heart J* (2009) 30:2631–71. doi:10.1093/eurheartj/ehp298
192. Sheldon R. Tilt testing for syncope: a reappraisal. *Curr Opin Cardiol* (2005) 20:38–41.
193. Natale A, Akhtar M, Jazayeri M, Dhala A, Blanck Z, Deshpande S, et al. Provocation of hypotension during head-up tilt testing in subjects with no history of syncope or presyncope. *Circulation* (1995) 92:54–8. doi:10.1161/01.CIR.92.1.54
194. Naschitz JE, Rosner I, Rozenbaum M, Gaitini L, Bistrizki I, Zuckerman E, et al. The capnography head-up tilt test for evaluation of chronic fatigue syndrome. *Semin Arthritis Rheum* (2000) 30:79–86. doi:10.1053/sarh.2000.9201
195. Razumovsky AY, DeBusk K, Calkins H, Snader S, Lucas KE, Vyas P, et al. Cerebral and systemic hemodynamics changes during upright tilt in chronic fatigue syndrome. *J Neuroimaging* (2003) 13:57–67. doi:10.1111/1/j.1552-6569.2003.tb00158.x
196. Natelson BH, Intriligator R, Cherniack NS, Chandler HK, Stewart JM. Hypocapnia is a biological marker for orthostatic intolerance in some patients with chronic fatigue syndrome. *Dyn Med* (2007) 6:2. doi:10.1186/1476-5918-6-2
197. Strickberger SA, Benson DW, Biaggioni I, Callans DJ, Cohen MI, Ellenbogen KA, et al. AHA/ACC scientific statement on the evaluation of syncope. *J Am Coll Cardiol* (2006) 47:473–84. doi:10.1016/j.jacc.2005.12.019
198. Bloomfield DM, Kaufman ES, Bigger JT, Fleiss J, Rolnitzky L, Steinman R. Passive head-up tilt and actively standing up produce similar overall changes in autonomic balance. *Am Heart J* (1997) 134:316–20. doi:10.1016/S0002-8703(97)70140-6
199. Plash WB, Diedrich A, Biaggioni I, Garland EM, Paranjape SY, Black BK, et al. Diagnosing postural tachycardia syndrome: comparison of tilt testing compared with standing haemodynamics. *Clin Sci (Lond)* (2012) 124:109–14. doi:10.1042/CS20120276

APPENDIX A

1994 FUKUDA RESEARCH CASE DEFINITION FOR CHRONIC FATIGUE SYNDROME

Patients can be classified as having CFS if they meet the following criteria:

1. The individual has had severe, clinically evaluated, persisting or relapsing fatigue for six or more consecutive months. The fatigue is not due to ongoing exertion or other medical conditions associated with fatigue. The fatigue significantly interferes with daily activities and work.
2. The individual has four or more of the following symptoms, persisting or relapsing and concurrent with the fatigue:
 - Post-exertional malaise lasting more than 24 h
 - Unrefreshing sleep
 - Significant impairment of short-term memory or concentration
 - Muscle pain
 - Pain in the joints without swelling or redness
 - Headaches of a new type, pattern, or severity
 - Tender lymph nodes in the neck or armpit
 - A sore throat that is frequent or recurring
3. A thorough medical history, physical examination, mental status examination, and laboratory tests are necessary to identify other conditions with similar symptoms that require treatment. The diagnosis of chronic fatigue syndrome cannot be made without such an evaluation.

APPENDIX B

COMMON CONDITIONS IN THE DIFFERENTIAL DIAGNOSIS OF PEDIATRIC ME/CFS

Autoimmune/Rheumatology Autoimmune hepatitis Rheumatoid and other inflammatory arthritis Sjogren syndrome Systemic lupus erythematosus Wegener's granulomatosis	Hematological/Immunological Anemias Common variable immunodeficiency Leukemia/lymphoma Post-cancer fatigue	Psychiatric Anorexia Nervosa Bipolar disorder Chronic psychosocial stress Generalized anxiety disorder Major depressive disorder Personality disorder Post-traumatic stress disorder
	Infections Acute mononucleosis (EBV, CMV) Brucellosis Coxsackie virus Giardia and other intestinal parasites Hepatitis B or C HIV Leptospirosis Lyme and other tick-borne infections Babesia microti anaplasma phagocytophilum Ehrlichia Chaffeensis Mycoplasma pneumoniae Parvovirus B19 Post-infectious fatigue syndrome Q fever Toxoplasmosis Tuberculosis	Respiratory Aspergillosis Asthma/allergies Chronic sinusitis Cystic fibrosis Sarcoidosis
	Neuromuscular/Neuroanatomic Cervical spine stenosis Chiari I malformation Cranio-cervical instability Tethered spinal cord Inflammatory myopathies Multiple Sclerosis Muscular dystrophy syndromes Myasthenia Gravis Neuropathies Post-concussion syndrome	Sleep disorders Central apnea Klein-Levin syndrome Narcolepsy Obstructive apnea Periodic leg movements
Cardiovascular/Autonomic: Aberrant coronary artery, coronary aneurysms Cardiomyopathy Coarctation of the aorta Patent foramen ovale Primary dysautonomia Pulmonary hypertension Rheumatic fever Valvular disease (congenital and acquired)		Toxic substances Alcohol or drug misuse Ciguatera poisoning Lead or mercury poisoning Organophosphate poisoning Reactions to medications, e.g., antihistamines, antipsychotics, sedatives, tricyclic antidepressants
Endocrine/Metabolic Addison's disease Gonadal dysfunction syndromes Hyper- and hypo-thyroidism Hyper- and hypo-calcemia Inborn errors of metabolism Metabolic syndrome Mitochondrial disorders Pituitary tumors or disorders		Other conditions: Athletic overtraining or underperformance syndrome Marfan syndrome Mast cell activation syndromes
Gastrointestinal/Nutritional Celiac Disease Chronic liver disease Eosinophilic gastroenteritis Inflammatory bowel disease Pancreatic insufficiency Vitamin B12 deficiency Vitamin D deficiency		

APPENDIX C

MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS)
IN CHILDREN AND ADOLESCENTS

FACT SHEET

WHAT IS ME/CFS

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease characterized by the body's inability to produce sufficient energy for the normal range of human activity. There is severe, overwhelming fatigue with a substantial loss of physical and mental stamina. The patient's energy reserves are substantially reduced. The cardinal feature is a worsening of symptoms and malaise (feeling ill) following minimal physical or mental exertion. This post-exertional malaise can persist for hours, days, or weeks and is not relieved by rest or sleep. Other symptoms include cognitive problems ("brain fog"), unrefreshing or disturbed sleep, light-headedness, a variety of painful conditions, and other symptoms in multiple body systems.

ME/CFS occurs worldwide. In different countries it is labeled chronic fatigue syndrome, myalgic encephalomyelitis or the acronym ME/CFS. A new name, systemic exertion intolerance disease (SEID), has been proposed but is not in general use. The name "chronic fatigue syndrome" has been criticized because it can be confused with "chronic fatigue," which is common in many other illnesses.

Myalgic encephalomyelitis/chronic fatigue syndrome usually occurs as sporadic (isolated) cases, but in 20% of patients it affects more than one family member. Clusters of cases or outbreaks of the illness, (epidemics) have been found worldwide and in several of these outbreaks, the illness has been prominent in schoolchildren.

ME/CFS IN CHILDREN AND ADOLESCENTS

At least one million Americans are thought to have ME/CFS and a substantial but unknown number are under the age of 18 years. Adolescents 12–17 years old are more likely than younger children to develop ME/CFS, but children as young as two years of age have developed the disease. In adolescents, more girls than boys have ME/CFS.

CAUSE OF THE DISEASE

The cause of ME/CFS is unknown, but several factors may be involved. In some families, genetic factors may produce a susceptibility to the illness. The illness often follows an acute infection such as infectious mononucleosis, and immune system changes found in ME/CFS are similar to changes found in some viral infections, but no known infectious agent

has been shown to be the cause. In sporadic (non-epidemic) cases, the illness is not thought to be transmissible by casual contact. ME/CFS may also be triggered by a toxin, an immunization, or by major trauma. ME/CFS is not a psychological illness. Depression and anxiety can occur secondary to ME/CFS, as occurs in other chronic illnesses, but Major Depression and ME/CFS can be distinguished by behavioral, immunological, and hormonal testing.

SYMPTOMS AND DIAGNOSIS

The diagnosis of ME/CFS is made from the characteristic pattern of symptoms and the exclusion of other fatiguing illnesses because there is no medical test for the disease. Many patients remain undiagnosed. The main diagnostic features of the illness have been incorporated into several different case definitions. We recommend the following clinical diagnostic criteria, which have been found to be useful in pediatric patients:

- There is loss of mental and/or physical stamina and a substantial reduction in ability to take part in personal, educational, and/or social activities.
- There is a new onset of fatigue that is not the result of ongoing exertion and is not relieved by rest. Fatigue can worsen with prolonged upright posture.
- Normal activity or mild/moderate exertion is followed by malaise (feeling ill) and worsening of ME/CFS symptoms. Recovery can take days, weeks, or months.
- Sleep is unrefreshing, with disturbed quantity or rhythm that can include daytime hypersomnia, nighttime insomnia, day/night reversal.
- Any of the following cognitive problems can be present: difficulty in concentration; impaired short-term memory; difficulty understanding information and/or expressing thoughts; difficulty finding words or numbers; absent-mindedness, or slowness of thought. Cognitive problems can worsen with prolonged upright posture and/or with physical or mental activity.
- Pain can be widespread or localized. Commonly seen are: chronic daily headaches; pains in the muscles, the abdomen, the joints, and/or the lymph nodes; and/or sore throats. Pains can be worsened by prolonged upright posture. Rarely is pain absent.

Myalgic encephalomyelitis/chronic fatigue syndrome symptoms often fluctuate significantly in intensity during the day, or from day to day. To diagnose ME/CFS, some or all symptoms must be present every day. The symptoms' intensity must be mostly moderate to severe and symptoms must have persisted or recurred for at least 6 months. (A provisional diagnosis and appropriate management can be instituted before 6 months.) Other fatiguing illnesses must be excluded by history, physical examination, and medical testing.

Other symptoms that can be present in many, but not all, pediatric patients are:

- Orthostatic intolerance: prolonged upright posture can induce lightheadedness, increased fatigue, cognitive worsening, headaches and/or nausea.
- Hypersensitivity to light, noise, touch, odors and/or medications.
- Thermoregulatory imbalance: low body temperature, intolerance to heat and/or cold, or cold hands and feet.
- Gastrointestinal symptoms: abdominal pain, nausea, or anorexia.

Young people with ME/CFS often do not look ill but can appear noticeably pale. Routine blood tests are frequently normal, but specialized testing can show abnormalities in patients' immune, nervous or cardiovascular systems, or in cellular energy production.

Myalgic encephalomyelitis/chronic fatigue syndrome has often been misdiagnosed as school refusal (school phobia) or as Munchausen's syndrome by proxy (a condition in which a parent fabricates their child's illness).

PROGRESS AND RECOVERY

Myalgic encephalomyelitis/chronic fatigue syndrome in adolescents usually starts suddenly with a fever and flu-like symptoms. Sometimes the onset is gradual. In younger children, a gradual onset over months or years is more likely. It can be difficult to diagnose ME/CFS in younger children because they may not recognize that their fatigue and other symptoms are abnormal. The diagnosis can be made retrospectively when the child is older. The first sign of the illness might be the child's marked limitation of activity, noticed by a parent or teacher. Young people with ME/CFS can be very

ill at the onset of the illness, but because routine blood tests are frequently normal, the diagnosis is often uncertain. Even when no other illness is found, a definitive diagnosis of ME/CFS cannot be made for 6 months, but a provisional diagnosis can be made sooner. Early diagnosis can lessen the impact of the illness by ensuring an appropriate management plan.

The severity of ME/CFS varies. Some young patients are severely disabled and bedridden, while others can go to school, and a few can even do sports. Most are between these extremes. Over time, slow improvement is likely. Recovery rates are uncertain but rates of up to 40% have been reported. Dramatic improvement is more likely to occur in the first four years. Remissions and relapses are common. Relapses can be caused by overexertion or by infectious illnesses. Young patients whose health improves to near pre-illness levels are likely to find that they need more rest than their contemporaries.

MANAGEMENT/TREATMENT

Establishing the diagnosis of ME/CFS can relieve uncertainty in the minds of the patient and the parents. There is currently no medication or intervention that will cure the disease. Management differs for individual patients. Determining the optimum balance of rest and activity (pacing of activities) can help prevent post-exertional worsening of symptoms. Medications are helpful to treat pain, insomnia, and orthostatic intolerance. Young patients with ME/CFS commonly respond to lower dosages of many medications. Advice on nutrition can be helpful. Supportive psychotherapy can sometimes benefit mildly affected young patients, but inflexible, graded exercise (GET) is harmful and can lead to worsening of symptoms.

EDUCATION

Myalgic encephalomyelitis/chronic fatigue syndrome is the most common medical cause of long-term absence from school. Most students with ME/CFS fall behind in their education. Students with ME/CFS might need a personalized school schedule and the school might need to provide reasonable accommodations and/or home tutoring. Legal and procedural requirements for students to receive services for their disabilities vary significantly from place to place.

APPENDIX D

MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) IN CHILDREN AND ADOLESCENTS

FACT SHEET FOR SCHOOLS

Major contributions by Faith Newton, Ed. D.

WHAT IS ME/CFS?

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease, characterized by the body's inability to produce sufficient energy for the normal range of human activity. The patient's energy reserves are substantially reduced.

There is no medical test for the illness. The diagnosis is made from the characteristic pattern of symptoms. The main symptoms include:

- Severe, overwhelming fatigue with loss of mental and/or physical stamina and a substantial reduction in ability to take part in personal, educational, and/or social activities.
- The cardinal symptom of worsening of symptoms and malaise (feeling ill) following minimal physical or mental exertion, which can persist for hours, days, or weeks and is not relieved by rest
- Cognitive problems ("brain fog"), unrefreshing or disturbed sleep, and a variety of painful conditions. (Rarely pain is absent.) Cognitive problems may worsen with prolonged upright posture.

To diagnose ME/CFS, some or all of the above symptoms must be present every day for at least 6 months; symptoms must be moderate or severe; and other fatiguing illnesses must be ruled out by history, physical exam, and medical testing. Additional symptoms are often present and include:

- Orthostatic intolerance, which is the development of symptoms due to prolonged upright posture (standing or sitting) that result in lightheadedness (and sometimes passing out), increased fatigue, cognitive worsening, headaches, and/or nausea.
- Hypersensitivities to light, noise, touch, odors, and/or medications.
- Problems with thermoregulation such as low body temperature, intolerance to heat and cold, and/or cold hands and feet.
- Gastrointestinal symptoms such as abdominal pain, nausea, and/or loss of appetite.

ME/CFS often starts suddenly following a viral illness, but it can start gradually. Symptoms can vary unpredictably in severity from day to day and from week to week. Students with ME/CFS often do not look ill, but can appear to be very pale. The cause

of ME/CFS is unknown, but the disease is not thought to be transmitted by casual contact. There is currently no medication or intervention that will cure ME/CFS. Successful management is directed toward determining the optimum balance of rest and activity to help prevent post-exertional worsening of symptoms. Medications are helpful to treat pain, insomnia, orthostatic intolerance and other symptoms

EDUCATIONAL IMPLICATIONS

Myalgic encephalomyelitis/chronic fatigue syndrome is the most common cause of long-term absence from school due to illness. Absence from school is usually due to poor physical and cognitive function, not behavioral factors. Some students can attend school daily, others can manage part-time, while others are homebound, and some are confined to bed. ME/CFS is unpredictable. Sometimes a student has enough energy for school at the start of the week, but is unable to manage school on Thursday and Friday. A student might appear fine one day but the next day might be unable to come to school, sometimes for several weeks. There might also be long periods where she/he is unable to complete schoolwork at home.

Most students with ME/CFS experience worsening of their school performance as ME/CFS symptoms impact education. Cognitive problems include confusion, difficulty with concentration, slow information processing, short-term memory problems, impaired word retrieval, and easy distractibility. These problems can manifest in several ways. If the teacher has asked the student to complete a task and she/he is interrupted, she/he might not remember what the teacher asked her/him to do. The student might require extra time to answer questions or complete assignments. The student might temporarily lose the ability to retrieve information learned the day before. Classroom noise can worsen distractibility. This distractibility can result in teachers perceiving that the student is uninterested, or cannot pay attention. Students with ME/CFS may be unable to handle simple math calculations. They can often complete the steps to solve a complex calculus problem, but make simple addition or multiplication mistakes. Intellectual reasoning is usually retained in spite of cognitive problems

and many students are capable of taking academic classes with their peers, provided that the number of their classes is strictly limited. Cognitive exertion can trigger post-exertional worsening of general symptoms.

Symptoms of ME/CFS tend to worsen after physical exertion. Participation in sports can deplete the student's energy reserves. Some students may manage a short physical activity, but not an activity that requires stamina. The student needs to be able to recognize when she/he is experiencing the onset of fatigue and to inform the teacher, and *must* stop and rest. The student might want to continue participating, but failure to stop and rest at the onset of increased fatigue can cause a serious relapse of symptoms. Students with ME/CFS should never be pressured to push themselves to their limits.

EDUCATIONAL ACCOMMODATIONS

Students may need a personalized school schedule. The following accommodations can be helpful:

IN THE SCHOOL

- A single point of contact for teachers.
- A shortened day/week: the student might need to come in late, leave early, and/or attend school for only 2 or 3 days a week.
- A reduction in course load and flexible scheduling where only classes in selected subjects are attended.
- A quiet place for the student to rest, if fatigue is evident to the student or the teacher.
- Use of the elevator to access different floors.
- Exemption from, or modification of, the physical education program.
- Provide homebound instruction or "Distance Education" for students who are partly or completely homebound.

IN THE CLASSROOM

- Provide two sets of textbooks, one for school and one for home.
- Give clear oral, or written directions, with frequent feedback.
- Help the student to organize work with the use of an assignment book and/or online calendar to record assignments and work completed.
- Use the buddy system, so that someone can take notes in class, allow taping of classes, and/or give the student an outline of material taught.
- Use multi-sensory instruction, e.g., visual aids like graphic organizers and non-linguistic representations to better suit the learning style of the student.

- Teach tasks serially instead of having the student multitask. Break work down into manageable segments—short frequent projects are better than long-term projects.
- Permit the use of electronic devices such as a laptop or tablet and allow work to be completed online.
- Allow flexibility with assignments and deadlines, and modifications of the number of problems and/or assignments to be completed.
- Permit a student with orthostatic intolerance to move around during classes and allow salty snacks and a water bottle in the classroom.
- Provide tutorial or homebound instruction, if the student is too sick to attend school.

ASSESSMENTS/TESTING

- Test knowledge of material in multiple ways, e.g., oral instead of written tests, or coursework instead of exams.
- Extended time and a quiet room might be needed for testing, as well as adjusted time for assessments, depending on the time of day when the student functions best.
- Tests/Final Exams may need to be given over several days or sessions, with water and snacks available.

CURRICULUM

- Identification/prioritization of essential content.
- Focus on mastery of skills rather than completion of assignments.
- Use of frequent, short-term projects instead of long-term projects.
- A reduction in the number and length of assignments, projects, quizzes, and tests.

SOCIAL DEVELOPMENT

The classroom and the school cafeteria might be the only place where the student with ME/CFS is able to socialize with her/his peers. When possible, this should be facilitated. Access to extracurricular activities is also important for social reasons.

RESOURCES

National Association of Special Education Teachers Chronic Fatigue Syndrome, www.naset.org/3349.0.html.
 Association of young people with ME, AYME www.ayme.org.uk.
 Association of New Zealand Myalgic Encephalopathy Society, www.azmes.org.nz.

APPENDIX E

SAMPLE PHYSICIAN'S LETTER

This letter is an example, and it needs to be adapted so that it is applicable to the student's country and is very specific for the student's particular symptoms.

Dear Special Education Administrator:
Or Special educational needs coordinating officer:
Or School Principal:

Jane XXXX is under my care for myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS). This illness has caused Jane to experience severe fatigue and a lack of physical and mental stamina. Jane's body is unable to produce sufficient energy for the normal range of activities for her age, and her energy reserves are substantially reduced. If Jane exceeds her diminished energy reserves, it can take her several days, weeks, or even months, to recover back to her baseline.

The illness has caused Jane to have cognitive problems, muscle pains, poor sleep and increased sensitivity to light, to noise, and to a cold environment. Jane also tends to feel faint if she has to stand up for any length of time. Jane's cognitive problems can cause her to have difficulty concentrating, understanding complex concepts, remembering words, and working with numbers. Jane has a poor working memory and increased distractibility. Classroom noise can worsen these difficulties. It is important to note that intelligence is not compromised by this illness and, provided that Jane has appropriate accommodations, she can be expected to attain educational success.

The occurrence and severity of Jane's symptoms are quite unpredictable and vary from day to day. The illness may result in Jane missing a significant number of days during the school year, or she might need to arrive late or leave early from school. Jane will only be able to manage a reduced subject load. It will, therefore, be necessary for the school to be accommodating and flexible in response to Jane's likely absences and her need for a reduced curriculum.

Currently, Jane is not well enough to engage in any sports. Please excuse her from physical education activities until I am able to confirm if, and when, her health has improved enough that these activities will not make her illness worse.

I support an application for educational services appropriate to Jane's needs. A list of my recommendations for accommodations and modifications for Jane is attached. Please let me know if I can be of further assistance.

Sincerely,

XXXXXXXXXXXX, MD

APPENDIX F

PEDIATRIC PATIENTS WITH ME/CFS ANTICIPATING SURGERY:
SPECIAL CONSIDERATIONS*

Myalgic encephalomyelitis/chronic fatigue syndrome is a complex, debilitating disease characterized by severe overwhelming fatigue, with a substantial loss of physical and mental functional capacity. The cardinal feature is malaise and worsening of symptoms following minimal physical or mental exertion, which can persist for hours, days, or weeks, and is not relieved by rest or sleep. Other symptoms include cognitive impairment, non-restorative sleep, generalized or localized pain, and immune, neurological, and/or autonomic symptoms. Improvements and exacerbations in symptoms are common, and function can vary from day to day and week to week.

Most young people with ME/CFS demonstrate vasovagal syncope, postural tachycardia syndrome (POTS), neurally mediated hypotension (NMH) and increased venous pooling on tilt table testing. Syncope can be precipitated by catecholamines (epinephrine), sympathomimetics (isoproterenol), and vasodilators (nitric oxide, nitroglycerin, α -blockers, and hypotensive agents). Care should be taken to hydrate patients prior to surgery and avoid drugs that stimulate neurogenic syncope or that lower BP. Many patients benefit from extra IV fluids in the perioperative period.

Propofol, midazolam, and fentanyl are generally well tolerated. However, studies in adults have shown that some patients with ME/CFS can be sensitive to histamine-releasing anesthetic agents (such as pentothal) and muscle relaxants (curare, Tracrium, and Mevacurium). If possible, they are best avoided. Young patients can also be extremely sensitive to sedative medications, including benzodiazepines and antihistamines.

Herbs and complementary and alternative therapies are often used by patients with ME/CFS. The anesthesiologist/anesthetist should ask patients about such therapies (155). The American Society of Anesthesiologists recommends that all herbal medications be discontinued 2–3 weeks before an elective procedure.

OF MOST CONCERN ARE:

- Garlic, ginkgo, and ginseng—can increase bleeding by inhibiting platelet aggregation.
- Ephedra (ma huang)—can cause hemodynamic instability, hypertension, tachycardia, arrhythmia.
- Kava and valerian (increase sedation).
- Echinacea—allergic reactions and possible immunosuppression with long-term use.
- St. John's Wort—multiple pharmacological interactions due to induction of cytochrome P450 enzymes.

Stopping kava (also known as awa, kawa, and intoxicating pepper) can trigger withdrawal, so this herbal should be tapered over 2–3 days.

Although early studies have shown mild HPA depression in some adolescents with ME/CFS (62), supplemental cortisol is seldom needed unless the patient is severely ill. Those patients who are being supplemented with cortisol should have their doses doubled or tripled before and after surgery.

Mild immunological abnormalities can be found in this illness, but patients are not usually immunocompromised and are generally no more susceptible to opportunistic infections than the general population.

SUMMARY RECOMMENDATIONS

- Ask about herbs and supplements, and advise patients to taper them off at least 1 week before surgery.
- Hydrate the patient prior to surgery. Consider additional post-operative fluids.
- Use hypotensive agents, sympathomimetics, catecholamines, and vasodilators with caution.
- Use sedating drugs sparingly.

*Based upon "Considerations Prior To Surgery for Adult ME/CFS Patients" by Dr. CW Lapp MD, Director, Hunter-Hopkins center.

APPENDIX G

ORTHOSTATIC INTOLERANCE

Individuals with Orthostatic Intolerance (OI) develop an exacerbation of symptoms with quiet, upright posture and the amelioration (although not necessarily complete resolution) of those symptoms with recumbency (156). OI can be associated with a variety of treatable circulatory disorders, the most commonly recognized of which in pediatric ME/CFS are postural tachycardia syndrome (POTS) and NMH (48-55, 157).

The main symptoms of chronic OI are shown in **Table A1**. These clinical features are usually attributed to two prominent physiological changes in response to upright posture: 1. a reduction in cerebral blood flow, and 2. an exaggerated adrenergic compensatory response to upright posture (156). As can be readily appreciated, the symptoms in **Table A1** overlap with many of the features of ME/CFS, including fatigue, exercise intolerance, cognitive problems, and headaches. In all controlled studies, compared to healthy individuals, those with pediatric ME/CFS have a higher prevalence of abnormal circulatory responses to upright tilt testing or prolonged standing (48-55). Studies that employ measures of HR variability consistently demonstrate a sympathetic predominance of HR variability in pediatric ME/CFS (or a relative loss of parasympathetic activity) (158,159), along with elevated levels of supine catecholamines compared with healthy adolescents (160). The relevance of OI syndromes for ME/CFS extends to the fact that open (unblinded) treatment of the circulatory abnormalities is associated with improvement in ME/CFS symptoms and function in a large proportion of adolescents (48, 51, 157, 161).


Table A1. Symptoms of orthostatic intolerance (in approximate order of frequency of occurrence).

Fatigue	Problems with short-term memory and concentration
Intolerance of low impact exercise	Nausea
Lightheadedness	Chest pain
Near-syncope or syncope	Palpitations
Blurring of vision	Diaphoresis
Headaches	Tremulousness
	Vomiting

PHYSIOLOGIC RESPONSES TO UPRIGHT POSTURE

In response to standing, approximately 500–750 mL of an adult's blood volume is redistributed to vessels below the level of the heart. A similar circulatory change is thought to occur in adolescents. At all ages, the response to the gravitational pooling of blood is a reduction in blood return to the heart, in turn leading to a drop in cardiac output, less stretch of baroreceptors, and ultimately less blood flow to the brain. The nervous system response involves an increase in sympathetic neural outflow, improved vasoconstriction, up to a 40-bpm increase in HR, and the return of enough venous blood to maintain BP and cerebral perfusion (162-164). Symptoms of OI can appear when these adjustments do not occur in an efficient manner.

Figure A1



Legend: The three main pathophysiologic influences on orthostatic intolerance (OI) are shown in this Figure. Increased pooling of blood, or defective vasoconstriction in the lower half of the body, along with lower intravascular volume are each important, and can be present in the same individual. Upon assumption of an upright posture, exaggerated sympathetic nervous system and adrenal hormone responses lead to increased release of epinephrine (Epi) and norepinephrine (NE). It is postulated that the relative balance of NE to Epi is one factor in determining whether the phenotype of OI is POTS or neurally mediated hypotension (NMH). Some patients with POTS in the early phase of orthostatic testing go on to develop a classic NMH pattern later in the test.

Figure A1 illustrates the three main physiological contributors to OI: excessive dependent pooling of blood, low blood volume, and an exaggerated catecholamine response. A variety of pathophysiologic influences can contribute to increased peripheral pooling of blood or decreased vasoconstriction. Those with ME/CFS often have low blood volume (57-59), which has been associated with lower renin:aldosterone ratios (58) and with lower ADH levels (165). Physical inactivity results in reductions in plasma volume, thereby aggravating symptoms of OI and interfering further with daily function (102, 166, 167). In patients with increased pooling of blood in the peripheral circulation, or low blood volume, or both, the assumption of upright posture is associated with less return of blood to the heart, and a markedly increased catecholamine response (168,169). Goldstein has suggested that the relative balance of epinephrine to norepinephrine can influence the pattern of circulatory response (170). ME/CFS patients with more norepinephrine can maintain BP longer because it has vasoconstrictor properties, while its effects on the heart cause tachycardia. In contrast, epinephrine causes skeletal muscle vasodilation, and can therefore contribute more to hypotension. Patients who develop tachycardia early during tilt table testing can develop NMH as the orthostatic stress becomes more prolonged, usually 5–59 min after the initial orthostatic tachycardia (171-173). As described in this Primer, the treatments of these disorders overlap almost completely.

FORMS OF ORTHOSTATIC INTOLERANCE IN ME/CFS

ORTHOSTATIC HYPOTENSION

Orthostatic hypotension is defined by a sustained BP reduction of at least 20 mm Hg systolic or 10 mm Hg diastolic during the first 3 min after assuming an upright posture (124). This problem is rarely seen in children except at times of febrile illness, acute dehydration, hemorrhage, adrenal insufficiency, excessive histamine release, or as a response to certain medications.

A more common pediatric variant, termed *initial orthostatic hypotension* (IOH), is characterized by a transient drop in BP immediately after standing, but resolving within 60 seconds. Its recognition requires a continuous beat-to-beat BP measurement device. The diagnosis is missed by standard, automated sphygmomanometer measurements (174, 175). Although this is not usually a condition that requires clinical treatment, chronic orthostatic symptoms (e.g., lightheadedness) in those with IOH have been reported (54), suggesting that they can develop other orthostatic abnormalities (such as POTS or NMH) on more prolonged testing.

POSTURAL TACHYCARDIA SYNDROME (POTS)

Postural tachycardia syndrome is increasingly being recognized as the most common form of OI in pediatric ME/CFS. As is the case for pediatric ME/CFS, postural tachycardia syndrome is more common in females than males, is more common after the onset of puberty, and often follows an apparent infectious illness (124, 156, 176-178).

POTS should only be diagnosed (a) if there is no OH in the first 3 min of standing or tilt testing, and (b) if there is an increase in HR of ≥ 40 beats per minute (bpm) from recumbent to upright in the first 10 min of standing or passive upright tilt (124). The adult HR criterion is lower, a 30-bpm change. Using the adult HR definition would misclassify approximately 40% of healthy adolescents as having POTS (179). Therefore, a 40-bpm increase in HR is necessary as the criterion for adolescents. Regardless of age, the diagnosis of POTS also requires that (c) the HR abnormalities must be accompanied by consistent orthostatic symptoms. POTS should not be diagnosed by a HR elevation alone, if the individual is dehydrated, or is being treated with vasodilating medications. Conversely, the diagnosis can be obscured if the individual is tested after consumption of substances that increase plasma volume, such as salt tablets, or if the patient is being treated with serotonin reuptake inhibitors, or stimulant medications. All these can be used to treat orthostatic intolerance.

NEURALLY MEDIATED HYPOTENSION

Neurally mediated hypotension was initially identified in pediatric and adult ME/CFS in the mid-1990s (48, 49, 51). Reported frequencies of POTS were substantially lower in the early reports. For reasons that are unclear, POTS is now recognized more frequently, possibly related to increased dietary sodium intake in ME/CFS subjects over time, to the duration of orthostatic stress, or to other as yet unidentified factors.

Reflex forms of hypotension and syncope include vasovagal syncope, neuro-cardiogenic syncope, delayed OH, and NMH (180). The latter term is the most accurate description of the events seen in ME/CFS patients who have chronic daily orthostatic symptoms in the absence of clinical syncope and develop a characteristic drop in BP during tilt testing.

Neurally mediated hypotension in both children and adults is defined as at least a 25 mm Hg reduction in systolic BP with a slowing of the HR at the time of pre-syncope or hypotension, identified during standing or upright tilt table testing, and associated with provocation of characteristic orthostatic symptoms (48). It occurs after the 3-minute cutoff for OH. The HR can be elevated early in the test, but slows when hypotension becomes severe. Like ME/CFS, NMH is more common in females (180). Hypotension can be missed if the period of orthostatic testing lasts less than 10 min. The diagnosis usually requires prolonged head-up tilt testing for 40–60 min (51).

The pathophysiology of NMH is reviewed elsewhere (163, 180-184), but as in POTS, in NMH, the reduction in venous return initiates a series of responses that ultimately results in withdrawal of sympathetic tone and relatively unopposed vagal tone. Sympathetic withdrawal in turn leads to vasodilation, and if the individual remains upright, the ultimate result can be either a profound drop in BP or syncope, occasionally associated with a junctional bradycardia or brief periods of asystole. Marked elevations in epinephrine levels are present in the period before syncope (169, 184). Factors that can provoke NMH include prolonged standing, heat, sudden stretch of mechanoreceptors in the gastrointestinal tract, bladder, and lungs, the sight of blood, and situations involving pain (180). Often a combination of precipitating factors is present.

Although many subjects with NMH only have isolated episodes of syncope, separated by long periods of normal function, chronic daily orthostatic symptoms can also be present. Chronic fatigue as well as impaired quality of life is reported in those referred for evaluation of recurrent syncope (185–187). Approximately 25% of patients evaluated for chronic OI by some groups have had neuro-cardiogenic syncope without POTS (170). Thus, not all chronic OI is related to POTS physiology. More work is needed to determine the mechanisms by which cognitive symptoms persist despite adequate control of HR and BP.

While there is variability in the rates of OI reported in adult studies of ME/CFS, provocation of fatigue with orthostatic stress is almost universal at all ages among those with ME/CFS and in the related condition fibromyalgia (50, 188). In pediatric ME/CFS, rates of OI exceed 90% of affected subjects in some studies (157, 189), and differences in cardiovascular responses can be detected with as little as 20° of upright stress (55).

Individuals who experience chronic symptoms of OI but do not meet criteria for POTS or NMH on orthostatic testing can be classified as having low orthostatic tolerance. Treatment can be offered in the same manner as it would be for those with confirmed circulatory disorders, provided symptoms are sufficiently severe.

TESTING FOR ORTHOSTATIC INTOLERANCE

Two main forms of testing for OI—standing tests and head-up tilt tests—are used in clinical practice. Methods for conducting each test vary. There is no gold standard test for OI, and we do not know all of the pathophysiological contributors to symptoms such as lightheadedness, as some classical “orthostatic” symptoms can be reproduced by maneuvers that do not involve upright posture.

HEAD-UP TILT TABLE TESTING

Head-up tilt table testing is usually performed with a motorized table that has a foot board for weight-bearing (190). The patient lies supine, loosely restrained by safety straps to prevent injury if loss of consciousness occurs. After a variable period of supine rest, usually 15 minutes, but in some studies up to 60 minutes, the tilt table is brought upright, usually to 60–70°. Higher angles for tilt testing can produce syncope in healthy controls. The duration of upright tilt also varies between centers, depending on which form of OI is being evaluated. Tilt testing for 10 min is sufficient to detect POTS, but upright tilt for 45–60 min is required for detection of NMH. A variety of methodological factors can affect tilt response (190–192), including the degree of movement permitted, the ambient temperature, the duration of the pre-tilt fast, whether the patient is permitted to remain on medications, the pre-test sodium intake, instrumentation (arterial catheters are associated with higher rates of syncope), pharmacological agents used to provoke hypotension [e.g., isoproterenol (193), nitroglycerine], and the definition of an abnormal test (192). We do not endorse reproduction of syncope as the end point of testing, as POTS and NMH can be identified and the table returned to the horizontal position before syncope occurs. In most laboratories, HR is monitored continuously, as is BP, although intermittent BP measurements are performed in some centers, approximately every 1–2 min for 5–10 min, then every 5 min unless presyncopal symptoms are identified. Some laboratories measure end-tidal CO₂ to detect orthostatic hypocapnia (194–196). Before and during the test, at approximately 5 min intervals, the patient is asked to rate changes in symptoms on a 0–10 scale (lightheadedness, warmth, fatigue, headache, shortness of breath, mental foggy, and pain).

Not all individuals with ME/CFS and orthostatic symptoms require head-up tilt testing. For example, if the clinical history is consistent with neuro-cardiogenic syncope,

head-up tilt testing is no longer thought to be necessary for the diagnosis (191, 192, 197). We would caution that care must be taken in the most impaired individuals with ME/CFS given the potential for an increase in symptoms during, and after, the tilt test. In this group, brief orthostatic supine, seated, and standing vital signs over 1–3 min in some instances are sufficient as an indication of orthostatic tolerance. In all individuals with ME/CFS who develop a provocation of their typical symptoms during the tilt test, we recommend administration of 1–2 L of normal saline as a means of improving autonomic tone and avoiding a prolonged post-tilt exacerbation in ME/CFS symptoms (172).

STANDING TESTS

Two forms of standing tests are described in the ME/CFS literature: active standing (59, 60) and leaning against a wall (131). Either form of standing test can be performed in a medical office. The test does not require specialist consultation or specialized equipment, and is much less costly than a tilt table test. The duration of supine rest before the test varies, but a consistent baseline HR and BP in adolescents can be obtained within 5–15 min. Although the duration of upright posture can be as long as 60 min (59), most centers perform a 10-min standing test to identify POTS and to ascertain whether there is worsening of ME/CFS symptoms during orthostasis, acknowledging that such a brief period of testing will miss many instances of NMH. As in the head-up tilt test, symptoms are recorded immediately before standing and at 1–2 min intervals when upright. The test must be witnessed to avoid the potential for injury in the event of syncope. Movements such as fidgeting and tensing the lower limb muscles are discouraged. See OI: Standing Test protocol and Standing Test Data Sheet.

Few papers have compared the various orthostatic testing methods. When tilt testing and active standing have been compared, this has usually been just for brief periods of upright posture (167, 198). The first 5 min of upright tilt and active standing generate similar HR changes (167, 198, 199). Beyond the first 5 min, however, Plash and colleagues recently demonstrated that passive tilt testing provokes a larger HR change in those with POTS than active standing (199). Application of lower body, negative pressure is a method of orthostatic testing, but it is rarely performed outside of research settings (160).

ORTHOSTATIC INTOLERANCE: STANDING TEST PROTOCOL

The standing test begins with the subject lying supine with an automated BP cuff set to measure the baseline HR and BP. These are recorded each minute for 5 min. At the fifth minute, the patient's current symptom intensity is rated on a scale of 0–10.

The patient is then instructed to stand, leaning back against a wall in a comfortable but motionless position. The patient's feet should be 2–6 inches away from the wall. The HR and BP are recorded and any symptoms are noted each minute for a maximum of 10 min. At the conclusion of the standing period, the patient is instructed to lie supine again, while the BP, HR, and symptom intensity are measured for a further 2 min.

Specific instructions for the patient are as follows:

"We'd like you to stand as still as possible for up to 10 minutes. During the standing test, you must be as motionless as possible in order to get an accurate result. Therefore, try not to wiggle your toes or fingers, scratch your nose, or move your arms or legs. We will monitor for any movements and will remind you not to move or wiggle. We want you to tell us if you are feeling anything different, or uncomfortable, during the test. Be as specific as possible. We need to know if you feel you can't stay standing any longer, and if this is the case, you can sit down. It is not necessary to remain standing for the entire 10 minutes, but we'd like to measure how long you can do this. Each minute we will check your blood pressure and heart rate with an automatic blood pressure measuring device."

COMMENTS

If the subject reports any symptoms, list these in the comments column of the data form, corresponding to the time recorded for the BP and HR. The comment section should also note if, and when, the subject had to sit down and mention whether the BP and HR were performed sitting or while still standing.

DEFINITIONS

Postural tachycardia syndrome (POTS): an increase in HR of at least 30 beats per minute (bpm) in adults, or 40 bpm in adolescents from the supine baseline to the maximum HR during the 10 min of standing, together with the reproduction of orthostatic symptoms. Florid POTS is considered any HR >120 bpm.

Orthostatic hypotension: a reduction in systolic BP of >20 mm Hg or in diastolic BP >10 mm Hg in the first 3 minutes.

Neurally mediated hypotension: at least a 25 mm Hg decrease in systolic BP from baseline supine values, with no associated increase in HR, together with the emergence of pre-syncope symptoms.

ORTHOSTATIC INTOLERANCE: STANDING TEST DATA SHEET

Name: _____ Date of Test: _____

Medications in last 2 weeks: _____

Abbreviations:

LH Lightheadedness (includes dizziness), PN Muscle pain/ache, FTG Increased fatigue, HOT Warmth/hot flash,
HA Headache, NAU Nausea, SW Sweating, COG Cognitive difficulties, SOB trouble breathing, VOM emesis

	Heart Rate	Blood Pressure	Symptoms, Comments
Supine			
1 min			
2 min			
3 min			
4 min			
5 min			
Standing			
1 min			
2 min			
3 min			
4 min			
5 min			
6 min			
7 min			
8 min			
9 min			
10 min			
Supine			
1 min			
2 min			

10 INDEX

Tables are indicated by t following the page number.

A

abdominal bloating, 22
 abdominal pain, 8, 9, 18, 22, 27, 28, 43, 44
 acetaminophen, 18
 acid taste, 28
 acne, 26
 acrocyanosis (dependent limb discoloration), 15t, 24
 activities of daily living, 19, 30
 activity management, 5, 16-20, 22, 30, 33, 43
 acupuncture, 18, 23
 acute onset, ME/CFS, 4
 adenosine triphosphate (ATP), 7
 adolescent development, 7
 adrenal insufficiency, 7, 11t, 49
 aerobic metabolism, 7, 19
 age of onset, 4, 5
 agglutinins, cold, 6
 alanine transaminase, 10t
 albumin/globulin ratio, 10t
 albuterol, 26
 alcohol consumption, 22, 26, 41t
 alkaline phosphatase, 10t
 allergies, 6, 11t, 12t, 15t, 22-23, 27-28, 41t, 47
 alternative and complementary therapies, 23, 47
 amitriptyline, 18t
 anaerobic metabolism, 7, 19
 anaphylaxis, 21, 28
 Anaplasma phagocytophilum, 11t, 41t
 anemia, 11t, 23, 27, 41t
 anger and chronic illness, 12, 21, 29
 anhedonia, 13, 14t
 anorexia, 8, 9, 15t, 41t, 43
 antibodies, 6, 10t, 11t
 anxiety 10, 12, 13, 14t, 15, 18t, 19t, 21, 25t, 26, 41t, 4
 apnea, obstructive 11t, 17, 41t
 apoptosis, 6, 7
 appetite, 13, 18t, 22, 25t, 26-28, 44
 salt appetite, 25t, 26
 aspartate transaminase, 10t
 aspirin, 18
 asthma, 12t, 15t, 26, 41t
 astrocytes, 7
 atenolol, 25
 athletic overtraining syndrome, 11t, 41t
 atopic disorders, 28
 attention deficit disorder (ADD), 16, 32
 attention span, 11, 32
 autoimmune disorders, 5, 6, 12t, 41t
 autonomic dysfunction, 4, 12t, 41t, 47, 50

B

Babesia microti, 11t, 41t
 back pain, 27
 bacteremia, 26
 B-cell depletion, 6
 bed, elevation of head, 24
 bed rest, 19, 29
 bedpan, use of, 29
 bedridden patients, 16, 29, 43
 behavioral symptoms, 12, 15t, 42, 44
 Beighton score, 27
 beta-adrenergic agonists, 26
 beta blockers, 18, 25t, 26
 bicycles, recumbent, 20
 bilirubin, 10t
 biofeedback, 18
 bisphosphonates, 30
 blackouts, 23
 blood pooling, 24, 47, 48
 blood tests, 5, 15t, 16, 28, 43
 blood volume, low, 7, 24, 48
 blue sclerae, 26
 body temperature, low, 8, 9, 10, 13, 14t, 43, 44
 bone pain, 28
 Borrelia burgdorferi, 6
 brain blood flow, 7, 13,
 brain dysfunction, 5
 "brain fog," 11, 23, 28, 32, 42, 44, 50
 brain imaging, 7, 15t
 bruising, easy, 26
 bruxism, 28, 29
 bupropion HCl, 19t

C

caffeine, 17, 20, 21, 22, 26
 calcium, 10t
 Canadian Clinical Case Definition (CCC), 8
 cannabis and cannabinoids, 18
 carbohydrates, 17, 22, 23, 24
 case definitions and ME/CFS diagnosis, 4, 5, 8, 40, 42
 catecholamines, 13, 24, 26, 47, 48
 catheters, indwelling, 27
 celiac disease, 10t, 11t, 27, 41t
 central line (IV), 26
 central nervous system abnormalities, 4, 7
 cerebral blood flow, 7, 11, 48
 cervical instability, 28, 41t
 cervical stenosis, 11t, 28, 41t
 Chiari malformation, 11t, 12t, 28, 41t
 child protection services (CPS), 14, 16
 child psychiatrists, referral to, 13, 21

chronic fatigue immune dysfunction syndrome, 4
 chronic illness, 4, 12, 21, 22, 31, 42
 circulatory abnormalities, 5, 6, 7, 10, 11t, 48, 49, 50
 clinical history, 5, 8, 9t, 10, 14, 26, 28, 40, 43, 44, 50
 clinical signs, 8, 15t
 clonazepam, 18t
 clonidine, 25
 cluster outbreaks of ME/CFS, 4, 6, 42
 coenzyme Q10, 18t
 coexisting conditions. *See* comorbid medical conditions 11-12
 cognitive behavioral therapy (CBT), 22, 30
 cognitive effort, increased, 7, 11,
 cognitive impairment, 3, 4, 6-9, 11, 12, 14, 14t, 15t, 19-21, 25t, 26, 31-33, 42-44, 46-49, 52
 impact on learning, 11, 32
 management of, 20-21
 cold agglutinins, 6
 cold hands and feet, 8, 9, 10, 43, 44
 cold intolerance, 8, 9, 13, 14t, 43, 44, 46
 cold packs, 18
 colonoscopy, 11t
 communication difficulties, 29, 31
 co-morbid conditions, 4, 5, 6, 8, 10, 11, 12t, 13, 14t, 16, 18, 18t, 19t, 22, 23, 26-29
 allergies, 28
 gastrointestinal issues, 27-28
 gynecologic issues, 11t, 12t, 23, 27
 joint hypermobility, 26-27
 oral and dental issues, 28-29
 orthostatic intolerance, 23-26
 complementary and alternative therapies, 23, 47
 complete blood count (CBC), 10t
 compression garments, 24
 concentration difficulties, 9, 11, 13, 16, 20, 32, 42, 44, 46, 48,
 confusion, 16, 32, 44
 connective tissue laxity, 26-27
 constipation, 23, 27, 28
 consultations, telephone or email, 17, 30
 contraceptives, hormonal, 25t, 26, 27
 coping skills training, 21-22
 cortisol, 7, 11t, 47
 course of illness, 4-5, 29
 Coxsackie virus, 6, 41t
 crash, post-exertion, 4, 5, 7-11, 13, 14t, 15t, 15-17, 19, 20, 23, 27, 29, 42-45
 C-reactive protein (CRP), 10t
 creatinine, 7, 10t
 cromolyn, 28
 crying, 15
 cure for ME/CFS, none available at present, 5, 16, 19, 22, 23, 43, 44
 curriculum, education accommodation and, 33, 43, 45, 46

cyclokapron (tranexamic acid), 27
 cyproheptadine, 18t
 cystic fibrosis, 4, 41
 cystitis, interstitial, 12t
 cystoscopy, 11t
 cytokines, 6
 Cytomegalovirus (CMV), 6, 10, 41t

D

daily routine, importance of, 21
 day/night cycle, 9, 17, 21, 22, 33, 42
 defecation, pain with, 27
 dehydration, 17, 24, 49,
 dental and oral issues, 28-29
 dependent limb discoloration (acrocyanosis), 15t, 24
 dependent rubor, 10, 24
 depoprovera (medroxy-progesterone acetate), 25t, 27
 depression, 11t, 12, 13, 14t, 19t, 21, 25t, 42, 47
 desmopressin acetate, 25t
 developmental history, 3, 4, 5, 8, 9, 10, 14, 15t, 26, 40, 43, 44, 50
 dexamphetamine, 20
 diabetes, 4
 diagnosis of ME/CFS
 core symptoms, 8
 diagnostic criteria, 4, 5, 6, 8, 9, 40, 42
 differential diagnosis, 11, 11t, 27, 29, 41t
 exclusionary medical conditions, 11, 11t, 12, 12t
 laboratory testing, 5, 8, 10, 10t, 16, 40
 patient history, 3, 4, 5, 8, 9, 10, 14, 15t, 26, 28, 40, 43, 44, 50
 physical examination, 3, 5, 8, 9, 10, 40, 43, 44
 worksheet, 8, 9
 diapers, use of, 29, 30
 diarrhea, 15, 15t, 23, 28
 diet and nutrition, 5, 10, 16, 22, 23, 25, 27-28, 30, 41t, 43
 dietary supplements, 18, 18t, 23, 47
 diphenhydramine, 18t
 diplopia, 28
 disbelief about nature of illness, 12, 13, 14t, 29, 31, 32
 dislocations, anatomic, 27
 distance education, 33, 45
 distractibility, 11, 20, 21, 32, 44, 46
 dizziness. *See* lightheadedness
 DNA, 11t
 doctor's note/physician's letter, 33, 46
 dothiepin, 18t
 drinks (fluid intake), 20, 21, 22, 25, 26, 28, 30, 32, 47
 drug use, 10, 18, 41t, 47
 dry mouth (xerostomia), 18, 28
 duloxetine HCl, 19t, 25t, 26
 dysmenorrhea, 12t, 18, 25t, 26, 27, 30
 dyspareunia, 27
 dysphoric disorder, 12t
 dysthymia, 25t, 26
 dysuria, 18, 27

E

eating disorders, 16. *See also* appetite
 educational accommodation. *See* schools and educational accommodation
 educational plan, 32–33
 Ehlers-Danlos Syndrome (EDS), 12t, 26–27
 Ehrlichia chaffeensis, 11t, 41t
 ejaculation, 7
 electrocardiogram (ECG/EKG), 11t, 24
 electrolytes, 10
 electrolyte drinks, 22
 electronic devices, 17, 33, 45
 elimination diet, 28
 emotional distress, 6, 12, 15, 21, 26, 29, 30, 31
 emotional changes in adolescence, 7
 endometriosis, 12t, 27
 endoscopy, 11t
 energy drinks, 20, 22
 energy envelope, 19–20, 30
 energy limits, 13, 14t, 19–20, 22, 23, 30, 32, 42, 43, 44, 45, 46
 enteroviruses, 6
 environment for care, 12, 30
 eosinophilic esophagitis, 12t
 eosinophilic gastroenteritis, 11t, 41t
 epidemiology, 4
 epilepsy, 4
 epinephrine, 26, 29, 47, 48, 49
 Epstein-Barr virus (EBV), 6, 10, 41t
 erythrocyte sedimentation rate, 10t
 escitalopram, 19t, 25t
 estradiol, 11t
 etiology, ME/CFS, 4, 5–6
 exercise. *See also* physical activity, 7, 13, 16, 17, 18, 19, 20, 21, 22, 24, 30, 43, 48, 48t
 guidelines, 19, 20, 30
 exertion, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14t, 15, 15t, 16, 17, 18, 19–20, 21, 23, 27, 29, 33, 40, 42, 43, 44, 45, 47
 exhaustion, 7, 19, 29
 eyes, 11, 18, 30
 eyelids, eversion of upper, 26

F

fabricated illness, 13–14, 15t
 facial flushing, 28
 facial pallor, 10, 15t, 24, 24t
 factitious disorder by proxy (FDP), 13, 14, 15t, 16, 31, 32, 43
 fainting, 24, 46
 family history, 10, 15t, 25t
 family, ME/CFS impact on, 6, 13, 14t, 15t, 16, 17, 19, 20, 22, 29, 30–31, 32

fatigue. *See also* tiredness, 4, 5, 6, 8, 9, 10, 11, 13, 14t, 15t, 17, 18t, 19, 20, 21, 23, 24t, 25t, 26, 27, 28, 33, 40, 41t, 42, 43, 44, 45, 46, 47, 48, 48t, 49, 50, 52
 Management of, 19–20
 Fatigue Severity Scale, 20
 fatiguing illnesses, differential diagnosis, 3, 5, 9, 42, 44
 febrile illness, 17, 24, 49
 fermentable polyols and saccharides, 22, 23
 ferritin, 10t
 fever, 4, 10, 15t, 17, 21, 28, 41t, 43
 glandular fever (infectious mononucleosis), 21
 Q fever, 41t
 rheumatic fever, 41t
 fibromyalgia, 10, 12t, 18, 18t, 19t, 26, 49
 fludrocortisone, 25t, 26
 fluid intake (drinks), 20, 21, 22, 25, 26, 28, 30, 32, 47
 fluoride supplementation, 28
 FODMAPs, dietary, 22, 23
 folate, 10t
 follicle stimulating hormone (FSH), 11t
 food fads, 22
 food intolerances, 6, 12t, 27, 28
 forgetfulness, 32
 foster parents, 14
 fructose intolerance, 12t
 frustration, 12, 29
 Fukuda research case definition, 8, 40
 functional ability 4, 9, 11, 12, 19, 20, 26, 27, 31, 32, 33, 42, 44
 functional assessment, 5, 10
 functional improvement, 10, 16, 17

G

gabapentin, 19t
 gamma glutamyl transaminase, 10t
 garlic, 22, 47
 gastroenteritis, eosinophilic, 11t, 41t
 gastroesophageal reflux, 12t, 27, 28
 gastrointestinal symptoms, 8, 9, 16, 22, 23, 26, 27, 28, 43, 44
 food intolerances, 6, 12, 18, 22, 27, 28, 29
 motility disturbances, 12t, 25t, 27
 genetics, 5, 6, 7, 42
 gene expression, 5, 7
 genitalia, 7
 glomerular filtration rate (GFR), 10t
 glucocorticoids, inhaled, 26
 gluten sensitivity, 27
 goniometer, 27
 Gorlin's sign, 26
 graded exercise therapy (GET), 22, 30, 43
 gray matter, 7
 grief, 12, 21
 growth spurt, 7
 guilt, 13, 14t, 21,
 gynecologic issues, 11t, 12t, 23, 27

--

H

headache, 6, 8, 9, 11, 15t, 18, 18t, 19t, 23, 25t, 26, 28, 29, 40, 42, 43, 48, 48t, 50, 52
heart rate, 10, 15t, 24, 51, 52
heart rhythm, 24, 47
heartburn, 22, 28
heat intolerance, 8, 9, 13, 14t, 23, 43, 44, 49
hematuria, 27
hemorrhage, 24, 49
hemosiderin deposition, 26
hepatitis, 41
hepatitis B immunization, 31
hepatobiliary iminodiacetic acid (HIDA) scan, 11t
herbal remedies, 17, 23, 47
hives, 28
home visits by physician, 8, 30
homebound instruction, 32, 33, 45
visiting teachers, 32
homebound patients, 4, 20, 30, 31, 32
hormonal contraceptives, 25t, 26
hospital admission, 12, 15t, 30
hot environment, adverse effects, 23, 24
human herpesvirus 6 (HHV-6), 6
human papilloma virus (HPV) immunization, 31
25-hydroxy cholecalciferol, 10t
hyperalgesia, abdominal, 18, 18t
hyperesthesia, 29
hypermobility, joint, 6, 10, 12t, 13, 14t, 15t, 23, 25t, 26-27, 28, 29
hyperreflexia, 28
hypersensitivities, 8, 9, 12, 12t, 13, 14t, 23, 27, 28, 43, 44, 46
hypersomnia, 9, 17, 29, 42
hypertension, 25t, 41t, 47
intracranial, 28
hyperthyroidism, 11t, 41t
hypoglycemia, 12t
hypotension, 6, 9, 10, 12t, 20, 24, 25t, 26, 28, 47, 48, 49, 50, 51
neurally mediated (NMH), 6, 9, 12t, 24, 47, 48, 49
orthostatic (OH), 12t, 24, 49, 51
hypothalamic-pituitary-adrenal (HPA) axis, 7, 47
hypothermia (low body temperature), 8, 9, 10, 13, 14t, 43, 44
hypothyroidism, 11t, 41t
hypovolemia, 24

I

IACFS/ME (International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis), 2
IgA (immunoglobulin A), 10t, 21
IgE (immunoglobulin E) mediated allergies, 12t, 27, 28
IgF (immunoglobulin F), 11t
IgG (immunoglobulin G), 10t, 21
immune system, 4, 5, 6, 7, 11t, 12t, 21, 41, 42, 43, 47

immune dysfunction, 4, 5, 6
immunization, 6, 23, 31, 42
immunoglobulin, intravenous (IVIG), 6, 21, 30
immunoglobulins, 11t
improvement. *See also* functional improvement, 4, 5, 6, 10, 16, 17, 20, 21, 22, 23, 26, 28, 29, 43, 47, 48
induced illness, 13, 14, 15t, 31
indwelling catheter, use of, 29
infections and ME/CFS, 6, 7, 10, 11t, 22, 26, 41t, 42, 47
infectious mononucleosis, 4, 6, 7, 11t, 21, 41t, 42
inflammation, 7
influenza
flu-like symptoms, 4, 6
immunization, 6, 31, 42
insomnia, 3, 9, 17, 18t, 21, 25t, 26, 42, 43, 44
management of, 3, 17, 18t, 25t, 26, 43, 44
insulin resistance, 12t
intellectual reasoning, 32, 44
intelligence quotient (IQ) scores, 32
interstitial cystitis, 12t
intracranial hypertension, 28
intravenous immunoglobulin (IVIG), 6, 21, 30
intravenous (IV) saline, 25t, 26, 30, 50
iron deficiency, 10t, 12t, 19, 23, 27
irritable bowel syndrome/disease, 10, 12t, 23, 27
itching, 28

J

joint hypermobility, 6, 10, 12t, 13, 14t, 15t, 23, 25t, 26-27, 28, 29
joint pain, 9, 18, 28, 29, 40, 42

L

laboratory testing, 3, 5, 8, 9, 10, 10t, 11t, 15, 16, 27, 28, 40, 41t, 42, 43, 44
lactate, 7, 11t
lactose intolerance, 12t, 27
laparoscopy, 11t
learning, ME/CFS symptoms and, 11, 32, 45
legal proceedings and child protection services, 14, 16, 31, 32, 43
leukotriene receptor antagonists, 28
lidocaine patch, 18
lightheadedness (includes dizziness), 3, 6, 8, 9, 15, 18t, 23, 24, 25t, 26, 28, 42, 43, 44, 48t, 49, 50, 52
liniments, 18
lip swelling, 28
lisdexamphetamine, 20
liver function tests, 10t
local anesthetics, 29
loss of interest, 13
low body temperature (hypothermia), 8, 9, 10, 13, 14t, 43, 44
luteinizing hormone (LH), 11t
lymph nodes, 9, 10, 18, 40, 42
Lyrica (pregabalin), 19t

M

magnesium, 18, 18t, 23
 magnetic resonance imaging (MRI), 10, 11t
 major depressive disorder (MDD), 11t, 12, 13, 14t, 19t, 21, 25t, 41t, 42
 maladaptive cognitive responses, 22
 malaise, postexertional 3, 4, 8, 9, 11, 13, 15, 20, 40, 42, 44, 47
 management of ME/CFS, 3, 5, 8, 9, 11, 13, 15, 16, 19, 21, 22, 40, 42, 44, 47
 physician/patient relations in, 5, 15, 29
 massage, 18, 23
 mast cell activation syndrome (MCAS), 6, 12t, 28, 41t
 medications, 3, 5, 8, 9, 13, 14t, 17, 18, 18t, 19t, 20, 21, 22, 23, 25, 26, 28, 29, 30, 41t, 43, 44, 47, 49, 50, 52
 depression and anxiety, 18t, 19t, 25t
 fatigue, 18t, 20, 25t
 generalized pain, 18t, 19t, 23, 30
 headache, 18t, 23, 25t
 orthostatic intolerance, 25t, 26, 30
 sleep disorders, 17, 18t
 medroxyprogesterone, 25t, 27
 melatonin, 18t
 memory impairment, 9, 11, 13, 16, 29, 32, 33, 40, 42, 44, 46, 48t
 meningitis, aseptic, 21
 menorrhagia, 27
 menstruation (menses), 4, 7, 25t, 27
 mental confusion, 23, 32, 50
 mental exertion, 3, 13, 17, 20, 42, 44, 47
 mental stamina, 3, 4, 8, 9, 11, 19, 29, 42, 44, 46
 mercury amalgam fillings, 28
 metabolic abnormalities, 5, 7, 11t, 12t, 41t
 metabolic syndrome, 12t, 41t
 methylphenidate, 20, 21, 25t
 microbial pathogens, 6
 microglia, 7
 midodrine, 25t, 26
 migraine, 12t, 18, 28, 30
 milk intolerance, 12t, 27
 mindfulness-based cognitive therapy, 22, 30
 mitochondrial dysfunction, 7, 41t
 mitral valve prolapse, 12t
 modafinil, 20
 monitoring of patients, 5, 9, 10, 16, 25t, 29, 50, 51
 mononucleosis, infectious, 4, 6, 7, 11t, 21, 41t, 42
 montelukast, 26, 28
 mouth prop, for dental procedures, 28
 MRI (magnetic resonance imaging), 10, 11t
 multiple sclerosis (MS), 20, 41
 multisystem disease, 5
 multitasking, 11, 45
 Munchausen syndrome by proxy (factitious disorder by proxy) (FDP/MSBP), 13–14, 15t, 16, 31, 32, 43

muscle pain and tenderness, (myalgia), 9, 10, 18, 25t, 26, 28, 40, 42, 46, 52
 music, 22
 myofascial pain syndrome, 12t

N

naps, importance of, 17
 narcolepsy, 11t, 41t
 narcotic analgesics (opiates), 18, 26
 natural killer (NK) cells, 6
 natural remedies, 23
 nausea, 6, 8, 9, 15, 16, 18, 22, 23, 24t, 27, 28, 29, 43, 44, 48t, 52
 neurally mediated hypotension (NMH), 6, 9, 12t, 24, 47, 48, 49
 neuro-anatomic abnormalities, 23, 28, 41t
 neuro-cardiogenic syncope, 24, 47, 49, 50
 neuroendocrine system 5, 7
 neuro-endocrine-immune dysfunction syndrome, 4
 neurological abnormalities, 4, 10, 11, 11t, 12t, 28, 47
 neurological examination, 10, 28
 neuropsychological testing, 33
 noise, hypersensitivity to, 8, 9, 13, 14t, 43, 44, 46
 nomenclature, 4
 nonsteroidal anti-inflammatory drugs (NSAIDs), 18, 27
 norepinephrine, 25t, 26, 48
 numbness, 28
 nutrition and diet, 16, 22–23, 25, 27–28, 30, 41t, 43
 nystagmus, 28

O

obesity, 12t
 occlusal guard, 29
 odors, hypersensitivity to, 8, 9, 12t, 14, 29, 43, 44
 onset of ME/CFS, 4, 5, 6, 10, 12, 13, 17, 23, 27, 28, 42, 43, 45
 opiates (narcotic analgesics), 18
 oral and dental issues, 28–29
 oral rehydration fluids, 17, 25, 26, 27, 28
 orthostatic hypotension (OH), 12t, 24, 48, 49, 51
 orthostatic intolerance (OI), 3, 4, 7, 8, 9, 12t, 14t, 15t, 16, 23–24, 32, 33, 43, 44, 45, 48–52
 management of, 24, 25t, 26, 30, 43, 45
 pathophysiology and testing for, 23, 24t, 48, 48t, 49, 50, 52
 symptoms and diagnosis, 8, 9, 15t, 23, 24, 44, 48, 48t, 49
 osteopenia and osteoporosis, 29
 ovarian varices, 11t, 27
 overexertion, 4, 5, 6, 43
 oxidative stress, 7
 oxygen consumption, impaired, 7

P

pacing of activities, 17, 18, 19–20, 43
 pain, 3, 8, 9, 11, 12t, 15, 16, 17, 18, 18t, 19t, 20, 21, 23, 26, 27, 28, 29, 30, 31, 40, 42, 43, 44, 46, 47, 48t, 49, 50, 52
 localized management, 3, 8, 9, 11, 12t, 18, 18t, 22, 23, 26, 27, 28, 29, 30, 40, 42, 43, 44, 46, 47, 48t, 49, 50, 52
 management, 18, 18t, 19t, 23, 29, 31, 43, 44
 pallor and facial pallor, 10, 15t, 24, 24t
 panic attacks, 13, 14t
 paracetamol, 18
 parent-child relationship, ME/CFS impact on, 13, 14, 15, 15t, 16, 17, 19, 21, 22, 23, 30, 31, 32, 43
 parvovirus B19, 6, 41t
 passive stretching, 30
 pathophysiology, ME/CFS, 4, 5–7, 11, 22, 48, 49, 50
 patient education, 5, 16
 patient support groups, 22
 Peds QL (Pediatric Quality of Life Inventory), 17
 pelvic congestion syndrome (PCS), 12T, 27
 pelvic pain, 18, 27
 pelvic venous incompetence, 12t
 peri-menstrual symptoms, 27
 periodic limb movement disorder, 12t
 periodontal disease, 28
 peripherally inserted central catheter (PICC), 26
 pervasive refusal syndrome (PRS), 13, 15–16
 pharyngitis, 10
 phenothiazine anti-emetics, 26
 phosphate, 10t
 physical activity. *See also* exercise, 3, 4, 5, 8, 9, 10, 13, 15, 15t, 16, 17, 18, 19–20, 22, 27, 42, 43, 44, 45, 48
 genetic expression and, 7
 for homebound patient, 30
 metabolic abnormalities, 7
 pacing of activities, 19–20
 participation in sports, 20, 33, 43, 45, 46
 recommendations for activity levels, 5, 16, 17, 18, 20, 22, 30, 33, 45, 46
 physical examination, 3, 5, 8, 9, 10, 11, 16, 40, 43, 44
 physical therapy, 18, 20, 27, 30
 physician's recommendations, sample letter, 46
 picky appetite, 18t, 22, 27, 28, 44
 Pilates, 23
 plasma volume, 19, 48, 49
 polycystic ovary syndrome, 12t
 polysomnography, 11t, 26
 polytherapy, 26
 pooling of blood, 24, 47, 48,
 post-concussion syndrome, 11t, 41t
 post-exertional malaise (PEM), 11, 15, 40, 42
 post-exertional symptoms, 3, 4, 5, 7, 8, 9, 10, 11, 13, 14t, 15t, 16, 17, 18, 19–20, 21, 23, 27, 29, 40, 42, 43, 44, 45,

post-infectious fatigue syndrome, 4, 41t
 postural tachycardia syndrome (POTS), 6, 8, 9, 12t, 15t, 24, 24t, 25t, 28, 47, 48, 49, 50, 51
 precipitating factors, 5–6
 predisposing factors, 5–6
 pregabalin (Lyrica), 19t
 premenstrual syndrome, 12t, 13, 26, 27
 prevalence, ME/CFS, 3, 4, 5, 6, 15t
 probiotics, 23
 prodromal illnesses, 4, 24
 progesterone, 25t, 26, 27
 prognosis, 4–5, 30
 prolactin, 11t
 propranolol, 25t
 protein intolerance/hypersensitivity, 12t, 27–28
 pruritus, 28
 psychiatric illnesses in the differential diagnosis of ME/CFS, 11, 12–16, 21, 41t
 psychological reactions, 4, 12, 12t, 32, 42
 behavioral symptoms, 12, 14, 15, 15t, 21, 31, 32, 42, 46
 emotional reactions, 4, 7, 12, 15, 21, 26, 29, 30, 31
 psychotherapy, 21, 43
 puberty and ME/CFS, 7, 23, 49
 pulmonary function tests, 11t
 push-crash cycle, 19, 20
 pyrexia and fever, 4, 10, 15t, 17, 21, 28, 41t, 43
 pyridostigmine, 25t
 pyruvate, 11t

Q

quality of life, 4, 26, 49
 quercetin, 28

R

range of motion, 8, 20, 30
 rashes, 28
 RAST (radioallergosorbent) blood test, 11t, 28
 recumbent exercise, 20,
 referral of patients, 5, 11, 13, 14, 18, 21, 24, 28
 rehydration fluids, oral, 25
 relapses, 4, 17, 19, 20, 22, 31, 33, 43, 45
 renal function tests, 10t
 restless leg syndrome, 12t, 18t
 riboflavin, 18t
 rituximab 6
 rubor, dependent, 10

S

salbutamol, 26
 saline, intravenous, 25t, 26, 30, 50
 salt depletion, 24, 25
 salt intake, 22, 25, 25t, 26, 32, 33, 45, 49, 50
 saunas and hot tubs, 24
 school absence/attendance, 3, 4, 11, 15, 15t, 21, 31, 32, 33, 44, 45
 school nurses, 31

school refusal (school phobia), 13, 15, 32, 43
 schools and educational accommodation, *See also*
 homebound instruction, 20, 32, 33, 43, 45, 46
 education of school personnel about ME/CFS, 5, 15, 16, 20, 29, 31, 32
 educational plan, 32–33
 fact sheet for schools, 44–45
 impact of symptoms on learning, 11, 20, 32, 44, 45
 importance of education, 32
 physician/patient/family/school relationships, 15, 16, 17, 29, 31, 32, 33, 46
 sports participation, 20, 33, 43, 45, 46
 selective norepinephrine reuptake inhibitors (SNRIs), 19t, 25t
 selective serotonin reuptake inhibitors (SSRIs), 19t, 25t, 26, 49
 self-esteem and self-image, 7, 13, 14t
 self-hypnosis, 22
 sense of achievement, 5, 21, 22, 32
 Sertraline HCL, 19t, 25t
 severely affected patients, 4, 8, 16, 17, 19, 22, 27, 28, 29–30, 32, 43, 47
 severity of symptoms, 3, 4, 5, 6, 7, 8, 9, 11, 14, 14t, 16, 17, 19, 20, 21, 23, 25t, 26, 27, 28, 29, 30, 31, 33, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51
 sex ratio, ME/CFS, 4, 5, 7, 23
 shortness of breath, 23, 50
 short-term memory impairment, 9, 16, 40, 42, 44, 45, 48t
 siblings of patients, 4, 5, 6, 8, 10, 12, 13, 14t, 16, 17, 20, 21, 22, 29, 30–31
 sicca syndrome, 12t
 sinusitis, chronic, 12t 28, 41t
 skin, fragile or stretchy, 26
 skin tests, 11t, 28
 sleep problems, 3, 4, 6, 8, 9, 11, 12t, 13, 14t, 15t, 17, 18, 18t, 22, 26, 33, 40, 41t, 42, 44, 46, 47
 social activities, 4, 5, 9, 11, 14, 16, 17, 19, 20, 21, 32, 42, 44
 social development, 33, 45
 social isolation, 5, 7, 13, 14, 16, 42, 44
 socioeconomic groups, 4
 sodium chromoglycate, 26
 sodium intake, 22, 24, 25, 25t, 26, 32, 33, 45, 49, 50
 somatic complaints, 12, 15
 somatoform disorders, 13, 16
 sore throat, 9, 18, 40, 42
 speech difficulties, 29
 spinal cord, tethered, 11t, 28, 41t
 sporadic cases, ME/CFS, 4, 6, 42
 sports, 33, 43, 45, 46
 Stamina, loss of, 3, 8, 9, 15t, 19, 33, 42, 44, 46
 standing tests, in-office, 11t, 24, 24t, 49, 50, 51, 52
 stigma, of ME/CFS, 12, 31

stress, 4, 6, 7, 8, 12, 15, 16, 18, 21, 22, 24, 26, 28, 29, 30, 32, 41t, 48, 49
 orthostatic, 4, 7, 8, 24, 48, 49
 stretching, 20, 30
 striae, 26
 subluxations, 27
 subnormal body temperature, 8, 9, 13, 14t, 43, 44
 suborbital shadows, 10
 substance abuse, 16
 sudden onset, ME/CFS, 4, 6, 43, 44
 suicide and suicidal thoughts, 13, 14t, 19t
 sunbathing, 24
 supplements, dietary, 18, 18t, 23, 25, 28, 30, 47
 supportive therapy, 18, 20, 21, 22, 27, 30, 43
 surgery, special considerations for, 31, 47
 swallowing difficulties, 15, 28, 29
 swimming, 20
 syncope, 10, 24, 24t, 26, 28, 29, 47, 48t, 49, 50
 systemic exertion intolerance disease (SEID), 4, 42
 systemic lupus erythematosus (SLE), 11t, 41t

T

tachycardia, postural orthostatic tachycardia syndrome, 6, 8, 9, 12t, 15t, 20, 23, 24, 24t, 25t, 28, 47, 48, 49, 50, 51
 Tai Chi, 18
 teeth, 28–29
 telephone consultations, 17, 30
 temper tantrums, 12, 15
 temporomandibular joint disorder (TMD), 10, 12t, 28, 29
 testosterone, 11t
 tethered spinal cord, 11t, 28, 41t
 thermoregulatory imbalance, 8, 9, 43
 third molars, (wisdom teeth) impacted, 28, 29
 thoracic outlet syndrome, 12t, 28
 thyroid, 10t, 11t, 41t
 thyroid autoantibodies, 6, 11t
 thyroid function test, 10t
 thyroid stimulating hormone (TSH), 10t
 thyroxine, free (free T4), 10t
 tick-borne infections, 11t, 41t
 tilt-table testing, 11t, 24, 24t, 33, 47, 48, 49, 50
 tiredness, 8, 10, 12, 19, 20, 26. *See also* fatigue
 toileting difficulties, 29, 30
 tongue swelling, 28
 topiramate (Topamax), 19t
 touch, hypersensitivity to, 8, 9, 12t, 18, 29, 30, 43, 44
 toxins, 5, 6, 42
 tranexamic acid (cyclokapron), 27
 transcutaneous electrical nerve stimulation, 18
 transferrin, 10t
 transglutaminase, 10t
 travel difficulties, 17, 32
 trazodone, 17
 treatment of ME/CFS. *See* management of ME/CFS
 trembling, 15

tremulousness, 26, 48t
 tricyclic antidepressants (TCAs), 18t, 19t, 26, 41
 truancy (school refusal), 13, 15, 32, 43
 tryptase, 11t, 28
 tube feeding, 16, 17, 27, 29, 30
 tutoring, for homebound students, 4, 33, 43, 45
 twin studies, 6

U

ulcer, aphthous, 28
 ultrasound diagnosis, 11t
 urea, 10t
 urinalysis, 10t
 urination, 28
 urticaria, 28

V

validation of illness, 5, 16, 43
 valproic acid, 19t
 varicose veins (varices), 11t, 26, 27
 vasoconstrictors, 25t, 26, 48
 vaso-vagal syncope, 24, 47, 49
 venlafaxine HCL, 19t
 venogram, ovarian, 11t
 venous return to the heart, 24, 49
 ventricular lactate, 7
 viral illness, 6, 42, 44
 viral-like symptoms, 4
 visual dimming, 23
 visualization, 22
 vitamin B 12, 10, 10t, 20, 23, 41t
 vitamin C, 23
 vitamin D/D3, 10t, 23, 29, 30, 41t
 VO₂ max, 7

vomiting, 28, 48t
 vulvodynia, 12t

W

warm baths, 18
 weakness, 28, 29
 weight changes, 13, 14t, 18t, 19t, 22, 26
 wheat/gluten sensitivity, 22, 27
 wheelchair dependence, 3, 4, 16, 29
 wheezing, 28
 white blood cells, 6
 white matter, 7
 white-outs, visual field, 23
 wisdom teeth, (third molars), impacted, 28, 29
 Wood Mental Fatigue Inventory, 17
 word retrieval, 9, 11, 42, 44, 46
 working memory impairment, 11, 32, 46
 worsening of symptoms, post-exertional, 4, 5, 7, 9, 10, 11, 13, 14t, 15, 15t, 16, 17, 19, 20, 23, 27, 29, 43, 44, 45
 worthlessness, feelings of, 14t
 wound healing, delayed, 26

X

xerostomia (dry mouth), 18t, 28
 X-ray, chest, 11t

Y

yoga, 18, 23
 yogurt, 22

Z

zafirlukast, 28
 zolpidem, 17

ABOUT THE ARTIST

The drawing on our cover, entitled, *Blue Boy*, is the work of adolescent ME/CFS patient **Lilly Klontz**. Lilly was diagnosed with ME/CFS at age 12. When Lilly could no longer do any physical activities, and when the simplest of tasks became challenging, she decided that art was going to be her outlet and replace what she had lost. Despite all the obstacles presented by ME/CFS, Lilly keeps a positive attitude toward life: “I still have dreams and plan to attend college upon graduating high school.” *Blue Boy* was selected from the entries of an international art contest of young ME/CFS patients. We believe it captures the essence of what it is like to be a pediatric ME/CFS patient: feeling fatigued and suffering from malaise, patients do not have the stamina to join other young people in their activities. Yet, they have hopes, and dreams of performing these activities upon recovery, or partial recovery.

Monograph cover and layout design by Lia Di Stefano, liadida@icloud.com, liadidadesign.com